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9ABSTRACT
Background
Diabetes is a condition characterized by a number of metabolic disturbances. Self-management,
that aims at normalizing these disturbances, constitutes the backbone of diabetes treatment.
Successful management, judged by good metabolic control, aims at reducing the risks of various
complications, commonly associated with diabetes. A number of factors may affect how patients
take care of themselves. Amongst these is the patients’ knowledge of the current treatment
guidelines. For being efficient, however, this knowledge must also be translated into actual
compliance. Importantly, various psychological determinants may also have an impact on self
care which, again, could affect the diabetes outcomes. With this respect, depression and sense of
coherence (SOC) may be of interest. Depression is a common finding in diabetes and it has been
associated with adverse outcomes, especially among patients with type 2 diabetes. SOC, which
refers to the extent to which individuals are able to use various resources to sustain and improve
health, offers another kind of an approach to the issue of diabetes management. According to the
theory,  strong  SOC  in  diabetes  would  translate  in  more  prudent  self-management  practices
which, again, would reduce the prevalence of diabetic complications.
Aims
The aim of this thesis was to investigate the adherence with dietary recommendations in patients
with type 1 diabetes, and to study the association between self-reported and measured
compliance with recommendations. We also investigated the relevance of the SOC in diabetes
self care, patients’ perceptions of their disease, and microvascular complications. Moreover the
associations between depression and the metabolic syndrome and mortality were evaluated.
Subjects and methods
This study is part of the large national Finnish Diabetic Nephropathy (FinnDiane) study. The
study, that was launched in 1997, aims at identifying factors that predispose individuals with
type 1 diabetes to various diabetic complications. Included in the current papers are all
individuals with type 1 diabetes, in the FinnDiane study, that fulfilled the inclusion criteria of
each individual study. Thus in Study I, 817 individuals with a completed diet questionnaire and
at least one 3-day food record were included. In Study II, included were 1,104 participants who
had, in addition to the Orientation to Life Questionnaire (a measure of SOC), also completed the
diet and/or leisure-time physical activity questionnaire. Study III consisted of 1,264 individuals
from whom the Orientation to Life Questionnaire and the diabetes questionnaire were collected.
Required were also data on microvascular complications and glycaemic control. In all 1,226
participants were investigated in Study IV. These patients were included based on the availability
of the Beck Depression Inventory (BDI) score and data on the components of the metabolic
syndrome. Finally in Study V, all participants who consented to link their data with the data in
the Drug Prescription Register were included. For this study, mortality data were obtained from
the Finnish Cause of Death Register. Studies I-IV were cross sectional in design, while that of
the Study V was longitudinal.
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Results
Compliance with dietary guidelines was highest for the intake of protein (90% of the subjects
met  the  recommendations),  alcohol  (82%)  and  sucrose  (77%).  A  substantial  proportion  of  the
participants consumed less carbohydrates (48%) and fibre (96%) than recommended. For sodium
chloride (73%) and saturated fatty acids (72%) the recommended intakes were frequently
exceeded. Of the micronutrients, the recommendations for vitamin D, folate and iron were most
frequently unmet (68%, 77%, and 49%, respectively). Self-reported compliance (“always” or
“most of the time”) with dietary recommendations was reflected in more frequently meeting the
recommendations for carbohydrates, total fat, saturated fatty acids, and alcohol intakes. Despite
this, the observed frequencies of meeting the actual guidelines among these patients were, for
many nutrients, only modest (e.g., 55% for carbohydrates and 35% for saturated fatty acids).
Moreover, the frequencies of meeting the recommendations for fibre intakes were equally low
among self-reportedly compliant and non-compliant individuals. With regards to thiamine,
folate, vitamin C, potassium, zinc, and iodine, those self-reportedly compliant were observed to
meet the recommendations more often. In women, higher SOC score (indicating stronger SOC)
was associated with more prudent food choices. In men, the SOC scores were positively
associated with higher level of physical activity. Weak SOC was associated with higher HbA1c
levels among women, reflecting less favourable glycaemic control. In men, weak SOC was
associated with the presence of diabetic nephropathy. Four factors were formed from the diabetes
questionnaire (conceptions of HbA1c, complications, diabetes control, and hypoglycaemia).
Higher factor scores describing less favourable self-reports were observed for conceptions of
HbA1c and  hypoglycaemia  among  those  with  weak  SOC.  Moreover,  in  men,  weak  SOC  was
associated  with  the  complications  –factor.  In  women,  the  metabolic  syndrome  was  a  more
frequent observation among those with symptoms of depression. Of the individual components
of the metabolic syndrome, the BDI score was associated with the waist and triglyceride
components in women. Purchases of antidepressant agents reduced the 10-year cumulative
survival, mostly so among women with such purchases at around the baseline visit. The
purchasers of antidepressant agents died mostly of chronic diabetic complications, while the
predominant underlying cause of death among non-purchasers were cardiovascular diseases.
Conclusions
The intake of many nutrients, among patients with type 1 diabetes, was not in line with the
dietary recommendations. Especially those of carbohydrates, fibre, saturated fatty acids, sodium
chloride, vitamin D, folate and iron were frequently unmet. Self-reported compliance with the
dietary recommendations was associated with somewhat higher frequency of meeting some of
the guidelines. Sense of coherence was significantly associated with patients’ self care. However,
the effect was different in men and women, in whom physical activity and dietary intake,
respectively, were affected. SOC was also a factor in glycaemic control and was involved in
shaping the patients’ conceptions of their disease. In a cross sectional setting, notably in women,
depression was associated with the metabolic control and especially its waist and triglyceride
components. Subsequently depression, again most strongly among women, was associated with
increased mortality.
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1. INTRODUCTION
Diabetes mellitus (henceforth referred to as diabetes) affects a considerable number of
individuals worldwide. It has been estimated that a total of 171 million people were affected by
diabetes in the year 2000 (1). According to the projections for year 2030, the global prevalence
will reach 439 million individuals, which is 7.7% of the world population (2). The number of
individuals with diabetes diagnosis in Finland is around 290,000. Of these individuals, type 1
diabetes is found in 40,000. With the estimated number of undiagnosed cases of type 2 diabetes
(200,000), almost 6% of the Finnish population is currently affected with the disease.
Independent of the type of diabetes in question, the disturbed blood glucose control is the
central issue in these individuals. Importantly, due to the hyperglycaemic state, patients with
diabetes bear an increased risk of various vascular complications and, related to the appearance
of these complications, an increased risk of death (3, 4). Therefore, with the aim to normalize the
blood glucose levels, a number of self-management practices are conducted. Amongst these, the
importance of regular blood glucose monitoring, diet, physical activity and medication adherence
are strongly emphasized. In the public health care system patients are, indeed, provided with
detailed information on how to best achieve the treatment goals. A myriad of information is,
however, also available from other sources such as internet and peer groups, increasing the
possibility of obtaining misinformation. Thus, it is important to assess whether self-reported
compliance with given guidance is manifested in actual compliance.
How the self care practices are actually executed may also be affected with various
psychological determinants. Depression, for example, could affect the individual’s ability to
carry  out  the  numerous  tasks  required  to  maintain  the  optimal  metabolic  balance,  the  task
normally carried out by the very body itself. Indeed, for reasons not completely known,
individuals with diabetes have an increased risk of depression (5). Importantly the comorbid
depression, in patients with diabetes, have shown to increase the risks of complications (6) and
mortality (7, 8). Majority of the studies have, however, been conducted among patients with type
2 diabetes. Due to differences in the daily management of type 1 and type 2 diabetes, the impact
of psychological determinants may also differ.
The theory about the sense of coherence (SOC) provides another kind of an approach to the
issue of diabetes self care. Interestingly, Aaron Antonovsky developed the theory in order to
explain why people stay healthy (9). This salutogenic approach is thus different from the
pathogenic one, frequently seen in medicine, where the quest for factors behind diseases prevails.
The SOC refers to an orientation we have adopted during our development in childhood and
early  adulthood.  Depending  on  the  quality  of  this  orientation,  we  may  either  see  the  world
around us as something that makes sense or something that seems erratic. The adopted
orientation may also determine whether or not we are able to find a meaning behind the events
that take place in our lives. Moreover, Antonovsky theorized, when confronting with various
demands  of  life  individuals  with  strong  SOC tend  to  have  the  resources  and  the  means  to  use
them in  order  to  improve  ones  well  being.  On the  contrary  those  with  weak  SOC would  show
less  refined  ways  of  coping  with  the  daily  hassles.  How  SOC  is  related  to  self  care  in  type  1
diabetes is an understudied phenomenon.
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2. REVIEW OF THE LITERATURE
2.1 Diabetes
Diabetes refers to a group of metabolic disorders that are characterized by increased plasma
glucose concentrations and disturbances in lipid and protein metabolism (10). Differing in their
aetiology, these disorders are the result from defects in insulin secretion, insulin action, or both.
Perhaps the earliest description of the disease was by the ancient Egyptians as early as 1550 BC.
However, the term “diabetes” which means “to run through” was apparently first used in the
second century AD to describe the condition that causes increased urine output. Polyuria was
later associated with the sweetness of the urine, as Indian physicians indicated in the 5-6th
centuries the urine’s honey-like taste, stickiness, and its ability to strongly attract ants. However,
it was not until Thomas Willis had, in the 17th century, replicated the observations made by his
oriental colleagues regarding the sweet taste of the urine, that the diagnostic procedures started to
improve greatly.
Today, according to the diagnostic criteria set by the World Health Organization (WHO),
diabetes is assumed when fasting plasma glucose concentration is ?7.0 mmol/l, or ?11.1 mmol/l
after the two-hour glucose load of 75g (11). Importantly, these criteria distinguish individuals
with significantly increased risk of diabetic complications and premature death. In a clinical
setting, observation of typical symptoms of diabetes, such as excessive thirst, polyuria and
weight loss, with a random plasma glucose concentration ?11.1 mmol/l may also lead to the
diagnosis of diabetes.
2.1.1 Classification of diabetes
Rather than being one entity, a number of conditions with different underlying causes fall under
the umbrella term of “diabetes”. The classification of diabetes is based on their aetiological
differences. The two major categories of diabetes are type 1 and type 2 diabetes, with the latter
being more dominant with respect to the number of affected individuals. These types of diabetes
have previously been called “insulin-dependent diabetes mellitus” (IDDM) and “non-insulin-
dependent diabetes mellitus” (NIDDM), respectively. The use of these terms is now discouraged,
however, as they are based on the description of treatment rather than the pathogenesis. Type 1
diabetes is characterized by an autoimmune destruction of pancreatic islet ?-cell, while type 2
diabetes results from defects in insulin secretion and is accompanied with insulin resistance.
Although the great majority of patients with diabetes are classified as having either type 1 or
type 2 diabetes, a host of other forms of diabetes also exist. Of these, latent autoimmune diabetes
in adults (LADA) shares features with both type 1 and type 2 diabetes. Similarly to type 1
diabetes, LADA involves an autoimmune destruction of the ?-cells. However, it typically has
slower rate of progression and later onset. Moreover, affected adults may retain some residual ?-
cell function and may thus not require exogenous insulin at the time of diagnosis.
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Idiopathic type 1 diabetes, more commonly observed among individuals of African and Asian
origin, does not have evidence of autoimmunity. However, some of these patients have
permanent insulinopenia and are prone to ketoacidosis.
Maturity onset diabetes of the young (MODY) is a condition that results from a genetic
defect of ?-cell function. The disease is usually inherited in an autosomal dominant pattern.
Patients with MODY show impaired insulin secretion with minimal or no defect in insulin
action. In gestational diabetes, hyperglycaemia of variable severity has its onset or first
recognition in pregnancy. The condition may or may not be treated with insulin, and may persist
postpartum.
2.1.2 Type 1 diabetes
Type 1 diabetes is a chronic autoimmune disease in which the destruction of insulin producing
pancreatic ?-cells leads to insulin deficiency (12). Although the clinical signs of type 1 diabetes
manifest only after a great majority of the ?-cell population have been lost, several silent
immunological  events  take  place  prior  to  that.  These  events  include  production  of  islet
autoantibodies (e.g., islet cell, glutamic acid decarboxylase, insulinoma-associated antigen-2, and
zinc transporter 8 autoantibodies), and activation of self-reactive lymphocytes that eventually
destroy the ?-cells (13). The onset of type 1 diabetes is typically prior to age 30, but can occur at
any age. Although the precise progress to full-blown type 1 diabetes is not known, the disease is
considered multifactorial. Type 1 diabetes occurs in genetically predisposed individuals after
having encountered some poorly understood environmental risk factors. Putative environmental
triggers include certain viruses, environmental toxins, and dietary factors such as early exposure
to cow’s milk, or gluten (14). Substantial body of evidence suggests that vitamin D plays a
protective  role  in  type  1  diabetes.  In  the  EURODIAB  study,  vitamin  D  supplementation  in
infancy significantly decreased the risk of type 1 diabetes (15). Similarly, in a Finnish study
among 10,366 children, both regular and irregular vitamin D supplementation reduced the
subsequent risk of type 1 diabetes (16).
Within the Multinational Project for Childhood Diabetes (DIAMOND), the WHO has studied
the  worldwide  incidence  of  type  1  diabetes  (17).  In  this  study,  considerable  differences  in  the
incidences of type 1 diabetes between countries have been observed. While the highest incidence
rates have been observed among European and North American populations, those of the Asian
populations are fairly low. Interestingly, of the 57 countries studied during the period 1990–
1999, the highest incidence figures were observed in Finland. Compared to countries like
Venezuela and China with a yearly incidence of 0.1/100,000, Finland stood far apart with its
40.9 cases per 100,000 inhabitants every year.
In the same study, a global increasing trend in the incidence of type 1 diabetes was observed.
Worldwide, the mean annual increase during the 10 year period was 2.8%, while the respective
figure for Finland was 4.2%. In a Finnish study, Harjutsalo et al. also reported an increase in the
incidence of type 1 diabetes (18). Between years 1980 and 2005 the annual incidence was
observed to increase from 31.4/100,000 to 64.2/100,000. The increase was particularly large
among the children aged 0–4 years. This substantial increase in the diabetes incidence during
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such a short time period cannot be explained by alterations in genetic susceptibility alone.
Indeed, various environmental factors are likely to contribute to this increase.
2.1.3 Metabolic syndrome
The metabolic syndrome is a cluster of factors that have been associated with an increased risk of
cardiovascular events and type 2 diabetes. These risk factors include abdominal obesity,
increased blood pressure, low high-density lipoprotein concentration, and increased fasting
glucose and triglyceride concentrations (19).
Reaven introduced the term Syndrome X in 1988 when addressing the relationships between
insulin resistance and compensatory hyperinsulinaemia in many patients with impaired glucose
tolerance or type 2 diabetes (20). Although compensatory hyperinsulinaemia may prevent the
development of distinct hyperglycaemia, individuals with insulin resistance are at heightened
risk of glucose intolerance combined with detrimental changes in lipid metabolism and blood
pressure (20, 21).
The WHO was the first to give a formal definition for the metabolic syndrome in 1998 (22).
To qualify for the metabolic syndrome, an individual must have either insulin resistance, type 2
diabetes, or impaired fasting glucose together with any two of the following criteria:
hypertension, elevated triglyceride concentrations, low HDL concentrations microalbuminuria or
abdominal or overall obesity.
Since the publication of the WHO criteria, a number of other criteria for the metabolic
syndrome have been issued. In 2001, the Adult Treatment Panel III (ATP III) published their
criteria for the metabolic syndrome (23). As opposed to the WHO, ATP III did not require one
essential criterion for the metabolic syndrome, but determined five criteria of equal importance:
abdominal obesity, hypertension, low HDL concentration, high triglyceride concentration and
glucose intolerance. The metabolic syndrome was assumed when at least three of these five
criteria were fulfilled.
The International Diabetes Federation proposed their criteria for the metabolic syndrome in
2005 (24). Similarly to ATP III, they used five criteria but emphasized the importance of the
abdominal obesity which had to be accompanied with any two of the remaining criteria. In 2009,
a number of organizations published a joint statement with “harmonized” criteria for the
metabolic syndrome, and once again removed adiposity from the centre of the syndrome to being
just one of the five components (19).
Despite extensive research conducted around the metabolic syndrome, the concept of the
syndrome remains controversial. According to some views patients should not be labelled with
the metabolic syndrome diagnosis but rather all cardiovascular disease (CVD) risk factors should
be individually and aggressively treated (25). Indeed, the WHO has stated that the metabolic
syndrome should not be a clinical diagnosis but instead it should be viewed as a pre-morbid
condition (26).
Traditionally, the metabolic syndrome has been associated with type 2 diabetes. However,
clustering of the same risk factors is  also evident among patients with type 1 diabetes.  Among
the FinnDiane population, the overall prevalence of the metabolic syndrome in men and women
was 38% and 40%, respectively (27). Importantly, beyond the traditional risk factors, the
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metabolic syndrome has been shown to be an independent risk factor for cardiovascular events in
type 1 diabetes (28).
2.2 Diabetic complications
Patients with diabetes have an increased risk of various long-term complications. These
complications affect small (microvascular) and large (macrovascular) vessels and account for
most of the increased morbidity and mortality related to diabetes (3, 4). The presence of
complications reduces the quality of life of the affected patients (29). Moreover, the presence and
severity of diabetic complications increase the need for hospitalization and thus also increase the
financial burden on the health care system (30, 31).
A number of risk factors related to these complications have been identified. Some of these,
such as glycaemia, blood pressure, lipidaemia, diet, and smoking are modifiable, while factors
like diabetes duration, age, and genes cannot be modified. The importance of glycaemic control
in the prevention of diabetic complications was conclusively demonstrated in the Diabetes
Control and Complications Trial (DCCT) (32) and its follow-up study the Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC) (33). The DCCT was a multicentre,
randomized clinical trial that was designed to assess whether intensive insulin therapy would be
more effective in delaying the onset and progression of diabetic complications compared to
conventional insulin therapy. In all 1,441 patients with either no retinopathy at baseline (the
primary-prevention  cohort)  or  mild  retinopathy  (the  secondary-intervention  cohort)  were
randomised to apply conventional or intensified insulin regimen. In the intensive treatment arm,
insulin was injected at least three times a day or alternatively continuous subcutaneous insulin
infusion was used. Among these patients, the insulin dose was adjusted based on the self-
monitored blood glucose concentrations, diet, and exercise. Conventional therapy, on the other
hand, consisted of one or two daily insulin injections, the doses of which were usually not
adjusted according to the blood glucose values. Compared to the conventional treatment,
intensive diabetes management resulted in a significant reduction in the mean glycated
haemoglobin A1c (HbA1c) level. Importantly, improvement in glycaemic control was associated
with significant reduction in the incidence and progression of diabetic retinopathy, nephropathy,
and neuropathy during the mean follow-up of 6.5 years.
With the emerging results from the DCCT the trial was ended in 1993 and all patients were
encouraged to intensively manage their diabetes under the supervision of their own healthcare
providers (33). Patients were additionally provided with the opportunity to enter the
DCCT/EDIC follow-up study, to which a total of 96% of the participants from the DCCT cohort
consented. One of the many aims of the DCCT/EDIC trial was to examine the long-term effects
of the previous DCCT intervention on the subsequent development and progression of diabetic
complications. During this follow-up, the difference in glycaemic control levelled off between
the two original treatment arms. After four years, for example, the median HbA1c values among
patients in the intensive arm increased from 7.2% observed during the DCCT to 7.9%. At the
same time, the median HbA1c values in the conventionally treated arm decreased from 9.1% to
8.2%. Despite this convergence of glycaemia patients initially intensively treated, as opposed to
those conventionally treated, were less likely to develop complications during the four and ten
16
years follow-up after the intervention close-out (34, 35). Early intensive treatment has also been
shown to have long-standing effects on the CVD risk as during a 17 year follow-up in the
DCCT/EDIC trial, intensively treated patients had 42% reduced risk of experiencing any CVD
event (36). Moreover, the risk of nonfatal myocardial infarction, stroke, or death from CVD was
reduced by 57%.
2.2.1 Diabetic nephropathy
Diabetic nephropathy is a common complication in diabetes. It affects roughly one third of the
patients with type 1 diabetes (37). Diabetic nephropathy is characterized by persistent excretion
of albumin into the urine, elevated blood pressure, and a progressive decline in renal function
(38). Importantly, diabetic nephropathy is associated with increased mortality among patients
with type 1 diabetes (4). Early identification of renal insufficiency is critical in delaying its
progression to more advanced forms.
Early detection of renal impairment involves the measurement of urinary albumin excretion
rate (AER) (39). This can be done by performing a timed urine collection. The results of which
need to be confirmed in at least two collections out of three. In a normal state, less than 30 mg
albumin per day is excreted into the urine (<20 ?g/min). In microalbuminuria, which is a risk
factor for overt nephropathy, the daily albumin excretion rate remains below 300 mg (<200
?g/min). In overt nephropathy, however, substantial amounts of albumin are excreted (?300
mg/day or ?200 ?g/min). Macroalbuminuria may eventually progress to end-stage renal disease.
In the advent of such renal failure, patients require dialysis or kidney transplantation for survival.
Not only AER, but also glomerular filtration rate (GFR) is used to evaluate the stage of
kidney disease (39). GFR is a measure of renal function. It tells how much blood is filtered
through the glomeruli in a given time, and thus describes the excretory function of the kidneys.
In renal failure the GFR is greatly reduced. GFR cannot be measured directly in humans, and it is
thus assessed by measuring the clearance of some filtration marker, instead. The central idea is to
measure the serum and the urine concentration of a certain compound, that is present in a fairly
static concentration in plasma and is freely filtered but neither reabsorbed nor actively secreted
by the kidneys. The urinary concentration is multiplied by the volume of the timed urine
collection and the obtained figure is subsequently divided by the concentration measured in
plasma. Various markers, such as inulin and compounds labelled with radioisotopes, have been
used to estimate GFR in the research setting. Their use is, however, labour-intensive and thus
other estimates are more commonly used in clinical practice. One possibility is to measure the
serum creatinine concentration. The use of this method is however limited by the fact that the
concentration is dependent on muscle mass and dietary intake, and considerable variation in its
endogenous production is found. A potential alternative is to measure the concentration of
cystatin C in blood, instead (40). This protein is produced at a constant rate, and its concentration
in blood is not affected by muscle mass, age or gender. Because cystatin C is not excreted into
the urine its clearance cannot be calculated. However, the creatinine clearance may be calculated,
instead. Although creatinine is freely filtered in the glomerulus, it is also actively secreted in the
peritubular capillaries. Therefore creatinine clearance overestimates the true GFR. A number of
formulas have been developed to compensate for interindividual variations in the creatinine
17
production, and thus to improve the estimates of GFR. In these formulas, factors such as gender,
age, body size, and ethnicity may be taken into account. Two of the formulas most frequently
used are the Cockcroft-Gault equation and an equation developed in the Modification of Diet in
Renal Disease study (41, 42).
Good glycaemic control is important in reducing the risk of development or progression of
nephropathy (43-45). There is also strong evidence that good blood pressure control delays the
progression of nephropathy in patients with diabetes (46-48). For the blood pressure
management in patients with type 1 diabetes, angiotensin-converting enzyme inhibitors are
recommended (39). Restricting daily protein intake to 0.8 g/kg body weight may be beneficial
for patients with advanced kidney disease. Moreover, physical inactivity and smoking are
discouraged as they may contribute to the progression of kidney damage (49, 50).
2.2.2 Diabetic retinopathy
Diabetic retinopathy results from the damage in the microvasculature of the retina. It progresses
from milder forms that are characterized by increased vascular permeability to proliferative
diabetic retinopathy, in which new blood vessels are formed. Diabetic retinopathy is the leading
cause of blindness among individuals in the working age (51-53). A number of different
mechanisms, such as macular oedema, detachment of retina, bleeding of the newly formed blood
vessels,  and  neovascular  glaucoma,  are  responsible  for  the  loss  of  vision.  The  presence  of
retinopathy is frequently associated with other complications, such as nephropathy (54, 55).
Importantly, patients with retinopathy also have an increased risk for all-cause mortality and
incident cardiovascular disease (56).
The risk of diabetic retinopathy increases with increasing duration of diabetes (57-59). In
some patients with type 1 diabetes diabetic retinopathy can be diagnosed within years after the
onset of diabetes (60). After 20 years of diabetes, however, almost all patients show some degree
of  diabetic  retinopathy.  In  the  Wisconsin  Epidemiologic  Study  of  Diabetic  Retinopathy,  some
form of retinopathy was observed in 8%, 25%, 60%, and 80% of patients with diabetes after 3, 5,
10 and 15 years, respectively (61). Some patients are, however, retinopathy-free despite a long-
standing type 1 diabetes of over five decades (62). Genetics may provide an explanation for such
protection as certain variants in the aldose reductase (AKR1B1) gene, for example, have been
shown to be associated with the development of diabetic retinopathy (63).
Besides diabetes duration, a number of other risk factors that contribute to the development
of diabetic retinopathy has been identified. One of the most important ones is metabolic control,
the effect of which has been demonstrated both in type 1 and type 2 diabetes (57, 59, 64, 65).
Other observed risk factors are high blood pressure, blood lipid abnormalities, male sex, and
smoking (58, 59, 66, 67). Despite the accumulated evidence about the impact of the risk factors,
their management is frequently suboptimal (68). In line with this observation, the prevalence of
diabetic retinopathy remains significant among patients with type 1 diabetes (59).
Diabetic retinopathy is frequently asymptomatic. Therefore patients are encouraged to have
their eyes regularly examined (53). Regular evaluation is also recommended because retinal
photocoagulation, that is used for the treatment of proliferative diabetic retinopathy, is most
effective at reducing vision loss when applied at certain stages of the condition (69). A number
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of techniques have been developed to detect diabetic retinopathy of which ophthalmoscopy is the
most commonly used (70). Other techniques include fluorescein angiography, fundus
photography, and single-field photography. Once vision-threatening retinopathy has been
identified, panretinal photocoagulation (“laser therapy”) may be performed. In this process, a
special laser is used to produce burns in the retina with the aim to halt vessel growth and leakage.
By meticulous screening and treatment of proliferative diabetic retinopathy, vision loss can be
prevented (71, 72). However, despite improved ability to diagnose and treat retinopathy,
blindness is still a major concern among patients with type 1 diabetes, as was demonstrated in a
25-year follow-up study where 7.5% of the patients with type 1 diabetes were registered as blind
(73).
2.2.3 Diabetic neuropathy
Diabetic neuropathies are a complex group of conditions that are characterized by progressive
loss of nerve fibres (74).  These complications are prevalent among patients with diabetes (75).
Importantly, they account for increased morbidity and mortality, and are the leading cause of
non-traumatic amputations (76, 77). Several factors contributing to the pathogenesis of diabetic
neuropathy have been suggested, including chronic hyperglycaemia, excessive activation of the
polyol pathway and subsequent sorbitol accumulation, formation of advanced glycation end
products, and oxidative stress (74). Moreover, longer diabetes duration increases the risk of
diabetic neuropathies (78). Of the modifiable risk factors, hyperglycaemia, elevated blood
pressure, and plasma lipid abnormalities are the main targets of the primary and secondary
prevention of these conditions (79).
Diabetic neuropathy may affect somatic and/or autonomic parts of the peripheral nervous
system. The disorder is diagnosed based on the presence of signs and symptoms of peripheral
nerve dysfunction after excluding other potential causative factors (80). Among others,
conditions such as hypothyroidism, excessive alcohol intake, renal impairment and vitamin B12
deficiency should be considered when making differential diagnosis (81, 82). Diabetic
neuropathies can be categorized into readily reversible neuropathy, generalized symmetric
polyneuropathies (chronic sensorimotor, autonomic, and acute sensory), and focal and multifocal
neuropathies (cranial, truncal, focal limb, proximal motor, coexisting chronic inflammatory
demyelinating polyneuropathy) (74). The clinical features of different neuropathies vary
substantially. In line with this, the symptoms of the conditions also vary and some of them may
frequently be even asymptomatic. Therefore it is recommended that all patients with diabetes
should be annually screened for diabetic neuropathy (81).
2.2.4 Macrovascular complications
Macrovascular complications such as coronary heart disease (CHD), cerebrovascular disease,
and peripheral vascular disease are frequently observed in patients with diabetes. Importantly,
mortality and morbidity related to cardiovascular events remains high in patients with type 1
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diabetes (83-85), and the presence of microvascular complications further increases the risk (86,
87).
Factors such as hypertension, dyslipidaemia, longer diabetes duration and smoking have
shown to increase the risk of macrovascular complications (86, 88-90). However, the
significance of glycaemia for the macrovascular complications in type 1 diabetes seems
ambiguous. Fuller et al., for example, showed such an association only in patients with type 2 but
not in type 1 diabetes (86). Moreover, in the Pittsburgh Epidemiology of Diabetes Complications
study, HbA1c did not predict the 10-year coronary artery disease event risk in patients with type 1
diabetes (89). Furthermore, although the DCCT clearly showed a reduced risk of microvascular
complications among intensively treated patients, only nonsignificant reduction was shown for
macrovascular events (32). Relatively young age of the participants may have contributed to
these results. Post hoc analyses of the DCCT data showed, however, that each 1 mmol/l rise in
the mean blood glucose concentration was associated with an 11% elevated risk of
cardiovascular  events  (91).  Moreover,  long-term  benefits  of  tight  glycaemic  control  on  the
macrovasculature were later detected in the DCCT/EDIC. Six years after the end of the DCCT,
the mean progression of the intima-media thickness was less among the intensively treated as
opposed to the conventionally treated patients (92). Furthermore, another eleven years later a
reduced rate of various macrovascular events was observed among patients in the original
intensive  treatment  arm  (36).  The  importance  of  good  glycaemic  control  was  also  shown  in  a
study by Lehto et al. In their report of a seven year follow-up study poor metabolic control,
together with previous history of myocardial infarction and a long diabetes duration, was a
strong predictor of CHD events among patients with type 1 diabetes (93). Interestingly, the
increased  risk  of  cardiovascular  events  is  not  limited  to  the  hyperglycaemic  levels  of  patients
with diabetes, but also seems to extend to the non-diabetic threshold. This was demonstrated in a
meta-analysis of 95,783 individuals, where a 33% increased risk of events was observed among
individuals with fasting glucose levels of 6.1 mmol/l, compared to those with glucose levels of
4.2 mmol/l (94).
2.3. Blood glucose control
Glucose is an important form of energy that is used throughout the body and it is the principal
source of energy in the brain. Due to its central importance in the metabolism, the blood glucose
concentration is normally under strict regulation. This control is primarily implemented by two
hormones, insulin and glucagon, that both originate from the pancreas. In the prandial state when
the blood glucose levels increase, the pancreas enhances its insulin secretion and reduces that of
glucagon. In that state, insulin enables the transportation of glucose into the cells and facilitates
its transformation into the storage form, glycogen. The net effect of this event is the reduction of
the blood glucose content. The opposite occurs between meals when blood glucose
concentrations are reduced. At this time, the predominating glucagon ensures that glucose is
released into the circulation and sufficient amount of glucose is available as energy. Besides
glucagon, a number of other hormones, including adrenalin, noradrenalin, cortisol, and growth
hormone, also counteract the effects of insulin.
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2.3.1 Hyperglycaemia and HbA1c
In a non-diabetic individual, fasting blood glucose concentration usually ranges between 3.5–5.5
mmol/l, and after meal concentrations between 5 and 8 mmol/l are observed. However in type 1
diabetes, due to lack of insulin secretion, the blood glucose levels tend to rise. This
hyperglycaemia, that is characteristic for diabetes, is a major risk factor for diabetic long-term
complications.
Daily blood glucose monitoring provides information regarding the current glucose content in
the blood. Frequent monitoring is useful in detecting acute glycaemic fluctuations and is used to
modify the insulin regimen. Evidence has emerged suggesting that acute hyperglycaemic
episodes, such as those frequently observed after meals, are independent risk factors for the
development of vascular complications (95). In patients with type 2 diabetes, the 2-hour
postprandial blood glucose levels better predicted all-cause and CVD mortality compared to the
fasting levels (96). Similarly, in the Framingham Offspring Study, the 2-hour postchallenge
glucose concentrations increased the risk of CVD events independent of traditional CVD risk
factors and levels of fasting or average hyperglycaemia (97). Based on the accumulated
evidence, it has been suggested that more aggressive glycaemic control, specifically targeted at
the postprandial hyperglycaemic excursions, may be required in order to reduce the risk of
cardiovascular disease (98). The proposed mechanisms through which acute hyperglycaemia
may contribute to the development of vascular complications are increased oxidative stress,
increased renal perfusion, hyperfiltration, increased collagen production in the kidney, and
decreased motor and sensory nerve conduction.
In addition to the daily blood glucose monitoring that provides information about the acute
glycaemic control, attention is also drawn to the chronic metabolic control. In blood, glucose has
a tendency to non-enzymatically attach to various proteins, such as haemoglobin found in
erythrocytes. The rate of this attachment depends on the amount of glucose available. The
measurement of HbA1c represents the extent to which haemoglobin in blood has been glycated
during the erythrocytes’ average lifespan of 120 days (99). Previously HbA1c was reported as the
percentage of glycated haemoglobin, but is nowadays given as mmol/mol. However, in practice
both units are frequently used in parallel. In non-diabetic individuals, the HbA1c values range
between 20–42 mmol/mol (4–6%), and in insulin-treated patients, values below 53 mmol/mol
(7%) reflect a good metabolic control. Both fasting and postprandial blood glucose levels
contribute to the average glycaemia. Their individual contributions, however, seem to vary
across the range of HbA1c levels (100). Among patients with mild to moderate hyperglycaemia
(HbA1c <8.4%), the postprandial glucose excursions predominantly contribute to the average
glycaemia. However in poorly controlled patients, fasting hyperglycaemia more strongly
contributes to the overall glycaemia.
In patients with diabetes, HbA1c is routinely checked. Patients may use this information to
modify their self care practices. Indeed, providing patients with immediate feedback of their
HbA1c measurements has shown to result in an improvement in their metabolic control over the
subsequent 6 to 12 months (101). Importantly, HbA1c has strong predictive value for diabetic
complications (32, 43, 102, 103). It seems, however, that there is no specific threshold for the
HbA1c value below which diabetic complications can be prevented (64). Instead, the results
stress the need to attain glycaemic control that is as close to normal as possible.
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2.3.2 Hypoglycaemia
Hypoglycaemia is a condition in which plasma glucose concentration falls below 4.0 mmol/l
(104). Hypoglycaemia is a common side effect of insulin treatment, and its risk is increased in
intensive insulin therapy (32). Other contributing factors include participation in strenuous
physical activity, omitting carbohydrate-containing meals, and generous consumption of alcohol
containing beverages. Generally hypoglycaemia is divided into “mild” and “severe” forms. The
distinction of which depends on whether the patient is independently able to treat the condition
or requires external help.
It has been estimated that each patient with type 1 diabetes experiences, on average, two
episodes of mild hypoglycaemia per week (105, 106), and the annual incidence of severe
hypoglycaemia ranges between 1.1 and 1.7 events per patient (106-108). However, the
occurrence of severe episodes of hypoglycaemia is unevenly distributed, with roughly 30–40%
of patients reporting having experienced them during the preceding year (106, 108-110).
Moreover, in a study by Pedersen-Bjergaard et al., only 5% of participants accounted for 54% of
all episodes of severe hypoglycaemia (106).
A number of risk factors for severe hypoglycaemia have been recognized, including strict
glycaemic control, impaired awareness of hypoglycaemia, history of previous episodes of severe
hypoglycaemia, the presence of peripheral neuropathy, and smoking (106, 111). Moreover, the
risk tends to increase with increasing duration of diabetes (106, 108).
In order to normalize the glucose metabolism a number of physiological responses, including
reduced insulin secretion and increased secretion of glucagon, adrenalin, noradrenalin, growth
hormone and cortisol, take place when the plasma glucose concentration falls. However in
patients with type 1 diabetes, who have lost the ability to regulate their insulin and glucagon
secretion, this chain of events is disturbed (Figure 1).
Figure 1. Glucose counterregulation with reducing plasma glucose concentrations (modified
from (112))
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Moreover, especially when frequently experiencing hypoglycaemic events, other counter-
regulatory deficits are also observed. The emergence of the initial symptoms of hypoglycaemia
(adrenergic symptoms), such as tremor and sweating (113), are associated with the secretion of
the counter-regulatory hormones. Neuroglycopenic symptoms such as poor concentration,
drowsiness, confusion, double vision, and difficulties in speech and physical coordination, that
are related to the reduced availability of glucose in the central nervous system, follow if plasma
glucose level is further reduced. Individuals who frequently experience hypoglycaemic events
may get used to the initial symptoms of hypoglycaemia and eventually fail to recognise them. Up
to 60% of patients with type 1 diabetes have been reported to have such an impaired awareness
of hypoglycaemia (114). Unless traced by glucose self-monitoring, these individuals may not be
aware of their low blood glucose levels until experiencing the neuroglycopenic symptoms.
Eventually convulsions, unconsciousness, and even death may follow if hypoglycaemia is not
treated.
Treatment of hypoglycaemia depends on the severity of the episode. In mild cases, ingestion
of glucose- or carbohydrate-containing foods is recommended. However, do to its faster action,
pure glucose (15–20 g) is preferred (39). Moreover, other macronutrients in food may slow down
the digestion and absorption of glucose and therefore prolong the hypoglycaemic episode.
Glucagon injection provided by another person is required to treat an unconscious individual.
Many patients with type 1 diabetes dread hypoglycaemia and the unpleasant symptoms that
are associated with it. When severe, hypoglycaemia leads to a temporary loss of control and may
thus cause embarrassment. Fear of hypoglycaemia can influence the self-management practices
in these individuals and the subsequent tendency to maintain hyperglycaemia may, again, have
other consequences in the form of increased risk of long-term complications. Frequent blood
glucose monitoring and appropriate corrective actions are central in the prevention of
hypoglycaemic events. Moreover in order to reduce the occurrence of hypoglycaemic events,
extra carbohydrate-containing snack may be in order prior to participating in strenuous physical
activity, when consuming larger amounts of alcohol, or if blood glucose levels are below 6
mmol/l at bedtime.
2.3.3 Glycaemic variability
Based on the extensive body of evidence regarding the association between the level of
glycaemia and diabetic complications, HbA1c measurement is currently considered the “gold
standard method” for assessing long-term glycaemic control (115). In the Diabetes Control and
Complications  Trial  (DCCT)  it  was  observed,  however,  that  at  a  given  HbA1c level the rate of
complications was higher among conventionally treated patients compared to those intensively
treated (65). This led the investigators to speculate whether other aspects of glucose homeostasis,
beyond HbA1c, would contribute to the increased risk of complications. One of the proposed
factors was glycaemic variability, that is the daily fluctuations of blood glucose concentrations.
Indeed, two individuals with equal HbA1c values may differ substantially with respect to how
much their daily blood glucose levels vary. It was postulated that, due to more frequent insulin
administration, intensively treated individuals in the DCCT would have experienced reduced
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glycaemic variability compared to those conventionally treated. Whether this phenomenon
would actually contribute to the risk of complications was not, however, known.
Using the DCCT data, Kilpatrick et al. aimed at answering this question (116). They
calculated the mean blood glucose values by the area under the curve, and subsequently
evaluated the glycaemic variability as the standard deviation of the mean blood glucose
measurements. Investigators found that the variability around patient’s mean blood glucose value
did not have any influence on the development or progression of retinopathy or nephropathy.
Thus, the investigators concluded that, on average, a patient with highly fluctuant glucose
concentrations has equal risk of complications as a patient with more stable daily glucose values.
In 2008 the DCCT data were, once again, analysed (91). This time Kilpatrick et al. evaluated
whether glycaemic variability had any effect on the risk of macrovascular disease in this
population. Consistent with the previous results regarding microvascular complications,
glycaemic variability did not associate with the risk of macrovascular complications. Instead,
mean blood glucose concentrations were predictive of cardiovascular events.
Bragd et al. set up a study to investigate whether glycaemic variability is an independent risk
factor in the development of microvascular complications (117). In all, 100 patients with type 1
diabetes were included in their study. The standard deviation of blood glucose (SDBG)
concentration was assessed from 70 measurements performed over a 4-week period. The onset
and progression of complications were then recorded over the 11 years of follow-up. According
to  the  results,  HbA1c was an independent predictor of the incidence and prevalence of
nephropathy. However, SDBG predicted the prevalence of neuropathy.
The effect of the HbA1c variability on diabetic complications has been assessed in the
FinnDiane study (118). In this study, complete data on renal status and HbA1c measurements,
and CVD events and HbA1c measurements were available from 2,107 and 1,845 patients,
respectively. These patients were followed for a median of 5.7 years. Compared to non-
progressors, the standard deviation (SD) of serial HbA1c was higher among those who progressed
to a higher albuminuria level or to end-stage renal disease (0.75 vs. 1.01, p<0.001). Similarly the
SD of serial HbA1c was higher among the incident CVD cases (0.79 vs. 0.87, p=0.023). Thus, the
results suggested that a larger HbA1c variability predicts both worsening of the renal status and
CVD events in patients with type 1 diabetes.
Monnier et al. proposed a potential mechanism through which glycaemic variability could
influence the risk of diabetic complications (119). Among 21 individuals with type 2 diabetes,
they aimed to assess the respective contributions of sustained hyperglycaemia and that of acute
fluctuations of glucose concentrations to the markers of oxidative stress. As a marker of
oxidative stress they used the 24-hour urinary excretion rate of 8-iso prostaglandin F??. In
multivariate models, Monnier et al. observed that glycaemic fluctuations resulted in most
pronounced responses in oxidative stress. Oxidative stress was not, however, evident during
chronic hyperglycaemia.
Today, the issue regarding glycaemic variability and diabetic complications remains
controversial. According to the opponents of the theory, the current evidence falls short and is
inconsistent (120). The issue is, however, important and therefore further investigation is
required to provide more insight into this unresolved question.
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2.4 Self-management of type 1 diabetes
A number of self care practices, such as home blood glucose monitoring, insulin administration,
diet and physical activity, are critical in the successful management of diabetes. Optimal
management is considered an ongoing process that is based on a patient-centred collaboration
with a multidisciplinary diabetes team. Within this alliance, the management plan should be
formulated while taking into consideration the patient’s characteristics such as age and medical
conditions. Successful implementation of this plan requires that the patient feels that the goals
and actions required to reach them are reasonable and achievable. The realization of the
management plan should be followed, and patients should be provided with ongoing education
and support.
2.4.1 Self-monitoring of blood glucose levels
One of the most important self care practices in type 1 diabetes is to monitor the fluctuations of
the blood glucose concentrations and, in case of hyper- or hypoglycaemia, make appropriate
adjustments to restore the near normal glucose levels. Individual variation exists in the targeted
blood glucose concentrations in patients with type 1 diabetes. However, the following goals for
the plasma glucose concentrations suit most individuals: 4–6 mmol/l prior to meal; 8–10 mmol/l
1.5–2 hours after meal; 6–8 mmol/l at bedtime; and 4–7 mmol/l at night (121). Individuals that
have a tendency to develop hypoglycaemia frequently may need to set higher goals for their
blood glucose concentrations.
Self-monitoring of blood glucose allows patients to evaluate their response to therapy. The
obtained information can subsequently be used to modify the insulin regimen. Frequently
observed high preprandial plasma glucose concentrations, for example, may indicate a need to
increase the basal insulin dose. On the other hand, repeatedly observed low plasma glucose
values in the mornings may suggest that the basal insulin dose is too high. Similarly, results from
the postprandial blood glucose monitoring provide important information on how accurately one
is able to estimate the required amount of bolus insulin, and whether corrective actions are
required. Moreover, blood glucose monitoring not only provides information about how well the
regimen is working but may also reduce potential anxiety related to hypoglycaemia.
The number of times the plasma glucose concentrations should be measured may vary, and
the frequency and timing of monitoring should be set based on the individual needs and goals.
More frequent self-monitoring, however, enables patients to better respond to changes in their
plasma glucose concentration. Currently, the American Diabetes Association (ADA)
recommends that individuals using multiple insulin injections or insulin pump therapy should
monitor their blood glucose levels at least three times a day (39). In practice, after having
established a working regimen, measurements in the morning, prior to meals, and at bed time are
generally sufficient. Additional measurements may be warranted when ill or when engaging in
strenuous exercise. Moreover, intensified blood glucose monitoring is required when making any
changes in the insulin regimen.
In  the  DCCT,  the  intensive  therapy,  that  was  subsequently  associated  with  reduced  risk  of
microvascular complications, included regular (?4 times per day) self-monitoring of blood
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glucose content (32). Despite these encouraging results, many studies have shown that adherence
to the blood glucose monitoring is frequently suboptimal (122-124). In a recent study, Hansen et
al. assessed the frequency and motives for measuring blood glucose concentrations among
patients with type 1 diabetes (125). Of the 1,076 patients investigated, 3.4% reported not
performing any measurements. Of the ones performing the measurements, only 39% did it on a
daily basis, and almost a quarter less than once a week. Higher age, female sex, and living with a
partner were the demographic characteristics positively related to the testing frequency. Of the
clinical characteristics, longer diabetes duration, multiple insulin injection therapy, lower HbA1c,
reduced hypoglycaemia awareness, and the number of mild hypoglycaemic episodes during the
preceding week were associated with a higher testing frequency. Of the late diabetic
complications, only autonomic neuropathy was positively associated with the testing frequency.
In the same study, 44% of the participants reported performing routine checks, while suspicion
of hypo- or hyperglycaemia motivated the measurements in 33% of the respondents. The
remaining participants reported a combination of these two as their motives for blood glucose
monitoring. In the multivariate model, age and severe hypoglycaemia within the preceding year
were positively, while the number of cigarettes smoked per day was negatively associated with
routine testing.
The association between the frequency of blood glucose monitoring and metabolic control
have been evaluated in a number of studies. Karter et al. reported that patients with type 1
diabetes  who  monitored  their  blood  glucose  concentrations  at  least  three  times  per  day,  as
recommended by the American Diabetes Association, had 1.0 percentage points lower HbA1c
levels compared to those with less frequent monitoring patterns (126). Schütt et al. investigated
the self monitoring of blood glucose among 19,491 patients with type 1 diabetes (127). In their
study, patients with type 1 diabetes performed, on average, 4.4 measurements of blood glucose
per day. Adjusted for age, gender, diabetes duration, insulin therapy, and study centre, the
monitoring frequency was associated with better metabolic control. With each additional
measurement per day, a reduction of 0.26 percentage points in HbA1c was observed. Evans et al.
studied the relation between the frequency of blood glucose monitoring and glycaemic control
among patients with type 1 and type 2 diabetes (122). In their study, increasing monitoring
frequency was associated with an improved glycaemic control in patients with type 1 diabetes.
However, no such association was observed in type 2 diabetes. Abdelgadir et al. later replicated
these results (128). Although it seems that the link between frequent blood glucose monitoring
and better glycaemic control is evident at least among patients with type 1 diabetes, a number of
studies have confirmed that patients with type 2 diabetes may also benefit from intensified blood
glucose monitoring (126, 129-131).
Continuous blood glucose monitors, that determine the glucose concentration of the
interstitial fluid on a continuous basis, are increasingly available. Compared to traditional self-
monitoring, continuous glucose monitoring systems offer a longer-term ongoing display of the
glucose concentrations. Particularly useful are the “real-time” applications that provide direct
feedback enabling self-learning and immediate corrective actions. To further improve safety,
monitors may be set to alarm when glucose concentrations beyond selected thresholds are traced.
The clinical effectiveness of these monitors in improving metabolic control was evaluated in a
meta-analysis that included six trials (132). In the studies included, 449 participants were
randomised to the use of continuous glucose monitoring devices, while 443 participants self-
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monitored their blood glucose. According to the results, continuous glucose monitoring was
associated with significant reductions in the HbA1c as compared with self-monitoring. Those
with the highest HbA1c values at baseline, and the ones most frequently using the sensors were
observed to benefit the most. Moreover, exposure to hypoglycaemia was also reduced during
continuous glucose monitoring.
2.4.2 Insulin administration
Due to the lack of sufficient endogenous insulin secretion, type 1 diabetes is characterized by
increased blood glucose concentrations. Thus, these patients rely on the delivery of exogenous
insulin for survival. In the pre-insulin era, no effective treatment for type 1 diabetes existed.
Some patients were, however, treated with the so called “starvation diet” advocated by doctor
Frederick Madison Allen (1879–1964). Central for this diet was an extensive reduction in energy
intake, especially that derived from carbohydrates. Although not completely successful, that
regimen could prolong life by a few years, at best.
The discovery of insulin in 1921 drastically changed the prognosis of individuals affected
with the disease, and since insulin became widely available it has constituted the cornerstone in
the management of type 1 diabetes. The general aim of exogenous insulin administration is to
mimic  the  effects  of  insulin  that  is  normally  excreted  from  the  pancreas.  In  practice,  with  the
insulin treatment one aims to keep the blood glucose concentrations at near normal levels.
Today intensive insulin therapy, whether with multiple daily injections or via an insulin
pump, is considered the best form of treatment in type 1 diabetes (39). In the insulin pump
therapy, small doses of rapid or short acting insulin are continuously administered via an insulin
pump to compensate for the missing basal insulin excretion. In the multiple daily injection
therapy, however, long acting basal insulin is injected once or twice a day with the aim at
mimicking the basal insulin production of the pancreas during night time and between meals. In
both forms of therapy, the basal insulin administration is accompanied with further doses of
rapid or short acting bolus insulin at meal times. Depending on the insulin preparation, the
activity of long acting insulin usually lasts between 8 and 24 hours. The activity of the bolus
insulin, however, peaks within hours from the administration and are thus used to compensate for
the meal-induced increase in blood glucose. Short acting insulin should be administered
approximately 30 minutes prior to a carbohydrate containing meal, while rapid acting insulin,
due to its faster action, can be administered immediately prior to or even right after the meal.
The required amount of bolus insulin depends on the amount of carbohydrates in the meal.
Carbohydrates are found in various quantities in different food items, and patients with diabetes
may use information from the food labels and various databases when assessing the carbohydrate
content in a given meal. After having identified how many grams of carbohydrates there are in
the meal, the patient will need to match it with an appropriate dose of insulin. Due to differences
in insulin sensitivity, however, substantial individual variation is found in the amount of insulin
required. Anywhere between 0.5 and 2 units of bolus insulin may be required for each 10 grams
of carbohydrates ingested (133). To find an appropriate carbohydrate-insulin-ratio, blood glucose
concentrations should be measured preprandially and 1.5–2 hours postprandially. In practice, the
27
amount of administered bolus insulin is sufficient when the postprandial rise in blood glucose
does not exceed 3 mmol/l.
In addition to the carbohydrate content of the meals, a number of other factors also influence
how much insulin is needed (Table  1). One of these factors is physical activity. Due to an
exercise-induced increase in insulin sensitivity and muscle glucose uptake, the amount of
exogenous insulin required may be reduced. Importantly, the hypoglycaemia-inducing effects of
exercise may extend beyond several hours after the activity has been discontinued (134). Another
factor that needs to be considered when administering bolus insulin is the preprandial blood
glucose  concentration;  when  experiencing  hypoglycaemia  prior  to  meal,  for  example,  bolus
insulin dose may need to be reduced. The ratio of insulin required to restore blood glucose
concentration may also vary according to the time of the day. The term “dawn phenomenon” is
used to describe an increased need of insulin to maintain normoglycaemia during the early
morning hours among some individuals with diabetes. This phenomenon has been associated
with a growth hormone-mediated impairment of insulin sensitivity in the liver and muscles.
Moreover, the current health status may modify how much insulin is needed. During critical
illness and psychological stress, the interactions that take place between the hypothalamic-
pituitary-adrenal axis, counter-regulatory hormones, and cytokines promote glucose production
and insulin resistance (135). As a net effect, these alterations induce hyperglycaemia. Therefore,
when ill, blood glucose concentration should be carefully monitored and appropriate insulin
administration continued even if caloric intake is reduced.
Table 1. Factors affecting the need of exogenous insulin in patients with type 1 diabetes
Factor Effect on the need of exogenous insulin
Insulin sensitivity Individuals with reduced insulin sensitivity require higher doses
of insulin to maintain normoglycaemia
Blood glucose concentration In case of increased blood glucose concentrations, higher
insulin doses are required to restore normoglycaemia
Meal carbohydrate content  With higher intake of carbohydrates, more insulin is needed
Physical activity When physically active, insulin dose may need to be reduced.
However, potential hyperglycaemia (>16.7 mmol/l or >13.9
mmol/l with signs of ketosis) should be corrected prior to intense
performance.
Illness/Stress With increased glucose production and insulin resistance, insulin
dose may need to be increased
Considering the multitude of factors associated with blood glucose concentrations,
assessment of the proper insulin dose may be challenging (136). Therefore sufficient patient
education is required. One example of such training course is The Düsseldorf Diabetes
Treatment and Teaching Programme (DTTP), first introduced in 1978. The DTTP consists of a
5-day structured inpatient training course for intensive insulin therapy. During this training,
patients are instructed how to match their insulin dose to the selected foods while maintaining
normoglycaemia. Since 1992 follow-up data on glycaemic control and severe hypoglycaemia of
participants have been collected. One year after the training course, data from a total of 9,583
patients revealed a reduction in patients’ mean HbA1c from 8.1% to 7.3% (137). Moreover, the
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program proved efficient in reducing the incidence of severe hypoglycaemia (from 0.37 to 0.14
per patient year).
Based on the experience obtained from the DTTP, the Dose Adjustment for Normal Eating
(DAFNE) trial was launched in the UK (138). However, to keep the costs down, outpatient
education was now provided as opposed to the inpatient training given in the DTTP. For the
DAFNE trial, adult patients with type 1 diabetes whose glycaemic control was moderate or poor
(HbA1c 7.5–12%) were recruited. Eligible patients had a diabetes duration of more than two
years and no advanced complications. In the trial, the patients were randomised to receive
training immediately (immediate DAFNE) or to continue with their usual care for six months and
only then receive the training (delayed DAFNE). In the five-day outpatient training, provided in
small groups, patients were instructed how to estimate a correct insulin dose by matching to the
carbohydrate content in each meal, rather than adapting the timing and content of meals to a
fixed insulin dose. In all, 169 patients participated in the trial. At six months, those in the
immediate DAFNE had lower HbA1c levels than the ones in the delayed DAFNE (8.4% vs.
9.4%).  This  was  achieved  without  increasing  the  risk  of  severe  hypoglycaemia.  Moreover,  the
dietary freedom and overall quality of life had significantly improved among those who received
training immediately.
DAFNE training has also been adopted in other places such as Australia,  where an audit  of
clinical outcomes after one year post training revealed a mean reduction of HbA1c from 8.2% to
7.8% (139). Compared to baseline, severe hypoglycaemic episodes were observed less frequently
after the training, and patients reported improved quality of life. Moreover, a small but
significant decrease in mean weight was observed (75.1 to 74.2 kg). The 5-day outpatient
training program was also implemented in Austria, where the reduction in the HbA1c and severe
hypoglycaemia sustained 3 and 12 years, respectively (140). Importantly, structured education
programs have been shown not only to improve outcomes but also to be cost-effective (137, 138,
141).
Despite the explicit benefits of intensive insulin therapy, a large portion of patients do not
reach the targeted HbA1c levels (32, 34, 142). One of the potential obstacles to good glycaemic
control is the increased risk of hypoglycaemic episodes associated with intensified insulin
therapy. In the DCCT, the incidence of severe hypoglycaemia was almost three times higher in
the intensive treatment group compared to the conventional therapy group (32). In another study,
during a 3 year period, 57% of the participants in the intensively treated, as compared to 23% of
those conventionally treated, experienced severe hypoglycaemic episodes (143). To reduce the
risk of hypoglycaemia, some patients may deliberately maintain mild hyperglycaemia. Indeed,
there is some evidence that fear of hypoglycaemia may impact the management of diabetes
(144). Another factor that might reduce the enthusiasm for intensive insulin treatment is weight
gain  that  is  occasionally  associated  with  it.  In  the  DCCT,  after  a  mean follow-up of  6.5  years,
33.1% and 19.1% of patients intensively and conventionally treated, respectively, were obese
(145). Importantly, those intensively treated patients who gained most weight exhibited a marked
increase in the CVD risk factors compared to those in the lowest quartile of weight gain (146).
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2.4.3 Diet
Nutrition  plays  a  central  part  in  the  daily  management  of  diabetes.  The  main  goal  of  nutrition
therapy is to help individuals optimize their metabolic control. In addition to glycaemic control,
actions to attain and maintain normal blood lipid concentrations, blood pressure, and body
weight, while taking into account personal and cultural preferences, are encouraged (147).
2.4.3.1 Dietary recommendations
Consistent with the recommendations for individuals without diabetes, patients with diabetes are
instructed to eat a healthy, balanced diet that provides sufficient amounts of energy and nutrients
to cover the individual needs (148). The majority of the daily energy intake should be derived
from carbohydrates (Table  2), intake of which should be distributed to different meals
throughout the day. Carbohydrate-containing foods such as legumes, fruits, vegetables and whole
grain products are not only a good source of energy but also contain vitamins, minerals and fibre.
Abundant intake of dietary fibre may help patients reduce glycaemia. Reflecting this, the
recommendations for fibre intake are, indeed, higher in patients with diabetes as compared to
those in the general population (148, 149).
Table 2. Recommendations for daily macronutrient and fibre intakes for adult patients with
diabetes
Nutrient Patients with diabetes (148) Healthy population (150)
Carbohydrates 45–60 50–60
   Sucrose <10 <10
Fibre, g 40 (or 20 / 4.2 MJ) 25–35  (or 12.6 / 4.2 MJ)
Fats 25–35 25–35
   SAFA and TFA <10 <10
   MUFA 10–20 10–15
   PUFA 5–10 5–10
Protein 10–20 10–20
Alcohol <5 <5
NaCl, g <6 <6 (women), <7 (men)
Recommendations are presented as percentage of total daily energy intake unless otherwise
stated; SAFA, saturated fatty acids; TFA, trans fatty acids; MUFA, monounsaturated fatty acids;
PUFA, polyunsaturated fatty acids.
Carbohydrate containing foods differ in their ability to increase the blood glucose
concentrations. To describe this difference, a glycaemic index has been calculated for various
food items. In this process, the area under the 2-hour blood glucose response curve that follows
the ingestion of a food item with a fixed carbohydrate load (50 g) is divided by that of a control
item (glucose or white bread) of an equal-carbohydrate load. The figure is then multiplied by 100
to obtain the glycaemic index. Of interest for diabetes management, a recent meta-analysis
reported a significant decrease in HbA1c following a low glycaemic index diet compared to the
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control diet (151). Adhering to the current dietary recommendations generally ensures that items
with low glycaemic index, such as fruits, vegetables, legumes and whole grain products, are
selected. Therefore, the glycaemic index has not been strongly promoted in the current dietary
recommendations (147, 148).
The intake of fat should be moderate. Due to its high energy content, moderation in fat intake
may be necessary in the prevention of obesity. In addition to the total amount of fat consumed,
attention  is  also  paid  to  the  distribution  of  different  fatty  acids.  In  specific,  reduced  intake  of
saturated and trans fatty acids are frequently stressed as they have been associated with increased
CHD risk (147-149). Based on recent evidence, the reduction in CHD risk seems most
pronounced when dietary saturated fatty acids are replaced with polyunsaturated fatty acids
(152). A number of other effects of dietary fatty acids have also been reported, including effects
on the serum lipoprotein concentrations (153), insulin sensitivity (154, 155), blood pressure
(156), serum triglyceride content (157), and coagulation factors (158). To ensure favourable fatty
acid intake, consumption of vegetable oil-based spreads, cooking oil, and fish 2–3 times a week
are recommended.
The remaining amount of daily energy should be obtained from protein. Currently, the
recommended daily allowance is 0.8 g of good-quality protein/kg body weight (159). This
amount is considered sufficient to maintain the nitrogen balance in an adult subject keeping a
stable weight. Proteins considered to have a good quality provide all the indispensable amino
acids (isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, and
histidine). Examples of such foodstuffs are meat, poultry, fish, eggs, milk, and soy. High-protein
diets, sometimes advocated for weight loss, are not currently recommended, as their long-term
health effects are not known. In patients with diabetic nephropathy, protein restriction may delay
the progression of the condition (160). In order to prevent malnutrition, however, daily protein
intake should not fall below 0.6 g/kg body weight, in these patients.
The consumption of alcohol should be limited to less than 5% of the total energy intake per
day. Abstinence from alcohol is, however, strongly recommended for pregnant and lactating
women, and for those with medical conditions such as liver diseases, pancreatitis, advanced
neuropathy, hypertriglyceridaemia or high blood pressure. Due to its high energy content,
excessive alcohol consumption may also contribute to obesity. If alcohol is consumed, patients
with type 1 diabetes are encouraged to drink it with food in order to avoid hypoglycaemia.
Moderate consumption of alcohol has shown to evoke cardioprotective changes in the
vasculature, such as increase in circulating levels of HDL cholesterol, apolipoprotein A1, and
adiponectin and decrease in fibrinogen levels (161). In line with these findings, light to moderate
alcohol consumption has been shown to reduce the risks of many cardiovascular outcomes, such
as  incident  CHD,  and  CVD  mortality  (162).  In  the  same  study,  more  abundant  alcohol
consumption, however, substantially increased the risks of various cardiovascular outcomes.
Similarly, among patients with type 1 diabetes, a U-shaped association between alcohol
consumption and risk of microvascular complications has been observed (163).
To control their blood pressure, patients with diabetes are recommended to restrict their salt
intake to less than 6 grams per day. Even stricter recommendations may be applied to individuals
with hypertension (164). Indeed, sodium restriction has shown to reduce blood pressure both in
hypertensive individuals (165) and among patients with diabetes (166). Recently the benefits of
reduced salt consumption have, however, been questioned (167-169). Longitudinal study
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conducted in the general population showed that those restricting their sodium chloride intake to
6.3 grams per day (mean 24-hour urinary sodium excretion of 107 mmol) had the highest hazard
ratio  of  CVD  deaths  (167).  These  were  followed  by  those  with  a  mean  daily  sodium  chloride
intake of 9.8 grams and 15.2 grams, respectively. Importantly, in their study patients with a
history of cardiovascular diseases were excluded. In patients with type 2 diabetes, Ekinci et al.
observed a 28% decrease in all-cause mortality for every 100 mmol rise in the 24-hour urinary
sodium excretion (168). Finally, a U-shaped association between urinary sodium excretion and
all-cause mortality was observed in patients with type 1 diabetes (169). In their study, urinary
sodium excretion was, however, inversely associated with the cumulative incidence of end-stage
renal disease. It should be noted that all the three above-mentioned studies relied on a single
urine collection, which may be insufficient to characterize habitual salt intake. Therefore, further
studies are needed to confirm these observations. Importantly, however, dietary sodium
restriction is associated with an increase in sympathetic nervous system activity (170), renin-
angiotensin-aldosterone system activity (171), insulin resistance (172, 173), and LDL
concentration (171). These are all factors that may be adversely associated with cardiovascular
events, and activation of these pathways, especially in patients with type 1 diabetes, may
overshadow any gains achieved from modest blood pressure lowering.
2.4.3.2 Dietary assessment
A number of different methods to assess food and nutrient intake are available (174). Factors
such as type of information required, target group, time frame, and costs involved need to be
taken into account when choosing the dietary assessment method. Using retrospective methods,
including 24-hour recall, questionnaires (e.g., food frequency), semiquantitative food frequency
recall, and diet history, it is possible to collect data on individual’s dietary intake during a given
time period in the past. In the 24-hour recall method, a trained interviewer aims at revealing in
detail all foods and drinks the respondent has consumed during the past 24 hours. During the
interview, various food models, photographic aids, and household measures may be used to
improve the accuracy of reporting the portion sizes. In order to capture data from weekdays and
week-end days, interviews need to be conducted during various days of the week. Due to the fact
that only one day is covered, the method is not suitable for assessing the habitual diet at an
individual level, but is more appropriately applied in a larger population. In the diet history
method, a structured interview is conducted with the aim to reveal the habitual dietary intake
during a lengthy period of time in the past (e.g., 6 or 12 months). During the interview, questions
regarding the habitual intake of central food groups (e.g., meat, dairy, cereals, fruits and
vegetables) during the past 7 days are presented. After this, the interview is extended to cover the
remaining time period of interest. Occasionally, a 3-day food record may also be used as a basis
of the interview. Food frequency questionnaire (FFQ) is a method to determine how often certain
food items are consumed. In this method a list of food items of special interest are provided
together with a panel of consumption frequencies (e.g., twice a day, once a week). For each food
item, the respondent selects the frequency that best describes his habitual consumption pattern.
With this method, qualitative data on dietary intake may be obtained. However, with the use of
semiquantitative FFQ, one is also able to collect data on portion sizes. In this method, the
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respondent either selects from a choice of portion sizes or standardized portion sizes are
alternatively used. Such self-report questionnaires are better suited for large studies, where
administration of diet records or 24-hour recalls, for example, would be too costly. Compared to
many other methods, FFQ may also be better for obtaining data on the consumption of food
items with high day-to-day variability. The retrospective methods, however, heavily rely on
individual’s memory and motivation. Moreover, accuracy of the recall may be related to the
interviewer’s and respondent’s characteristics, interview setting, instructions provided, and
characteristics of the respondent’s diet.
When using prospective methods, data are collected at the time the food is consumed or
shortly thereafter. These methods, that include diet records, collection of duplicate portions of
foods eaten, and observer monitoring, are less influenced by forgetting. The very act of recording
may, however, affect habitual intake or the willingness to report certain food items. In the diet
record method, respondents report in detail all foods and beverages consumed during the
allocated time period (usually 3-7 days). To improve the accuracy of the data collected, the
respondents are encouraged to report food preparation methods and portion sizes (either
estimated or weighted). Some individuals may consider the method burdensome, however, and
refuse to complete the record. Moreover, the method may change eating behaviour and/or cause
under- or over reporting for items that are considered unhealthy and healthy, respectively. The
method is,  however,  flexible  in  a  sense  that  it  is  not  restricted  by  a  fixed  food  list  as  FFQ,  for
example. In the duplicate portion method, the respondent collects a duplicate of each food item
and beverage consumed during a given period. The duplicate portion is then weighted and
subsequently chemically analysed. With the use of this method, one is able to collect accurate
data on a nutrient level. However, the method is expensive and calls for highly motivated
participants. Observer monitoring provides objective data on dietary intake. As a method it is,
however, labour intensive and thus expensive. Although it is not suitable for large studies, it may
occasionally be used to validate other dietary assessment methods.
To increase the accuracy of dietary data, different methods that vary with respect to their
strengths and weaknesses may be simultaneously used. Indeed in research, retrospective and
prospective  methods  are  sometimes  applied  within  the  same  protocol.  It  should  also  be  noted
that,  at  an  individual  level,  dietary  intake  often  varies  not  only  on  a  day-to-day  basis  but  also
from one season to another. An effort should be made to include various time periods, such as
weekdays and weekend days, and different seasons into the panel of observed days. To improve
reproducibility, the number of days observed may also be increased. Importantly, the number of
days required to reliably describe the usual intake of various foods and nutrients differ
substantially not only according to the food or nutrient in question but also to the characteristics
of the study population. In one study, for example, the number of days required to reliably
describe energy, macronutrient, sodium, potassium, phosphorus, and niacin intake varied from 3
to 6 days (175). However, to accurately describe vitamin A intake, up to 44 days were required.
Moreover, sufficient number of observed individuals are required in order to reliably study group
level differences in a research setting.
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2.4.3.3 Dietary intake in type 1 diabetes
Dietary intakes of adult patients with diabetes have been evaluated in a number of studies. One
of them is the EURODIAB IDDM Complications Study, in which nutritional intake and
compliance with dietary recommendations among insulin treated patients in 16 European
countries were assessed (176). In this study, data on dietary intake from 2,868 participants were
collected using a 3-day diet record. The EURODIAB study indicated a number of deviances
from the dietary recommendations in patients with type 1 diabetes. First, the average proportion
of fat-derived energy (mean ± SD, 38 ± 7 E%) exceeded the recommendations, and roughly one
third of the respondents reported a total fat intake within the recommended level. Second, the
intake of saturated fatty acids (14 ± 4 E%) also exceeded those recommended, with only 14% of
the patients meeting the recommendations. Third, the mean carbohydrate intake was 43 ± 7 E%,
and was thus below that recommended; only 15% of the participants reached the prevailing
carbohydrate recommendations. In line with the low carbohydrate intakes, a mere 0.4% of the
patients reached the recommended level for fibre intakes. Of the nutrients studied, protein
recommendations were, however, most frequently met (77%).
The Diabetes Nutrition and Complications Trial was conducted among 192 Spanish patients
with longstanding diabetes (either type 1 or type 2) (177). In this study, dietary data collected
with a 7-day diet record, revealed that adherence to the ADA nutritional recommendations was,
again, low. As in the EURODIAB study, patients with diabetes frequently failed to meet the
recommendations for carbohydrate and saturated fatty acid intakes. During the median follow-up
of 6.5 years, adherence to each of the ADA recommendations was not associated with the
reduction in the onset or progression of diabetic complications. However, meeting the
recommendation for MUFA/SAFA ratio (>1.5) was associated with an almost 4-fold risk
reduction in the onset of each microvascular complication (neuropathy, nephropathy, and
retinopathy). Similarly, 8.2-, 5.3-, and 4.0-fold risk reductions in the onset of neuropathy,
nephropathy, and retinopathy were observed among patients who met the recommendations for
PUFA/SAFA ratio (>0.4).
Dietary intake of adult patients with type 1 diabetes was also assessed in a small Australian
study (178). In this study including 54 patients, data on dietary intake were collected with a diet
history interview. Once again, dietary intakes of total fat and saturated fatty acids frequently
exceeded the recommendations.
The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study examined the dietary
habits among adult patients with type 1 diabetes compared to healthy controls (179). In all, 571
patients with type 1 diabetes and 696 healthy controls provided food frequency questionnaires
with plausible energy intake. According to the results, patients with diabetes were less likely to
meet the dietary recommendations than controls. The ones with diabetes reported a diet higher in
fat, saturated fatty acids, and protein but lower in carbohydrates. Only 16% of the patients with
diabetes restricted their saturated fatty acid intake to <10 E%.
Suboptimal dietary intakes have also been observed in studies conducted among children and
adolescents  with  type  1  diabetes.  Generally,  the  recommendations  for  total  fat,  saturated  fatty
acids, fibre, fruits, vegetables, and grains, in these studies, are frequently unmet (180-182).
However, there is also evidence of healthier dietary habits among youth with diabetes compared
to their healthy peers. Specifically, more regular eating habits, higher consumption of fruits,
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potatoes and root vegetables, fish, and sugar-free sweets have been observed in young patients
with diabetes (183).
2.4.3.4 Dietary intake and glycaemia
A number of dietary factors have been associated with glycaemic control. In one study,
adherence to a diet high in fruits, vegetables, low-fat dairy products, whole grains, poultry, fish,
and nuts, but low in fats, red meat, sweets, and sugar-containing beverages was inversely
associated with HbA1c (184). In another study, patients with good glycaemic control (HbA1c
<7.0%) were more often observed to eat peas, beans and broccoli, fruits and berries, and fish
than those with poor control (HbA1c??8.5%) (183). Moreover, sugar-free juices and soft drinks
were consumed more frequently among those with poor control. In their paper Øverby et al.
reported that adolescents with HbA1c??7.5% had lower intake of added sugar, higher intake of
fibre, and higher intake of fruits and vegetables compared to those with suboptimal glycaemic
control (185). In the same study, high fibre intake and regular meal pattern were associated with
better metabolic control.
Within the EURODIAB study, the HbA1c concentrations were observed to increase with
increasing intakes of total and potato-derived carbohydrates, but decrease with higher intakes of
carbohydrates of vegetable origin (186). Independent of carbohydrate and energy intakes,
however, total fibre intake was inversely related to HbA1c (187). The association between dietary
intake and glycaemic control was also assessed in the DCCT, where a diet low in carbohydrates
and high in total and saturated fats was associated with higher HbA1c levels (188). Consistent
with these findings, total fat intake was positively, while calories derived from dietary fibre were
negatively correlated with the progression of retinopathy (189).
In their study of 54 individuals with diabetes Tahbaz et al. did not observe any associations
between nutrient intakes and glycaemic control (178). A limited number of study subjects may
have contributed to this finding.
In the CACTI study, total fat and saturated fatty acid intakes were positively, while that of
carbohydrates negatively associated with HbA1c and many of the CHD risk factors (including
total, LDL-, and non-HDL cholesterol, Apolipoprotein B, diastolic blood pressure, and body
mass index) (179). Moreover, a high fat diet and high protein intake were associated with greater
odds of coronary artery calcification, reduced odds of which were observed in higher
carbohydrate intakes.
2.4.4 Physical activity
Physical activity refers to any energy requiring bodily movement that is produced by skeletal
muscles (190). Components that make up the physical activity profile are intensity, frequency
and duration, of which intensity refers to the level of strenuousness of the activity, frequency to
how often one participates in the activity, and duration to the time dedicated to the activity
during a given session. Another dimension of physical activity is the type of activity, e.g.,
jogging, skiing, and swimming.
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Regular physical activity has many health benefits (191). Besides its role in weight
management, physical activity has shown to reduce the risks of premature death, CHD, stroke,
type 2 diabetes, colon cancer, breast cancer, osteoporosis, and depression. Moreover, being
physically active is beneficial in reducing risk factors such as high blood pressure and high
cholesterol concentrations. A number of physiological changes related to various physical
activities have been identified that may explain some of the observed health benefits (192).
Among these are increased stroke volume, increased capillary density, increased bone density,
improved insulin sensitivity, improved immune function, and a reduced tendency of blood
coagulation.
2.4.4.1 Exercise-related changes in the metabolism
A number of metabolic changes, that are relevant for patients with diabetes, take place during
exercise (193). In healthy individuals, exercise-related decrease in plasma glucose concentrations
is associated with activation of glucose counterregulatory mechanisms such as increased
glucagon, adrenalin, noradrenalin, growth hormone, cortisol, and autonomic nervous system
responses (194). These changes are accompanied by a decrease in the plasma insulin
concentration. Together these homeostatic responses result in increased lipolysis, increased
endogenous glucose production and reduced glucose uptake in tissues other than skeletal muscle.
As a result, these changes ensure that a sufficient amount of fuel is available as energy
throughout the body.
In patients with type 1 diabetes, who rely on exogenous insulin, exercise does not reduce the
insulin concentration (195). On the contrary, with an increased absorption of insulin from the site
of injection, the plasma insulin concentration may even increase. In addition to the potential
hyperinsulinaemia, patients with type 1 diabetes also experience a loss in their glucagon response
(194). Together these metabolic abnormalities impair the release of glucose from the liver during
exercise. Inhibition of the glycogenolysis and the gluconeogenesis compromise the ability to
mobilize carbohydrates for fuel and hypoglycaemia will prevail. The risk of hypoglycaemia is
particularly related to moderate-intensity exercise for which energy is predominantly derived
from aerobic oxidation of carbohydrate and fat (193). Importantly, due to exercise-induced
increase in insulin sensitivity and repletion of muscle glycogen stores, the risk of hypoglycaemia
may be extended several hours after the exercise session (196).
Unlike in moderate-intensity exercise, patients with type 1 diabetes may experience a
progressive rise in their blood glucose concentrations during high-intensity exercise (193). High-
intensity exercise is characterised by intense activities of short duration that are predominantly
fuelled by creatine phosphate and anaerobic glycolysis. The rise in glycaemia, during high-
intensity exercise, results from an increase in the circulating levels of catecholamines and growth
hormone, and activation of the sympathetic nervous system, which boost the hepatic glucose
production.  Hyperglycaemia  results  if  the  production  of  glucose  exceeds  the  rate  of  its
utilization. In such a hyperglycaemic, hypoinsulinaemic condition individuals with type 1
diabetes are also at risk for ketoacidosis (197). The combination of insulin deficiency and
increased concentration of counterregulatory hormones leads to lipolysis and subsequent
oxidation of fatty acids to ketone bodies in the liver. This results in metabolic acidosis which, if
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not treated, may lead to death. Exercise is not, however, the only factor that may predispose to
the development of ketoacidosis. The condition is sometimes observed in relation to infections,
alcohol abuse, and pancreatitis. Moreover, ketoacidosis is occasionally detected in patients with
new-onset type 1 diabetes.
2.4.4.2 Recommendations related to physical activity
According to the current recommendations, a minimum of 30 minutes of daily physical activity
of moderate or vigorous intensity, above the general energy expenditure associated with normal
daily living, is recommended to the adult population (149). Additional benefits are expected with
an  increase  in  duration  and  intensity  of  the  activity.  Although a  number  of  factors  needs  to  be
taken  into  account,  patients  with  type  1  diabetes  may  also  participate  in  all  levels  of  physical
activity, given that they are in good glucose control and have no complications (196).
Importantly, patients with type 1 diabetes should monitor their blood glucose concentrations
prior to and after taking part in physical activities (196). When prolonged or particularly intense,
monitoring may be advisable also during the exercise. To prevent hypoglycaemia, patients with
type 1 diabetes are instructed to ingest added carbohydrate if the plasma glucose concentration is
below  5.6  mmol/l  prior  to  the  exercise  (196).  The  patients  are  also  instructed  to  reduce  their
insulin dose prior to the activity in order to reduce the risk of hyperinsulinization (147).
Moreover, injecting insulin in body parts that are actively involved in the movement during
exercise is not advised (195). In patients using insulin pumps an unplanned exercise is easy to
manage by disconnecting the device immediately prior to the activity (198). However, for other
patients, intake of additional carbohydrate may be required for unplanned activities (147).
Moreover, during prolonged physical activity of moderate to high intensity, ingestion of 20–60
grams of carbohydrates per every 30 minutes may be required (199).
In order to prevent ketoacidosis, participation in physical activity is discouraged when the
fasting glucose concentrations exceed 16.7 mmol/l, or 13.9 mmol/l when signs of ketosis are
present (196). Hyperglycaemia should be corrected using rapid or short acting insulin prior to
engaging in intense physical activities.
2.4.4.3 Assessment of physical activity
Physical activity can be assessed using various techniques that can be grouped into five
categories: behavioural observation, calorimetry, physiological markers, motion sensors, and
interviews and questionnaires. Behavioural observation is time consuming and resource
intensive, and is therefore not practical for daily routine monitoring or to be used in large-scale
studies. Direct calorimetry is a method to measure heat production (200). Measurement is
performed in a respiration chamber and is thus limited to studies that take place in the laboratory
environment. Energy expenditure can, however, also be measured indirectly with the use of
doubly labelled water (200). In this method, a dose of water labelled with the stable isotopes 2H
and 18O is given to the study subject. Deuterium is subsequently excreted as water, whereas the
oxygen isotope as water and CO2. Energy expenditure is assessed by measuring the excretion of
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these isotopes during a period of time. The difference between the two elimination rates is the
measure  of  CO2 production, and thus energy expenditure. Alternatively, estimation of energy
expenditure may be done using a formula to which data on oxygen consumption and carbon
dioxide production have been entered. The indirect calorimetry is regarded the gold standard
method to assess total energy expenditure, and is frequently used to validate other methods
(201).
Monitoring heart rate is another method to assess the level of physical activity (202). With
the use of a heart rate monitor one is able to, not only estimate frequency, intensity and duration
of physical activity, but also make fairly accurate estimates of the energy expenditure. The use of
heart rate monitoring is, however, limited because factors unrelated to physical activity may also
affect the heart rate. Another limiting factor is that changes in the heart rate may sometimes take
longer than changes in the levels of physical activity. Moreover, when performing similar tasks,
the  heart  rate  of  an  individual  with  a  higher  level  of  physical  fitness  is  slower  than  that  of  an
individual with a lower level of fitness.
Motion sensors, such as pedometers and accelerometers are easy to use and provide
continuous data on the subject’s movements during the monitoring period (202). They can be
applied to a large number of subjects over prolonged periods of time. The type of information
collected with a pedometer is, however, limited to the number of step counts accumulated (203).
Moreover  many  forms  of  activities,  such  as  those  performed  with  the  upper  extremities,  are
undetectable with the pedometers. Unattainable are also data on frequency, intensity and duration
of the activity. Some of these limitations may be overcome by the use of accelerometers which
record acceleration signals related to movements (204). Moreover, with the accelerometers one is
also able to estimate the time spent in inactivity. The use of accelerometers may, however,
underestimate various forms of physical activity, such as cycling and gym training. Development
of tri-axial accelerometers has enabled measurements of even minute movements in the three-
dimensional space.
When assessing physical activity in large-scale trials, the use of questionnaires, such as
diaries and recall questionnaires, is often most feasible. However, a number of limitations related
to these methods must be taken into account. First, methods that assess physical activity in the
past are limited by the ability of the respondents to recall relevant details retrospectively. Second,
the methods provide only subjective data and may be distorted by factors such as overestimation.
Moreover, completion of various activity diaries require a fairly large contribution form the
study subject, and may change the respondent’s behaviour. Despite these limitations, however,
questionnaires may be used to rank the individuals based on their level of physical activity (201).
2.4.4.4 Adherence to recommendations
A number of studies have assessed the adherence to the physical activity recommendations
among patients with type 1 diabetes. In a Canadian study among 697 patients with a mean age of
51 years, a total of 64% of the participants did not achieve the recommended levels of physical
activity (205). According to the results, factors associated with higher physical activity were
younger age, being single, higher income, and lower level of perceived disability. The
investigators concluded that higher levels of perceived disability may reflect the increased
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burden of diabetic complications. Thus, the findings highlight the need to individualize physical
activity programs around the individual’s specific limitations. In line with these findings, Wadén
et al. observed that physical activity was lower among patients with diabetic complications
(206). However they also found that patients with microalbuminuria, that is individuals without
any advanced diabetic complications, more frequently reported low-intensity physical activity
compared to those with normal urinary albumin excretion rate. According to the investigators,
these observations suggested that lower physical activity could actually precede the development
of microalbuminuria.
Observations from a Finnish study conducted in 213 adult patients with insulin-treated
diabetes revealed that only 35% of the participants engaged in some form of exercise on a daily
basis (123). Another 30% of the respondents participated in physical activities almost daily,
while a total of 14% were physically active less than once a week or never.
In a mixed population of adult patients with type 1 and type 2 diabetes, Thomas et al.
observed that one third of 406 patients reported that they had participated in exercise, sport or
physical activity during the preceding two weeks (207). Of these patients, only 9% exercised
sufficiently to achieve a substantial change in heart rate or breathing, while more than half of the
participants reported experiencing no such changes during exercise. The factors explaining
physical inactivity were patient’s perceived difficulty in taking part in exercise, tiredness,
distractions caused by television, lack of local facilities, and lack of spare time.
Brazeau et al. also investigated barriers to physical activity among adult patients with type 1
diabetes (208). Included in their study were one hundred participants with a mean age of 44
years and a suboptimal glucose control. According to the results, fear of hypoglycaemia was the
strongest barrier to physical activity. Other factors observed were work schedule, loss of control
over diabetes, and low levels of fitness. Interestingly, they also found that individuals with
greater perceived barriers to physical activity had poorer glycaemic control.
Participation in physical activities has also been investigated among youth. These studies
have provided mixed results. In one such study, sufficient adherence to the physical activity
recommendations among 91 children and adolescents with type 1 diabetes was found (209). In
all, 60% of the respondents reported spending a mean of 60 minutes a day in various activities,
while 2% of the patients reported not exercising at all. Another study of 101 children aged 10 to
18 years found that less than half of the participants engaged in daily exercise. Moreover, a total
of 43% of the children were found not to exercise at all (210). Yet in another study children with
type 1 diabetes, as opposed to healthy controls, were observed to be more sedentary (211).
Besides the diabetes status, female gender and older age were associated with low levels of
moderate to vigorous physical activity.
2.4.4.5 Physical activity and glycaemia
Despite the risks of exercise-related hypo- and hyperglycaemia, patients with type 1 diabetes
benefit from being physically active. In particular, considering the increased risk of
macrovascular complications, the favourable effects of physical activity on the vasculature are
highly valued. Unlike among patients with type 2 diabetes (212), the effects of physical activity
on glycaemic control in patients with type 1 diabetes are, however, less evident (213). One of the
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studies aiming to elaborate the association between physical activity and glycaemia in type 1
diabetes was conducted by the Hvidoere Study Group on Childhood Diabetes (214). In this
cross-sectional study among 2,269 adolescents from 19 countries, physical activity was
associated with markers of psychological health, such as greater well-being, less worry, and
better quality of life. However, no association was observed between physical activity and
glycaemic control. Similar conclusions have also been reached in a number of small exercise
interventions  (215-220).  In  one  of  the  most  recent  ones,  Wong  et  al.  reported  results  from  an
exercise intervention in 28 children and adolescents with type 1 diabetes (220). In their study, a
three-month home-based aerobic exercise intervention neither improved glycaemic control nor
peak oxygen uptake. In another study the effect of a 12- to 16 week aerobic exercise program on
fitness and lipid profile in young men with type 1 diabetes was evaluated (219). Despite a
number of beneficial effects, such as an increased peak oxygen consumption, and decreased total
cholesterol, LDL cholesterol, and apolipoprotein B concentrations, exercise did not improve the
HbA1c.  Moreover,  in  one  study  the  HbA1c actually increased during the three-month exercise
program (221).
A number of papers reporting an improvement in glycaemic control after exercise
intervention have also been published (222-224). Moreover, an association between higher
physical activity and better metabolic control has also been observed in cross-sectional settings.
For example in the FinnDiane –population, leisure-time physical activity was negatively
associated with HbA1c in women, but not in men (225). In another study it was observed that
children who spent either 120–360 minutes or 360–480 minutes in weekly exercise had better
glycaemic control compared to those whose weekly exercise lasted less than 60 minutes (209). In
line with these studies, greater physical fitness levels predicted better glycaemic control in
adolescents with type 1 diabetes (226). The cross-sectional studies are, however, limited in their
ability to reveal causality between physical activity and HbA1c as other lifestyle factors,
associated with physical activity, may explain the glycaemic control.
2.5 Psychological determinants
2.5.1 The theory of the sense of coherence
Aaron Antonovsky, a medical sociologist, advocated a salutogenic view of health. That is, rather
than stressing the factors that caused individuals get ill, as commonly done in medicine,
Antonovsky was drawn to find the reasons why people actually stayed healthy. One of the
reasons behind this quest was the observation that, although having gone through tremendous
experiences at the Nazi German concentrations camps, a number of survivors remained mentally
astonishingly well. Antonovsky believed that these individuals possessed certain qualities that
made them resilient to break down even under considerable strain. And strain, indeed, is
inevitable. In human existence stressors, originating from external or internal environment, are
omnipresent. Encountering these stressors creates tension. What stroke Antonovsky was that,
considering the multitude of various stressors, it is rather surprising how people manage to stay
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healthy in the first place. Importantly, Antonovsky believed that, rather than differing with
respect to the stressors encountered, individuals differed in how they perceived and handled
these stressors. Indeed, for Antonovsky, the importance lied in the tension management. With a
proper tension management, one may be able to prevent a stressor from turning into stress,
which, for Antonovsky, was a contributing factor in pathogenesis (9).
2.5.1.1 Generalized resistance resources and health
In his theory, Antonovsky stresses the significance of the generalized resistance resources
(GRRs). GRRs are any characteristics or resources of the person, the group, or the environment
that can facilitate effective tension management, that is coping (9). These resources may be
material,  such  as  money,  or  immaterial  like  knowledge,  self-esteem,  social  support,  and  health
behaviour. What is important is not only the availability of these resources but also whether or
not they are appropriately exploited. According to Antonovsky the extent to which life provides
us with a continued series of experiences, that build up the GRRs, is a major determinant in the
development of so called strong sense of coherence.
Another concept, nurtured by Antonovsky, was one about health. Antonovsky discouraged
the idea that health and disease, as concepts, could be located at opposite sides of the coin, as
often done in medicine. He, instead, envisioned a continuum of which opposite ends ease and
dis-ease would constitute (9). Individuals’ position on this imaginary continuum could then,
depending on the internal and external factors, oscillate between the these two poles. Thus, in
short,  what  is  common to  all  individuals  is  that  they  experience  stressors.  The  extent  to  which
one possesses and uses various generalized resistance resources determines how the tension, that
originated from the encounter with numerous stressors, is managed. The quality of this tension
management will, subsequently, determine individual’s position in the ease – dis-ease
continuum.
2.5.1.2 The sense of coherence
Based on these ideas, Antonovsky developed the theory about sense of coherence (SOC) (9,
227). According to Antonovsky, the SOC is
“a global orientation that expresses the extent to which one has a pervasive,
enduring though dynamic feeling of confidence that 1. the stimuli deriving
from one’s internal and external environments in the course of living are
structured, predictable, and explicable; 2. the resources are available to one
to meet the demands posed by these stimuli; and 3. these demands are
challenges, worthy of investment and engagement” (227).
The term SOC, thus,  refers to the individual’s capacity to form an authentic picture of his life,
and the ability to make use of all resources available to sustain and improve health. Central to
this ability were the concepts about comprehensibility, meaningfulness, and manageability (227).
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Comprehensibility is the cognitive component of the SOC, and it refers to the extent to which
individual perceives the confronted stimuli as something that makes sense, something that is
ordered, consistent and clear, rather than random, accidental and inexplicable. Meaningfulness,
the motivational component, refers to the extent to which a person feels that life makes sense
emotionally. Its manifestation tells that an individual feels that the challenges confronted during
the course of life are worthy of engagement rather than undesired burdens. Finally,
manageability  describes  individual’s  resources  that  are  at  his  disposal  at  the  time  they  are
needed, for example, when an untoward experience is encountered. Manageability represents the
behavioural or instrumental  component of the SOC. Lack of any of these three qualities would
then weaken the individual’s overall sense of coherence.
Antonovsky stressed that the SOC is an orientation, a way of looking at the world, that is not
specific to a particular place or situation (227). Subsequently, no direct association between SOC
and actual behaviour existed. The level of the SOC would rather explain the quality of
behaviour. The basis for this argument can be seen in the set of emotions aroused when
individuals face stressors. A person with a strong SOC would be more likely to experience
feelings of sadness, fear, anger, grief, and worry, as opposed to anxiety, rage, despair,
abandonment, and bewilderment, emotions of which would be faced by a person with a weak
SOC. Importantly, the first set of emotions provide motivational basis for action, while the latter
ones are paralyzing. Accordingly, when confronted with inevitable hardship or strain a person
with a strong as opposed to weak sense of coherence, would be more likely to choose corrective
actions and thus move towards the “ease” end of the health-disease continuum.
According to Antonovsky, the development of SOC starts in the infancy and lasts until the
early adulthood (227). In a favourable situation, during the course of early interactions between a
child and his primary caretaker(s), a child experiences feelings of security, consistency, and
continuity. These early experiences help the child to perceive the world as something that can be
counted on rather than something that is constantly changing. As a consequence, the child learns
to perceive the subsequent stimuli, that derive from the internal and external sources, as familiar
and predictable. Based on these early reinforcing experiences, the child forms a consistent image
of the world. The encountered experiences will thus promote the formation of a sound sense of
comprehensibility. Consistence of the responses is not, however, sufficient. What is also
important  is  the  quality  of  the  responses.  Indeed,  consistently  ignoring  the  child’s  needs  is  not
likely to support a healthy development of the SOC. For an auspicious development of the
meaningfulness component of the SOC, it is imperative that the child’s needs are adequately met.
Finally, the proper development of the last component of the SOC, that is manageability,
requires that the demands made upon the child are in an equilibrium with the resources available.
 While, according to Antonovsky, childhood is the time during which the basis of the SOC
are laid down, the development continues during the adolescence and early adulthood (227). The
occurrences taken place during this potentially restless period of life may either strengthen or
weaken the structure of the SOC that was established during the early development. At this time,
the development is particularly influenced by the engagements in long-lasting relationships,
social  roles  and  working  life.  In  the  third  decade  of  life,  after  having  exposed  to  a  pattern  of
experiences and having formulated a more or less comprehensible, meaningful, and manageable
image of the world, an individual has finally reached a somewhat fixed level of SOC. After this
point, Antonovsky argued, it would be unlikely that any radical changes in the level of SOC
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would take place. If, in some rare cases, permanent changes would take place, these would occur
if a new pattern of life experiences was maintained over a lengthy period of time (227).
Antonovsky argued that temporary changes in the SOC were possible, however. Any such
fluctuations around a mean could take place when an extremely intense life event would knock
an individual off the balance. Restoration of the previous level of the SOC would afterwards be
expected. The stability of the SOC has later been questioned (228). However, there are studies
showing stability among individuals with initially higher levels of SOC (229), and in older age
groups (230). Moreover, according to a systematic review, SOC seems to be comparatively
stable, but perhaps not as stable as Antonovsky had initially assumed (231).
2.5.1.3 Measuring the sense of coherence
After having postulated his theory about the SOC, Antonovsky constructed the Orientation to
Life Questionnaire to measure it (227). The original 29-item questionnaire (SOC-29) consists of
eleven questions about comprehensibility, ten about manageability, and eight about
meaningfulness. A shorter version with 13 items (SOC-13) is also frequently used. Response to
each question is given in a Likert-type scale that ranges between 1 and 7. The SOC score is
calculated by adding up the responses circled. A number of replies (13 in the SOC-29) are
presented in an inverse order, however, and need to be reversed prior to calculating the score.
The total scores of the SOC-29 and SOC-13 questionnaires range from 29 to 203, and 13 to 91,
respectively. Higher scores denote stronger SOC. Antonovsky did not provide any definite cut-
off values for strong or weak SOC. Subsequently, the SOC scores are often treated as continuous
variables in statistical analyses (232-234). Alternatively, populations may be divided into
fractiles based on the SOC score distribution, and the differences between these fractiles are then
assessed (235-237). By 2006, the Orientation to Life Questionnaire had been translated at least
into 33 languages, and have been used in Western and non-Western countries alike (238). The
questionnaire has shown to be reliable, valid, and cross culturally applicable (231).
2.5.1.4 The sense of coherence in research
The association between SOC and various self care practices have been investigated in a number
of studies. Among these is the population based EPIC-Norfolk study in which 18,287
participants  without  any  pre-existing  diseases  at  baseline  completed  the  Orientation  to  Life
Questionnaire (239). Independent of age, social class, and education level, patients with strong
SOC were less likely to be current smokers, and less likely to be physically inactive. Moreover,
they reported higher intakes of fruits, vegetables, and fibre, but also alcohol compared to those
with weak SOC. The association between SOC and dietary intake was also assessed in the
Northern Sweden MONICA Project (240). The major aim of this study was to monitor trends in
the CVD mortality and morbidity, and to detect their underlying risk factors. In 1999, the
Orientation to Life Questionnaire was also applied together with a food frequency questionnaire.
The results from 4,991 participants revealed that individuals with higher SOC scores pursued
more health-promoting food choices. In both sexes, strong SOC was associated with higher
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intake of vegetables, boiled potatoes, and rye crisp bread, and lower intakes of food items such
as pizza, soft drinks, french fries, hamburgers, and candies. Another cross-sectional study of
3,403 working age participants evaluated the association between SOC and physical activity
(241). In this Finnish population-based sample frequent exercise was associated with higher SOC
scores. The positive association between physical activity and strong SOC have also been
demonstrated among students (242). In patients with diabetes who had gone through a lower
limb amputation, higher SOC scores are associated with better adherence to instructions related
to foot care (243).
Sense of coherence has also been associated with a number of endpoints. In a cross-sectional
setting, women with weak SOC were 3.7 times more likely to have type 2 diabetes compared to
those with strong SOC (244). Another cross-sectional study among patients with type 1 diabetes
found  that  patients  without  complications  or  with  only  one  complication  had  stronger  SOC
compared to those with two or more complications (245). In men aged ?50 years of age, weak
SOC at baseline was associated with almost a 50% increased risk of type 2 diabetes during a 18-
year follow-up (236). In women, weak SOC predicted sickness absences during a 4-year follow-
up, while in men SOC was only cross-sectionally associated with psychological and somatic
health complaints (246). During an 8 year follow-up in the Helsinki Heart Study, a 25% lower
CHD incidence was observed among men in the highest as opposed to the lowest SOC quintile
(247). Among white collar workers with weak SOC, the risk was up to 63% higher compared to
those with strongest SOC. Moreover, during a mean follow-up of 8.3 years, in the EPIC-Norfolk
study, strong SOC was associated with a 20% reduced risk of all-cause mortality (248).
The association between SOC and glycaemic control is not fully established. In one study, 88
newly  diagnosed  patients  with  type  2  diabetes  were  followed-up  in  order  to  assess  the
relationship between SOC and glycaemic control (249). In this study, no correlation was
observed between SOC score and HbA1c. Similarly, no association was observed between SOC
and glycaemia among Hong Kong Chinese adults with type 2 diabetes (250). Studies
investigating the effect of the SOC on glycaemia among patients with type 1 diabetes are scarce.
The only ones, to our knowledge, are papers by Richardson et al. (245) and Lundmand and
Norberg (251) who, again, found no such association. Interestingly Cohen and Kanter observed,
in a mixed population of patients with type 1 and 2 diabetes, that SOC was related to glycaemic
control but only through adherence with self care behaviours (252).
Suominen et al. investigated whether SOC would predict subjective state of health in a
longitudinal setting (253). In all, 1,976 individuals from a random sample of Finnish population
provided sufficient data to be included in the analyses. After adjusting for a number of factors,
including age and initial subjective state of health, the baseline level of SOC was associated with
the subjective state of health at four years. In a systematic review a positive relation between
strong SOC and perceived good health, that is less subjective complaints and symptoms of
illness,  was  reported  (238).  In  another  review,  strong  SOC  was  positively  associated  with  the
quality of life (254). Strong SOC has also been shown to be an important resource to protect
from burnout (255). Moreover, in patients with type 2 diabetes, higher SOC scores, denoting
stronger SOC, were associated with lower perceptions of stress (241), higher diabetes-specific
psychosocial self-efficacy (234) and lower fear of hypoglycaemia among insulin treated
individuals (250).
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2.5.2 Depression
According to the WHO, depression is globally the number one factor contributing to the years
lost due to disability (256). After hearing loss and refractive errors, it is the third leading
disabling condition world wide. Depression is also the third leading cause of global burden of
disease, overridden only by lower respiratory infections and diarrhoeal diseases. Moreover, it is
projected that by year 2030 depression will be the number one factor contributing to the burden
of disease. According to the Health 2000 survey, conducted among the Finnish population, 7%
of the female and 4% of male respondents aged ?30 years had experienced an episode of major
depression during the preceding 12 months (257). In the same survey, 18% and 6% of the 18–29
year old women and men, respectively, had experienced symptoms of depression that potentially
fulfil the criteria for the major depressive disorder (258).
Symptoms of depression include lowered mood, reduced energy and decreased level of
activity (259). During a depressive episode, individuals typically experience reduced capacity for
enjoyment and interest. Moreover, deteriorated ability to concentrate is often accompanied by
marked fatigue even in the face of minimal effort. According to the Diagnostic and Statistical
Manual of Mental Disorders major depression may be present when, during a period of at least
two weeks,  a  minimum of  five  out  of  nine  symptoms are  detected  (260).  At  least  one  of  these
symptoms must be either depressed mood or loss of interest, and the other accompanying
symptoms may be considerable weight loss or gain, sleeping disturbances, agitated behaviour,
fatigue, feelings of worthlessness or guilt, reduced ability to think, concentrate or make
decisions, and suicidal thoughts or attempts. Various symptoms of depression, thus, involve not
only affective but also behavioural, cognitive, and somatic spheres of the human existence.
Based on the severity of symptoms, mild, moderate, and severe forms of depression, with or
without psychotic features (such as delusions and hallucinations), are distinguished. A distinction
is also made between a single and recurrent episodes of depression. Major depressive disorders
tend to recur frequently, however (261-263). The recurrence during a 15 year follow-up is 35%
and 85% among the general population and in the specialised mental healthcare setting,
respectively (261). Factors associated with the likelihood of recurrence include female gender,
larger number of prior episodes, never marrying, and longer depression duration (262). The
presence of subclinical residual symptoms after an episode of depression also increases the risk
of a future relapse (261).
2.5.2.1 Assessing depression
According to the International Consensus Group on Depression, clinicians should periodically
screen all patients for depression (264). Short questionnaires have been developed for simple and
cost-effective screening. One such questionnaire is the 2-item Patient Health Questionnaire
(PHQ-2), which inquires about loss of interest or pleasure and feelings of depression and
hopelessness over the past two weeks (265). In case of high scores, diagnosis should be
confirmed with an in-depth diagnostic assessment. Indeed, in clinical practice, the depression
diagnosis  should  be  confirmed  with  a  clinical  interview,  and  the  presence  of  conditions
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sometimes mistaken for depression, such as bipolar disorder, substance abuse and certain
medical illnesses, should be excluded.
In epidemiological research use of clinical interview may not always be practical. Instead,
various self-report questionnaires are frequently used to assess the symptoms of depression. One
such questionnaire is the Beck Depression Inventory (BDI) (266), which has been validated as a
tool for measuring depression in diabetes (267). The questionnaire contains 21 multiple-choice
questions, of which 13 are designed to measure cognitive variables and the remaining 8 somatic
variables. Although some of the symptoms in the somatic set of questions (e.g., fatigue and
libido) are observed in depression and diabetes, alike, the use of the full 21-item questionnaire
has shown to effectively detect depression also among individuals with diabetes (267). Upon
completing the questionnaire, each reply is scored from 0 to 3, and all items are summed up to
calculate the BDI score. The obtained score ranges between 0 and 63, where higher scores
denote more severe symptoms of depression. In the analyses, the BDI score can be used as a
continuous variable (268, 269). Moreover, in patients with diabetes, a cut-off value ?16 has
shown to exhibit adequate predictive value for depression (267).
2.5.2.2 Depression in diabetes
Patients with diabetes have an increased risk of depression. This observation is, by no means, a
modern one. Already in 1674 Thomas Willis, a British physician, suggested that diabetes was the
result  of  ”sadness  or  long  sorrow” (270).  In  a  more  recent  contribution,  Engum et  al.  reported
their cross-sectional observations of self-rated depression in a population-based sample of 65,648
individuals (271). According to the results, patients with type 1 (15.2%) and type 2 (19.0%)
diabetes, as opposed to nondiabetic population (10.7%), were more likely to be depressed. In a
meta-analysis of controlled studies, Anderson et al. reported that, compared to healthy controls,
individuals with diabetes had twice the risk of depression (5). In the same paper, 14% and 29%
of the patients with type 1 diabetes were considered depressed based on a diagnostic interview
and the use of a self-report scale, respectively.
With regards to type 2 diabetes, there is prospective date suggesting that major depression at
baseline doubles the risk of incident diabetes (272). Applicable to patients with type 1 and type 2
alike,  the  nuisance  of  diabetes  management  and  complications  related  to  the  disease  may
increase the risk of depression. Furthermore, poor metabolic control may additionally negatively
affect mood (273). The complex interactions between psychological, physical, and genetic
factors may additionally contribute to the association in an unknown way.
A number of risk factors, including female gender, lower socioeconomic status, physical
impairment and comorbidities, have been associated with depression among patients with
diabetes (271, 274). Among other negative consequences, depression reduces affected
individuals quality of life (275) and increases health care costs (276).
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2.5.2.3 Consequences to glycaemia
Important in diabetes, depression may also negatively affect the self care behaviours. In a mixed
population of patients with type 1 and type 2 diabetes, depressive symptom severity was
associated  with  a  less  prudent  diet  and  a  reduced  adherence  to  medication  regimen  (276).
According to a meta-analysis, the association between depression and nonadherence to diabetes
self care is strongest for the missed medical appointments (277). Of the other self care
behaviours, dietary guidance is most frequently ignored, followed by recommendations for
medication regimen, exercise, and glucose monitoring. Gonzalez et al. observed that even low
levels of depressive symptoms, beyond clinical depression, have a negative effect on adherence
to self care (278).
Depression, via reduced adherence to various self care practices, may deleteriously affect
glycaemic control. The association between depression and glycaemia was evaluated in a meta-
analysis of 24 cross-sectional studies which included 2,817 patients with type 1 and type 2
diabetes (279). According to the results, depression was associated with hyperglycaemia in both
diabetes sub-types. A more recent study of 1,540 participants with diabetes, however, failed to
identify any such association (271). Moreover, a number of studies have observed an association
between depression and glycaemia only in patients with type 1 diabetes. In one of these studies,
symptoms of depression were associated with lower adherence to dietary recommendations and
exercise, poorer physical functioning, and higher diabetes symptom reporting in patients with
type 1 and type 2 diabetes alike (280). However, depression was related to higher HbA1c only in
patients with type 1 diabetes. Similar conclusions were drawn in the paper by van Tilburg et al.
(268). Importantly, they also reported that variations in depressive mood, even below the level of
clinical depression, negatively affected glycaemic control in these patients.
Rather than the type of diabetes, it has been suggested, the complexity of the treatment
regimen may be crucial in determining the association between depression and glycaemic control
(281). In the study by Surwit et al., no association between depressive symptoms and glycaemia
was observed in individuals treated with diet and exercise, oral medications, oral medications
together  with  insulin,  or  a  maximum of  2  daily  insulin  injections.  However,  in  patients  with  a
more complex insulin injection regimen consisting of ?3 daily injections, higher BDI scores
were positively related to HbA1c. The investigators proposed that in a more complex treatment
protocol more opportunities for the negative mood to impact self care may be present.
Lustman et  al.  set  up  a  study  to  investigate  whether  poor  diabetes  self  care  would  actually
mediate the effect between depression and glycaemic control in patients with type 1 diabetes
(282). In their study, symptoms of depression and diabetes self care were observed to correlate
not only with each other but also with HbA1c. In the regression analysis, however, symptoms of
depression predicted the level of HbA1c independently of self care practices. The results
suggested that, while adherence to self care regimen is important in type 1 diabetes, other factors
beyond self care behaviour may mediate the association between hyperglycaemia and
depression. Two potential candidates, due to their association with depression and their known
hyperglycaemic effects, are insulin resistance and abnormalities in cortisol metabolism (273).
A number of studies have been undertaken to evaluate whether improved mood would
subsequently result in reduced HbA1c. Winkley et al. published a meta-analysis of studies
investigating the effects of psychological interventions on glycaemic control in type 1 diabetes
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(283). Included were 21 studies, most of which had used cognitive behaviour therapy (CBT).
According to the results, psychological interventions improved glycaemic control in children and
adolescents but not in adults. Since the publication of this meta-analysis a number of more recent
studies have been conducted. In one such study, Ismail et al. observed that a combination of
motivational enhancement therapy and CBT is useful in reducing HbA1c in patients with type 1
diabetes  with  persistent  sub-optimal  glycaemic  control  (284).  In  another  study,  CBT  -based
intervention among patients with type 1 diabetes not only reduced the symptoms of depression,
but also reduced HbA1c compared to the control group (285). A 12-week CBT in patients with
type 1 and type 2 diabetes resulted in clinically meaningful reduction in depressive symptoms
during the 12 month follow-up (286). Despite this improvement, however, no changes were
observed either in HbA1c or fasting glucose concentrations. Snoek et al. assessed the effects of
group cognitive behavioural therapy and blood glucose awareness training among poorly
controlled patients with type 1 diabetes (287). At 12 month follow-up, neither forms of the
interventions had significant effect on glycaemic control. The therapy was, however, efficient in
reducing the HbA1c in those patients who had the highest depression scores at baseline.
In addition to the nonpharmacological interventions a number of interventions assessing the
effect  of  antidepressant  agents  or  a  combination  of  antidepressants  and  psychological
interventions have been conducted. Although many of these interventions have shown
improvements in the symptoms of depression, their effect on glycaemic control has either been
limited or has not differed from the control treatment (288-292).
2.5.2.4 Consequences to the metabolic syndrome and mortality
A number of studies have revealed an association between depression and the metabolic
syndrome or its components in the general population. One such study was conducted by
Capuron et al., who observed a cross-sectional association between the metabolic syndrome and
depressive symptoms in a population of 323 men (293). An another study among 425 middle-
aged women showed that individuals meeting the criteria for the metabolic syndrome at baseline
had also more symptoms of depression (269). Moreover, those with higher BDI scores at
baseline also had an elevated risk for developing the metabolic syndrome during the 7.4 years of
follow-up. Muhtz et al. investigated these phenomena in 215 healthy men and women (294). In
their study, depressive symptoms were not associated with the metabolic syndrome per se.
However, women with depressive symptoms exhibited larger waist circumference, higher fasting
blood glucose, lower HDL –cholesterol concentration, and higher diastolic blood pressure. In a
large cross-sectional study among 3,880 apparently healthy individuals depression was
associated with a 1.94-fold risk of having the metabolic syndrome in women (295). Of the
individual components of the metabolic syndrome, the presence of depression increased the risk
of elevated waist circumference (2.23-fold) and hyperglycaemia (2.44-fold). In men depression
increased the risk of fulfilling the waist circumference component of the syndrome (1.77-fold)
but was not, however, associated with the metabolic syndrome. In the Third National Health and
Nutrition Examination Survey the prevalence of the metabolic syndrome was higher among
women with a history of depression (296).
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Depression has been associated with increased mortality not only in general population (297),
but also in diabetes (7, 8, 298, 299). In order to evaluate the effect of depression on mortality,
Egede et al. set up a population-based survey including individuals with and without diabetes
(299). In this study, 10,025 participants were followed-up for a duration of 8 years. Compared to
the reference group with no depression or diabetes, the presence of depression increased the risk
of all-cause mortality by 20%, while diabetes alone increased the risk by 88%. Coexisting
diabetes and depression was, however, most detrimental as it was observed to more than double
the risk of mortality. In another population-based sample of 9,990 individuals, the association
between depression and mortality was also investigated (298). The results of that study revealed
that among individuals with diabetes, depressive symptoms were associated with a 54%
increased death hazard during a 10 year follow-up. However, no such association was observed
in individuals without diabetes. In another study, during a mean follow-up of 4.4 years, major
depression in patients with type 2 diabetes increased the risk of all-cause mortality by 52% (7).
Katon et al. assessed the effect of depression on mortality in a sample of 10,704 individuals with
diabetes (8). During a follow-up of two years, comorbid depression increased the risk of all-
cause mortality by 36%. Studies in patients with type 1 diabetes are scarce, however. One such
study revealed an increased CHD mortality in individuals with comorbid depression (300).
However, in that study, no other causes of deaths were explored.
A number of potential mechanisms linking depression to health consequences have been
suggested. Besides reduced adherence to various self care practices, discussed above, depression
has also been associated with dysregulation of the autonomic nervous system and the
hypothalamic-pituitary-adrenal axis (301). Such dysregulation causes increased release of
catecholamines and corticosteroids which, by altering the cardiac autonomic tone, promoting
procoagulant and proinflammatory processes, and prolonging the QT interval, negatively affect
the vasculature. Another candidate for explaining the excess cardiac morbidity and mortality,
observed in depression, is the cardiotoxic side effects of certain antidepressant agents (tricyclic
antidepressants and monoamine oxidase inhibitors) (301). Such cardiotoxicity is, however, likely
to account for only a minor part of the increased mortality, because the effects are rarely severe
or life threatening, and selective serotonin reuptake inhibitors, with no such effects, are currently
preferred. Finally, inflammation associated with depression (302) could serve as a mediating link
between depression and the metabolic syndrome (303) which, again, increases the risk of
cardiovascular morbidity and mortality (304, 305). Figure 2 shows the multitude of associations
among psychological factors, health behaviour, metabolic control and diabetic complications.
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Figure 2. Schematic representation of relationships among health behaviour, glycaemic control, diabetic complications, and psychological
determinants. An example of each type of association is provided. ANS, autonomic nervous system; HPA, hypothalamic-pituitary-adrenal.
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3. AIMS OF THE STUDY
Self-management, such as prudent dietary intake, is central in the daily management of type 1
diabetes. Patients’ understanding of the dietary recommendations may, however, partly affect
whether the recommendations are adhered to or not. The association between self-reported and
measured compliance with the dietary recommendations among patients with type 1 diabetes has
not been previously investigated. Patients with diabetes are frequently burdened with various
psychological disturbances. Such disturbances may affect the ability to effectively manage
diabetes, and therefore negatively affect the diabetes outcomes. With this respect, depression and
sense of coherence may be of interest.
Figure 3 presents the framework of this study. The specific aims were:
I To examine the energy and nutrient intakes of adult patients with type 1 diabetes  and to
evaluate whether the intakes correspond to the current dietary recommendations.
Moreover we studied if the self-reported compliance with dietary guidance is
associated with the measured compliance with dietary recommendations.
II To investigate the associations between sense of coherence and self care practices,
including dietary habits and physical activity among patients with type 1 diabetes.
III To investigate if sense of coherence is associated with diabetic microvascular
complications in a cross-sectional setting. We also assessed its association with
glycaemic control and patients’ perceptions of their disease.
IV To study whether depression is cross-sectionally associated with the metabolic
syndrome and its components in patients with type 1 diabetes.
V To prospectively investigate the association between depression and all-cause and
cause specific mortality in patients with type 1 diabetes.
Figure 3. Framework of the study
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4. SUBJECTS AND STUDY DESIGN
All study subjects are participants in the Finnish Diabetic Nephropathy (FinnDiane) Study.
FinnDiane is a prospective multicentre study with the aim to identify genetic, clinical, and
environmental risk factors for diabetic complications in patients with type 1 diabetes. The study
was launched in 1997, and a total of 77 centres around Finland collaborate to recruit and
examine patients. Included are all university central hospitals, 16 central hospitals, 26 regional
hospitals, and 30 primary health care centres. Due to a scattered distribution of the study sites,
the distribution of participants follows fairly closely that of the general population in Finland.
The study protocol has been approved by the Ethics Committee of Helsinki University Central
Hospital and a written informed consent was obtained from each patient prior to participation.
The study is carried out in accordance with the Declaration of Helsinki.
In the FinnDiane Study, patients with type 1 diabetes are studied both at baseline and follow-
up visits. The prospective phase of the study was launched in 2004. However, patients are also
recruited to the baseline phase on an ongoing basis. Currently more than 4,700 patients with type
1 diabetes have been examined at baseline. Moreover, data from almost 1,600 participants have
been collected at follow-up visits. Besides at study visits, data are also obtained from medical
files at hospital archives and various registers. Patients are also provided with various
questionnaires to fill in during the visits or shortly thereafter. All data collected are entered into
the web browser-based platform BC|SNPmax version 3.5-088 (Biocomputing Platforms Ltd,
Espoo, Finland).
4.1 Study I
The study design in the first study is cross-sectional. Included were data from all patients with
type 1 diabetes who had returned the diet questionnaire and had filled in at least one three-day
food record by the end of December 2009 (n=817). Of the respondents, 673 (82.4%) had filled in
all six days of food records. A total of 39% of the respondents were men. The mean age of the
population was 47.5 ± 12.1 years (mean ± standard deviation), and the average duration of
diabetes was 32.1 ± 12.9 years. More detailed information about the study population is
presented in Table 3.
4.2 Study II
Cross-sectional data are also analysed in the second study. A total of 1,104 (44% men)
participants were included in this study. All participants had filled in the Orientation to Life
Questionnaire. Data on dietary habits and physical activity were available from 735 and 883
participants, respectively. Table 3 provides descriptions of the total population included in this
study.
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4.3 Study III
Included in this cross-sectional study are data from 1,264 patients with type 1 diabetes (Table 3).
All individuals had filled in the Orientation to Life Questionnaire by April 2010. Moreover, they
had completed a questionnaire regarding their conceptions of type 1 diabetes, and had data
available regarding microvascular complications and HbA1c. A total of 45% of the respondents
were men, with an average age of 44.9 ± 12.4 years, and mean diabetes duration of 28.2 ± 12.7
years.
4.4 Study IV
The design in the third study is cross-sectional. Study comprises of all patients with type 1
diabetes who had data on depression and the components of the metabolic syndrome available
(n=1,226). Of these patients 45% were men (Table  3). Mean age of the study population was
45.2 ± 12.4 years and mean diabetes duration 28.3 ± 12.9 years.
4.5 Study V
This is a prospective study of 4,174 participants (51% men) that were followed for an average of
nine years. Mean age of the study subjects at baseline was 39.5 ± 12.3 years, and diabetes
duration 22.3 ± 12.3 More detailed description of study subjects at baseline is seen in Table 3.
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Table 3.  Baseline characteristics of the study subjects
Study I
n=817
Study II
n=1,104
Study III
n=1,264
Study IV
n=1,226
Study V
n=4,174
Men (%) 39.4 43.8 44.8 44.7 51.5
Age (years) 47.6 (38.6 – 56.8) 44.1 (35.3 – 53.3) 44.9 ± 12.4 45.2 ± 12.4 39.2 (30.1 – 48.3)
Diabetes duration (years) 33.1 (21.4 – 41.4) 27.2 (17.3 – 37.1) 28.0 (18.2 – 37.6) 28.0 (18.1 – 37.8) 21.9 (12.2 – 31.4)
BMI (kg/m2) 25.0 (23.0 – 27.3) 25.1 (22.9 – 27.9) 25.0 (22.8 – 27.8) 25.1 (22.8 – 27.8) 24.7 (22.6 – 27.0)
Waist circumference (cm) 85 (77 – 93) 86 (79 – 95) 86 (78 – 100) 86 (79 – 96) 85 (78 – 93)
SBP (mmHg) 134 (122 – 148) 136 (125 – 150) 137 (125 – 151) 137 (125 – 151) 132 (121 – 145)
DBP (mmHg) 77 (70 – 84) 78 (71 – 84) 79 (71 – 85) 79 (71 – 85) 80 (73 – 86)
HbA1c (%) 8.0 (7.2 – 8.8) 8.0 (7.3 – 8.8) 8.0 (7.3 – 8.8) 8.0 (7.3 – 8.8) 8.3 (7.4 – 9.2)
Total cholesterol (mmol/l) 4.5 (4.0 – 5.2) 4.6 (4.1 – 5.2) 4.6 (4.1 – 5.2) 4.6 (4.2 – 5.3) 4.9 (4.3 – 5.5)
Low SES (%) 12.5 14.0 15.2 16.0 19.8
Current smoking (%) 13.9 17.9 19.0 18.5 23.4
Nephropathy (%) 16.9 22.1 24.7 24.6 22.9
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Low SES, low socioeconomic status (unskilled blue
collar workers). Data are presented as percentage, median (interquartile range), or mean ± standard deviation.
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5. METHODS
Patients were recruited at the participating study centres. At their regular visit, all adult patients
with  type  1  diabetes  were  invited  to  participate  in  the  FinnDiane  Study.  Type  1  diabetes  was
presumed  if  age  at  diabetes  onset  was  below  35  years  and  if  permanent  insulin  treatment  was
initiated within one year of the diagnosis. Consenting patient’s attending physician collected data
on medical history and current medication. During the visit the measurements of blood pressure
and anthropometric variables were conducted, and blood was drawn for subsequent assays.
Moreover, patients were asked to fill in a number of questionnaires regarding their smoking
habits, education, employment, physical activity, psychological determinants, and dietary intake.
Besides at study visits, data were additionally obtained from various registers.
5.1 Anthropometric measurements and blood pressure
During the visit, weight was measured in light clothing with a standardized scale and registered
to the closest 100 g. Height was measured and registered to the closest 1 cm. These
measurements were used to calculate the body mass index (kg/m2). Waist circumference was
measured at the midpoint between the lowest rib and the iliac crest. The blood pressure
measurements were performed in a sitting position using either a mercury sphygmomanometer or
an automated standardized blood pressure device. Two measurements were performed for each
patient. The first measurement was conducted after a 15-minute rest, and the second
measurement followed at a two minutes interval. A mean of these measurements was used in the
analyses.
5.2 Glycaemic control, and serum lipid and lipoprotein concentrations
At the study visit blood was drawn. For this, fasting was not requested. However, smoking and
consumption of coffee, tea and cola drinks were discouraged prior to the visit. HbA1c was
measured locally at each centre using standardized assays. Serum lipid and lipoprotein
concentrations were measured centrally at the research laboratory of Helsinki University Central
Hospital,  Division  of  Cardiology,  Finland.  Until  January  2006,  serum  total  cholesterol  and
triglyceride concentrations were determined using enzymatic colorimetric assays (ABX
Diagnostic, HORIBA ABX, Montpellier, France). Thereafter a Konelab 60i analyzer (Thermo
Fisher  Scientific  Inc.,  Waltham,  MA,  USA)  was  used.  Serum  HDL  cholesterol  concentrations
were  evaluated  with  a  HTS  7000  plus  Bio  Assay  Reader  (Perkin  Elmer  Inc.,  Waltham,  MA,
USA).  Serum  LDL  cholesterol  concentration  was  subsequently  calculated  with  the  Friedewald
formula (306).
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5.3 Smoking, social class, and employment
Smoking was self-reported in a questionnaire. Patients were requested to select one from the
predetermined alternatives: current regular smoker (at least once cigarette a day); quitted
smoking but previously used to smoke regularly; never regularly smoked. If quitted, the number
of cigarettes previously smoked were also queried. In the current studies, current regular
smoking designated “smoking”.
In the same questionnaire, participants reported the number of years spent studying since
secondary school as well as their education and occupation. Unskilled blue collar workers were
classified as having a low socioeconomic status (SES). The current employment status was also
reported.
5.4 Dietary variables
Since fall 2007, data on patients’ food selection and dietary intake were collected using a diet
questionnaire and a food record. The questionnaire and the food record (that also captures data
on physical activity, insulin administration, and blood glucose monitoring) were developed for
the purpose of the FinnDiane study. Prior to the study start, 13 healthy individuals and 13
patients with type 1 diabetes pretested the forms for clarity.
5.4.1 Diet questionnaire
First, at the study visit patients were asked to fill in a diet questionnaire (Appendix 9.1) which
aims to describe patients’ food consumption habits. In this questionnaire, questions such as types
of milk products, spreads, cooking fats and breads typically consumed, were included. In the
same questionnaire, numbers of cups of coffee and tea, numbers of portions of milk, sour milk,
and yoghurt or sour whole milk, and numbers of slices of bread typically consumed were also
reported. Included were questions regarding salt consumption and potential use of lactic acid
bacteria containing products and nutrient supplements. Patients were also queried whether they
had received any dietary guidance from the health care professionals and their self reported
degree of compliance with such guidance. Adherence to any special dietary regimen, and
whether it was initiated based on a recommendation from a health care professional, was
additionally asked. Finally, the questionnaire included a set of non-quantitative food frequency
questions. In this section, the frequency of consuming a number of food items e.g., fish, poultry,
sausages and cold cuts, eggs, legumes, vegetables, and soft drinks were queried. For each of the
items, patients were requested to choose from seven predetermined frequencies. Data were
recorded on the database, and the entries were monitored against the raw data to ensure quality
of the entries.
Dietary recommendations for patients with diabetes (148) were used to calculate a diet score
from  the  data  collected  with  the  diet  questionnaires.  The  development  of  the  diet  score  is
presented in Table 4.
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Table 4. Development of the diet score
Food item Recommendation on which scoring
is based (148)
Questions on which
scoring is based
Scoring
Fish Fish should be consumed at least FFQ on fish consumption 0   less than once a week
twice a week 1   once a week
2   at least twice a week
Fresh vegetables Plenty of vegetables, fruits and berries FFQ on fresh vegetable 0   less than once a day
should be consumed (500g per day) consumption 1   once a day
2   several times a day
Cooked As above FFQ on cooked vegetable 0   once a week of less
vegetables consumption 1   2-3 times a week
2   at least 4 times a week
Fruits and As above FFQ on fruit and berry 0   less than 4 times a week
berries consumption 1   4-7 times a week
2   several times a day
Sweet pastry Sugar-containing products should be FFQ on sweet pastry 0   more than once a week
used in moderation consumption 1   once a week
2   less than once a week
Candy As above FFQ on candy consumption 0   more than once a week
1   once a week
2   less than once a week
Soft drinks As above. With meals low-fat liquid FFQ on soft drink 0   more than once a week
milk products, and for thirst water are consumption 1   1-4 times a month
recommended 2   less than once a month
Low-fat liquid Low-fat liquid milk products should Type of milk AND number 0   none consumed
milk products be consumed approximately 0.5 litres of 2dl-portions consumed 1   >0 dl but <5 dl consumed daily
per day 2   ?5 dl consumed daily
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Table 4. (Continued)
Food item Recommendation on which scoring
is based (148)
Questions on which
scoring is based
Scoring
Vegetable based Vegetable based margarine or spread Type of spread consumed 0   no vegetable based spreads
spreads is recommended on bread 2   vegetable based spreads
Vegetable based Oil or liquid margarine for cooking is Type of cooking fat 0   no vegetable based cooking fat
cooking fats recommended. consumed 2   vegetable based cooking fat
Salt consumption <6 g salt/day is recommended. Low- In the table, how often is salt 0   salt added almost always prior to tasting
salt products should be preferred. Use added to food AND how      AND/OR low-salt products are seldom or
of salt in cooking should be restricted frequently low-salt products       never selected
are selected 2   no salt is added AND low-salt products are
     always of mostly selected
1   the remaining subjects
FFQ, food frequency questionnaire.
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Such diet  indexes,  that  aim to  describe  the  quality  of  the  overall  diet,  have  also  been  used
before (307, 308). In this process, each item in the diet questionnaire was evaluated against the
recommendations. Whenever an unambiguous food level recommendation could be found, the
item was included in the scoring system. With regards to the food items in the food frequency
section of the diet questionnaire, the discrete frequencies were converted into continuous
variables exhibiting number of times item is consumed per month. Thus a frequency of once a
week, for example, equals four, and once a day equals 28 times per month. Using these variables,
we were able to divide patients into tertiles based on their frequency of consuming each
particular item. For “recommended” food items (such as fish and vegetables), patients in the
highest consumption tertile were assigned the highest score (2), followed by those in the middle
tertile (1), and finally the ones in the lowest tertile (0). Reverse scoring was applied for food
items that were considered as “not recommended” (such as soft drinks and sweet pastry). The
systems applied to score the consumption of low-fat liquid milk products, vegetable based
spreads, vegetable based cooking fats, and salt is shown in Table 4.
Individual scores were summed up to provide a diet score. This score ranged between 0 and
22, and higher scores denoted a tendency to better comply with the dietary guidelines. Based on
the patients’ self-reported tendency to comply with the dietary recommendations, patients were
furthermore divided into two groups. Those self-reportedly compliant reported adhering to the
guidelines  always  or  most  of  the  time,  while  the  remaining  patients  were  considered  non-
compliant.
5.4.2 Food record
Upon returning the diet questionnaire, patients were mailed a three-day exercise and food record
(Appendix 9.2) together with complete instructions how to fill it in. The allocated three
recording dates were consecutive and included two weekdays and a weekend day. Roughly half
of the participants were allocated days from Thursday through Saturday, and the remaining
patients filled in the record between Sunday and Tuesday. In this record, participants reported all
food and beverage intakes, any physical activities, insulin administrations, and blood glucose
measurement results, together with the timing of these activities. Regarding the recordkeeping,
patients were not provided with any self care guidance but the importance of maintaining
habitual customs during the recording days was emphasized. Up to two reminders were sent to
the non-responders.
Patients were instructed to report their food and beverage intakes as accurately as possible.
Provision of the cooking methods, trade names, and even recipes, if known, were encouraged. In
the instructions, a variety of ways to report the amount of food stuffs consumed were presented,
including household measures (spoons, decilitres, glasses, plates), numbers, centimetres and
grams. In the same form, type and level of strenuousness of any physical activity was also
reported. Four grades of strenuousness were predetermined; light (no shortness of breath, no
sweating), moderate (slight shortness of breath, no sweating), strenuous (shortness of breath,
slight sweating), and vigorous (heavy shortness of breath, profuse sweating) (309). Duration of
activity was reported in minutes. Finally, separate columns to report insulin and blood glucose
value were provided. Regarding insulin, type (including trade name) and amount of administered
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insulin were reported. Blood glucose values were reported whenever they were monitored. For
monitoring, patients’ personal blood glucose monitoring equipment were used.
The three-day recording was repeated within two to three months. Those who filled in the
first record on Thursday-Saturday, were now allocated days from Sunday to Tuesday, and vice
versa. Again, up to two reminders were sent to the non-responders.
At arrival, the records were checked for completeness and in case of ambiguous recording
patients were contacted for clarification. Additionally, data from the previously returned diet
questionnaires were used to double check potential vague entries (e.g., fat free milk vs. milk).
Data on the food records were entered into Diet32 software (version 1.4.6.2, AIVO, Turku,
Finland) that is based on the Finnish National Food Composition Database, Fineli (310). Diet32
software was also used to calculate the nutrient intakes. Following the initial data entry, the
entries were double-checked against the data on the diaries to ensure the quality of the recorded
data.
5.5 Leisure-time physical activity
Patients’ leisure-time physical activity (LTPA) was assessed using a self-report questionnaire
(Appendix 9.3). This questionnaire was used in the Kuopio Ischemic Heart Disease Risk Factor
Study (309), to which it was adapted from the Minnesota Leisure Time Activity Questionnaire
(311). In this questionnaire, questions on type, frequency, duration, and intensity of patients
current and previous LTPA were included. Moreover, for 21 predetermined activities patients
were asked to retrospectively report the frequencies (times per month), average duration
(minutes), and intensities (four grades) of sessions during the preceding 12 months. These 21
activities from which more detailed information was collected include the most common forms
of physical activities, e.g., walking, cycling, skiing, running, domestic work, and swimming.
Based on these data, total amount of weekly LTPA was calculated. This was done by multiplying
the duration of the activity per week by the activity- and intensity-specific metabolic equivalent.
The metabolic equivalent of task (MET) expresses the energy cost of physical activity as
multiples of resting metabolic rate (312). It is defined as the ratio of metabolic rate during
particular physical activity to a reference rate of metabolic rate at rest.
Based on the amount of patients’ weekly MET hours, three groups were formed; sedentary
(<10 MET h/week), moderately active (10-40 MET h/week), and active (<40 MET h/week)
(225). Additionally, in the analyses the weekly MET h was treated as a continuous variables, as
appropriate.
5.6 Sense of coherence
To study the sense of coherence, Antonovsky’s 13-item Orientation to Life Questionnaire was
used (Appendix 9.4) (227). After a reverse scoring for questions 1, 2, 3, 7, and 10, total score
was calculated summing all individual scores up. Individuals with any missing replies were
excluded (n=57). In the analyses, the SOC score was used as a continuous variable. Moreover, in
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Study II, the lowest tertile of the SOC scores were considered to have weak SOC. In Study III,
weak SOC was defined as the lowest quartile of the SOC scores. However, for the purpose of
this thesis, data from Study III were re-analysed to conform with the methods used in Study II.
Thus, in these analyses, population was divided into tertiles based on their SOC score. Results
from these new analyses are presented in this thesis.
5.7 Symptoms of depression
Two  separate  methods  were  used  to  evaluate  the  symptoms  of  depression.  First,  the  Beck
Depression Inventory (BDI) was applied (Appendix 9.5) (266). The BDI score was calculated to
all patients who completed the questionnaire, and a cut-off value of ?16 was used to define
depression. Moreover, the BDI score was also treated as a continuous variable in appropriate
analyses. The BDI was not, however, introduced to the FinnDiane study until in 2003. Therefore,
in order to cover all patients, register data were also used. The Drug Prescription Register (DPR)
of the Social Insurance Institute of Finland contains all data regarding prescribed, purchased and
reimbursed medications in the outpatient care since late 1994. For the analyses, we searched for
all drugs under the classes N06A and N06CA (that is “antidepressant agents”) in the Anatomical
Therapeutic Chemical Classification System with Defined Daily Doses. The BDI and register
data were used in combination in Study IV. In Study V, register data were only used. In that
study, patients were divided into three groups. First group consisted of patients with purchases of
antidepressant agents within one year from the baseline visit. Those without any such purchases
at baseline but with purchases during the follow-up period formed the second group. Finally,
individuals with no purchases of antidepressant agents during the study period formed the third
group.
5.8 Diabetes questionnaire
During the visit, patients were also asked to fill in a diabetes questionnaire (Appendix 9.6).  A
panel of experienced physicians actively participating in the clinical work designed this
structured but non-validated questionnaire for the FinnDiane study. The questionnaire included
items  with  clinical  relevance  in  patients’  daily  lives.  The  purpose  of  this  questionnaire  was  to
capture patients’ subjective perceptions of their diabetes management. Amongst others, included
were questions about patients’ perceptions about the extent to which diabetes and diabetic
complications disturb their lives. In the questionnaire, patients’ recollections of their latest HbA1c
value were asked, as were their understanding of the significance of this value. Questions about
patients’ satisfaction with their current HbA1c level and insulin regimen were also included.
Furthermore, experiences on hypoglycaemic episodes, both hypoglycaemic sensations and
measured low blood glucose levels without hypoglycaemic sensations, were queried.
Predetermined alternatives were provided for all questions excluding the one regarding the latest
HbA1c measurement.
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5.9 Renal status and diabetic microvascular complications
The assessment of renal status was based on the urinary albumin excretion rate (AER) in at least
two out of three timed 24-hour or overnight urine collections. Until November 2002, urinary
AER was determined by radioimmunoassay (Pharmacia, Uppsala, Sweden). Thereafter
immunoturbidimetric method has been used (Hitachi 911 analyzer, Roche Diagnostics, Hoffman-
La Roche, Basel, Switzerland). Four classes differing with their AER were formed: those with
normal albumin excretion rate (AER <20 ?g/min or <30 mg/24 h), microalbuminuria (AER ?20
and <200 ?g/min, or ?30 and <300 mg/24 h), macroalbuminuria (AER ?200 ?g/min or ?300
mg/24 h), and end-stage renal disease (ESRD) (dialysis or kidney transplantation). Diabetic
nephropathy was defined as macroalbuminuria or ESRD. Retinal laser-treatment was used as an
indication of proliferative retinopathy. These data were obtained from patients’ medical files.
5.10 Metabolic syndrome
For the definition of the metabolic syndrome, the criteria established by International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation; International Atherosclerosis
Society;  and  International  Association  for  the  Study  of  Obesity  (19)  were  used.  These  criteria
define the metabolic syndrome with the coexistence of at least three of the following criteria:
waist circumference ?94 cm in men and ?80 in women, triglyceride concentration ?1.70 mmol/l
or drug treatment for elevated triglycerides, HDL cholesterol concentration <1.00 mmol/l in men
and <1.30 mmol/l in women or drug treatment for reduced HDL cholesterol, blood pressure
?130/85 mmHg or use of antihypertensive medication, and fasting blood glucose concentration
?6.11 mmol/l. By definition, all patients in the current population fulfilled the criterion for
hyperglycaemia. However, lipid medications were not included in the criteria. In the analyses,
metabolic syndrome was treated as a dichotomous variable. Moreover, based on the number of
fulfilled criteria, each patient was given a metabolic score that ranged from 1 to 5.
5.11 Mortality
Data on all-cause and cause specific mortality were obtained from the Finnish Cause of Death
Register (313). In this register, the underlying cause of death is registered based on the coroner’s
evaluation. In Finland, data on causes of deaths are retrospectively updated once a year, while
data on mortality is continuously updated. In study V, cardiovascular deaths included all deaths
due to diseases of the circulatory system. These included codes I00–I99 in the International
Statistical Classification of Diseases and Related Health Problems (314). Moreover, deaths due
to chronic diabetic complications (E10.2, E10.5, E10.6, E10.7, E11.2, E11.5, E11.6, E11.7),
cancers (C00–C97), acute diabetic complications (E10.0, E10.1, E11.0, E11.1), alcohol
consumption (F10, F19, G31.2, G62.1, G72.1, I42.6, K, 29.2, K70, K85.2, K86.0, Q86.0, X45,
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X46, X65, X66, Y15, Y16), and suicide (X60–X69, X79–X84) were separated. All other causes
deaths were considered as “other”.
5.12 Statistical methods
Data were mainly analysed using the SPSS statistical software package for Windows (SPSS,
Chicago, IL, USA). Version 15.0 was used in Study IV, and version 17.0 in the remaining
studies. However in Study V, SAS statistical software package version 9.2 was additionally used
when calculating the confidence intervals for the 10-year cumulative mortality data (SAS
Institute Inc., Cary, NC, USA). Descriptive statistic were reported as percentages for categorical
data, mean ± standard deviation for normally distributed data, and mean (interquartile range) for
data that were not normally distributed.
When comparing the groups in the univariate analyses, the Chi-squared test was used for
categorical variables. For continuous variables with a normal distribution independent sample t-
test was used when making comparisons between any two groups, and ANOVA for analyses
with more than two study groups. When making univariate analyses for continuous variables that
were not normally distributed, Mann–Whitney U test was used for comparisons between two
groups and Kruskal–Wallis test for comparisons among three or more groups. To study
correlations, Spearman rank order correlation coefficients were calculated for variables that were
not normally distributed.
For multivariate analyses in cross-sectional setting, logistic regression analysis was used
when predicting outcome variables that were dichotomous (e.g., metabolic syndrome yes/no),
and linear regression was used to predict continuous variables (e.g., number of the components
of the metabolic syndrome present). In prospective setting (Study V), cumulative mortality was
assessed using the Kaplan–Meier method. Moreover, in the same study, multivariate associations
were studied using the Cox proportional hazard model.
In  Study  III,  exploratory  factor  analysis  (maximal  likelihood  and  varimax  rotation)  was
applied to identify underlying constructs within the diabetes questionnaire. In general, factor
analysis aims to form meaningful clusters from a number of variables. This data reduction is
based on the examination of variables that strongly correlate with a group of other variables
(factors), but that do not correlate with variables in other groups. Number of factors identified
was based on eigenvalues >1.0, and items were considered to load highly if they had a factor
loading |?0.20| with the factor. The factor score was the sum of the scores for all items associated
with a given factor multiplied by its corresponding factor loading. Reliability of the
questionnaire was assessed calculating Cronbach’s ?, and values exceeding 0.60 were deemed
acceptable. In the same study, factorial analysis of variance was used to study the associations
between  SOC  status  and  HbA1c measurement and the factors formed in the abovementioned
factor analysis. In all analyses a p value <0.05 was considered statistically significant.
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6. RESULTS
6.1 Dietary intake and adherence to guidelines
Majority of the patients met the recommendations for daily protein intake, with no difference
between men and women (Figure 4). Recommendations for alcohol intake were also frequently
met. However, compared to men, women were observed to meet these recommendations more
often (78% vs. 85%, p=0.009). In all, 77% of all participants met the recommendations for
sucrose intake, the recommendations of which men were more frequently observed to meet (85%
vs. 72%, p<0.001). A total of 70%, 63%, and 52% of all patients met the recommendations for
monounsaturated fatty acids, polyunsaturated fatty acids, and total fat intake, respectively, with
no  differences  between  the  genders.  More  than  half  (51%)  of  the  participants  also  met  the
recommendations for carbohydrate intake, although women more frequently (54% vs. 47%,
p=0.038).
In all, 28% of the participants met the recommendations for saturated fatty acid intake.
Moreover, only 27% of the respondents reported sodium chloride intake within the
recommendations. Here, women were more prudent (36% vs. 14%, p<0.001). In both sexes, fibre
intake deviated the most from the recommendations. Only 4% of all participants consumed the
recommended 40g of fibre or more. Men, however, were observed to meet these
recommendations more often (6% vs. 2%, p=0.008). Fibre recommendations are, however, also
presented as grams per each 4.2 MJ. Partly due to their lower energy intake, women were
observed to meet these recommendations more often, albeit not frequently (8%).
Of the vitamins, a great majority of patients met the recommendations for vitamin E,
thiamine, riboflavin, vitamin B6, and vitamin C intake (Figure 5). Here gender differences were
observed for vitamin E and C, the recommendations of which were more frequently met by
women. The two genders also differed with respect to the frequencies of meeting the
recommendations for vitamin A intake, which more than 70 % of women and less than 60% of
men met (p<0.001). Of the vitamins, the recommendations for vitamin D and folate were most
frequently unmet in both sexes. While for vitamin D no gender differences were observed,
women met the recommendations for folate intake more frequently (28% vs. 15%, p<0.001).
All the participants met the recommendations for phosphorus and selenium intake. Moreover,
the majority of patients met the recommendations for potassium, magnesium, zinc, and iodine
intake. A total of 87% and 76% of women and men, respectively, met the recommendations for
calcium intake (p<0.001). Finally, roughly half of the respondents met the recommendations for
iron intake.
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Figure 4. Proportion (%) of men and women meeting the recommended daily intakes for
macronutrients,  fibre,  and  salt.  CHO,  carbohydrates;  E%,  percentage  of  total  energy  intake;
SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty
acids. Individual recommendations for given nutrients are presented in the brackets.
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Figure 5. Proportion (%) of men and women meeting the recommended daily intakes for
selected vitamins and minerals. Individual recommendations/MJ for given nutrients are
presented in the brackets.
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6.2 Self-reported compliance and dietary intake
A total of 61% of the participants reported adhering to the dietary recommendations always or
most  of  the  time  (compliant).  Compared  to  men,  women  rated  themselves  more  frequently  as
compliant (65% vs. 56%, p=0.022). Those self-reportedly compliant more frequently achieved
the recommendations for carbohydrate, total fat, saturated fatty acid, alcohol, and sodium
chloride intake (Figure 6). Despite these differences, however, the actual frequencies of meeting
the recommendations for carbohydrate, total fat, saturated fatty acid, and sodium chloride intake
were modest among those self-reportedly compliant. Moreover, those self-reportedly non-
compliant more frequently met the recommendations for protein and monounsaturated fatty acid
intake.
Figure 6. Proportion (%) of self-reportedly compliant and non-compliant participants meeting
the recommended daily intakes for macronutrients, fibre, and salt. CHO, carbohydrates; E%,
percentage of total energy intake; SAFA, saturated fatty acids; MUFA, monounsaturated fatty
acids; PUFA, polyunsaturated fatty acids. Individual recommendations for given nutrients are
presented in the brackets.
67
Self-reported compliance was reflected in more frequently meeting the recommendations for
thiamine, folate, vitamin C, potassium, iron, zinc, and iodine (Figure 7).
Figure 7. Proportion (%) of self-reportedly compliant and non-compliant participants meeting
the recommended daily intakes for selected vitamins and minerals. Individual
recommendations/MJ for given nutrients are presented in the brackets.
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6.3 Sense of coherence and diet score
The diet score was calculated for 686 participants (43% men). Median (range) diet score in men
and women was 11 (0–20), and 12 (2–22), respectively. The respective median (range) SOC
scores were 75 (23–91) and 71 (25–91). The diet score correlated positively with the SOC score
both in men (r=0.134, p=0.021) and women (r=0.290, p<0.001), suggesting that individuals with
stronger sense of coherence tend to make dietary choices that closer adhere to the dietary
guidelines. Women with weak SOC (first SOC tertile) had lower diet scores than women with
stronger sense of coherence (second and third SOC tertiles combined) (Table 5). In men no such
difference was observed. Moreover, in a linear regression model, adjusted for age,
socioeconomic status, nephropathy status, and HbA1c, higher SOC scores were associated with
higher diet scores in women (Table 6). In men, age adjusted SOC score was associated with the
diet score. However, further adjustment with socioeconomic status abolished the association.
Table 5. Patient characteristics according to sex and sense of coherence status
Men, n=484 Women, n=620
Tertiles: 1st 2nd and 3rd 1st 2nd and 3rd
SOC score 57 (49–63) 78 (73–82) 57 (48–62) 78 (73–82)
Diet score 10 (7–14) 11 (9–14) 11 (9–13) 13 (10–15)a
Weekly MET h 16 (7–31) 20 (9–37) 15 (8–30) 21 (12–37)b
Active, % 16 21 15 19
Sedentary, % 35 27 32 21b
Age, years 45 ± 12 45 ± 13 43 ± 12 45 ± 11c
Diabetes duration, years 28 (18–35) 27 (16–38) 28 (19–37) 27 (18–37)
Dietary guidance, % 89 86 91 90
Smoking, % 22 19 18 16
Low SES, % 15 18 12 12
Diabetic nephropathy, % 34 27 17 17
BMI, kg/m2 26 (23–29) 25 (24–28) 25 (23–28) 25 (22–28)
Waist circumference, cm 94 (85–106) 92 (86–98) 82 (76–89) 80 (75–89)
Systolic BP, mmHg 139 (129–154) 141 (131–153) 132 (120–145) 133 (122–145)
Diastolic BP, mmHg 79 ± 10 79 ± 10 78 ± 10 77 ± 9
HbA1c, % 7.9 (7.2–8.8) 7.9 (7.2–8.7) 8.3 (7.5–9.1) 8.0 (7.2–8.7)b
Total cholesterol, mmol/l 4.6 (4.0–5.2) 4.4 (4.0–5.0) 4.7 (4.2–5.2) 4.7 (4.2–5.2)
HDL cholesterol, mmol/l 1.4 (1.1–1.5) 1.4 (1.2–1.6) 1.7 (1.4–2.0) 1.6 (1.4–2.0)
Triglycerides, mmol/l 1.2 (0.8–1.8) 1.1 (0.8–1.5) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
Data are presented as median (interquartile range), %, or mean ± SD. SOC, sense of coherence;
MET, metabolic equivalent of task; Active, weekly MET h >40; Sedentary, weekly MET h <10;
SES, socioeconomic status. Sex specific statistical comparisons are conducted between
individuals in 1st SOC  tertile  vs.  those  in  the  2nd and  3rd tertiles. Mann-Whitney U test, Chi-
squared test, and independent samples t test are used, as appropriate. ap<0.001; bp<0.01; c p<0.05.
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Table 6. Linear regression analysis on the association between diet score and sense of coherence score
Men (n=297) Women (n=389)
B SE B ? p B SE B ? p
Model 1
   SOC score 0.045 0.018 0.143 0.014 0.075 0.013 0.291 <0.001
Model 2
   SOC score 0.038 0.018 0.119 0.035 0.065 0.012 0.249 <0.001
   Age 0.077 0.017 0.254 <0.001 0.088 0.015 0.282 <0.001
Model 3
   SOC score 0.030 0.020 0.095 0.133 0.060 0.014 0.225 <0.001
   Age 0.093 0.020 0.298 <0.001 0.082 0.017 0.265 <0.001
   Low SES -1.417 0.707 -0.128 0.046 -0.405 0.613 -0.036 0.509
Model 4
   SOC score 0.014 0.023 0.044 0.531 0.051 0.015 0.203 0.001
   Age 0.085 0.024 0.263 <0.001 0.080 0.018 0.264 <0.001
   Low SES -1.266 0.848 -0.108 0.137 -0.865 0.718 -0.073 0.229
   Nephropathy 1.445 0.653 0.162 0.028 -0.556 0.610 -0.054 0.363
   HbA1c -0.351 0.220 -0.115 0.112 -0.157 0.167 -0.057 0.347
SE, standard error; SOC, sense of coherence; SES, socioeconomic status.
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6.4 Sense of coherence and leisure-time physical activity
The weekly MET h, reflecting the level of leisure-time physical activity, was calculated for 883
participants (44% men). Six participants (4 men) who reported extremely high rates of physical
activity were excluded. Of the excluded participants, one man and one woman had weak SOC.
Among the remaining participants, the median (range) MET h was 19 (0–105) and 19 (0–133) in
men and women, respectively. The SOC scores correlated positively with the weekly MET h in
women  (r=0.104, p=0.020), but not in men (r=0.095, p=0.063). Both in men and women the
median  weekly  MET  h  was  lowest  among  those  with  weak  SOC  (Table  5). However the
difference was significant only in women. Moreover in women, the proportion of sedentary
individuals was greater among those with weak SOC. In a linear regression analysis, higher SOC
scores were associated with higher physical activity in men (Table 7).
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Table 7. Linear regression analysis on the association between weekly MET h and sense of coherence score
Men (n=383) Women (n=494)
B SE B ? p B SE B ? p
Model 1
   SOC score 0.185 0.082 0.115 0.024 0.062 0.074 0.037 0.407
Model 2
   SOC score 0.176 0.082 0.110 0.032 0.062 0.075 0.038 0.404
   Age 0.120 0.082 0.074 0.147 -0.010 0.087 -0.005 0.907
Model 3
   SOC score 0.206 0.095 0.127 0.031 0.072 0.086 0.042 0.404
   Age 0.212 0.100 0.127 0.035 -0.040 0.104 -0.020 0.704
   Low SES -1.955 3.374 -0.035 0.563 7.462 3.582 0.110 0.038
Model 4
   SOC score 0.234 0.103 0.152 0.024 0.041 0.097 0.025 0.671
   Age 0.284 0.112 0.182 0.012 -0.019 0.117 -0.009 0.874
   Low SES 0.857 3.724 0.016 0.818 7.264 4.048 0.106 0.074
   Nephropathy -3.537 2.976 -0.082 0.236 -3.753 3.599 -0.059 0.298
   HbA1c 1.201 1.059 0.078 0.258 -0.898 1.045 -0.050 0.391
MET, metabolic equivalent; SE, standard error; SOC, sense of coherence; SES, socioeconomic status.
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6.5 The role of sense of coherence in glycaemic control and diabetic
microvascular complications
The cut-off value for the lowest SOC score quartile in the whole population was <63. However,
to conform with Study II,  we reanalysed the data comparing the lowest SOC score tertile with
the remaining population. Thus, the cut-off value used to define weak SOC in the analyses
presented in this thesis is <66.
In women, the SOC score was negatively associated with the HbA1c (r=?0.122, p=0.002). In
men, no such association was observed (r=?0.039, p=0.380). The median HbA1c in men with
weak and strong SOC was no different [respective values 8.0 (7.2–8.8) and 7.9 (7.1–8.7),
p=0.843]. In women, however, those with weak SOC had worse glycaemic control [8.3 (7.5–9.1)
vs. 8.0 (7.2–8.7), p=0.002].
A total of 161 (32%) men had nephropathy judged by the presence of either
macroalbuminuria or ESRD. Weak SOC was observed in 36% and 26% of men with and without
nephropathy (p=0.021). Moreover, the median SOC score was lower among men with
established nephropathy [71 (59–79) vs. 75 (66–81), p=0.008]. In all, 234 (43%) men had severe
retinopathy. Weak SOC was equally prevalent among men with and without severe retinopathy
(31% vs. 28%, p=0.449).  No  difference  was  observed  in  the  median  SOC  score  between  men
with and without severe retinopathy [73 (63–80) vs. 75 (66–81), p=0.199]. A total of 160 (32%)
men reached the targeted HbA1c level of <7.5%. No difference in the prevalence of weak SOC
was observed between men reaching and not reaching this level (30% vs. 28%, p=0.751).
Moreover, no difference was observed in the respective median SOC scores among these men
[74 (65–80) vs. 73 (65–81), p=0.199].
In all 115 (19%) women had nephropathy. No difference was observed in the prevalence of
weak SOC among women with and without nephropathy (40% vs. 38%, p=0.750). Moreover, the
median SOC score did not differ among these women [70 (59–81) vs. 72 (60–80), p=0.728]. A
total of 227 (33%) women had retinopathy. Weak SOC was an equally common finding among
women with and without retinopathy (38% vs. 38%, p=0.867). Similarly, no difference in the
median SOC score among these patients was observed [71 (59–81) vs. 72 (61–80), p=0.644].
Only 173 (28%) women reached the targeted HbA1c level  of  <7.5%.  Weak  SOC,  in  these
women, was less frequently observed (29% vs. 41%, p=0.006). The median SOC score among
women reaching the targeted HbA1c level was higher [74 (64–81) vs. 71 (59–80), p=0.012].
In men, weak SOC was independently associated with nephropathy when adjusted for
diabetes  duration,  age  at  onset  of  diabetes,  socioeconomic  status  and  HbA1c (Table  8). In
women, however, weak SOC was associated with not reaching the HbA1c target after
adjustments for diabetes duration, age at onset and socioeconomic status (Table 9).
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Table 8. The association between weak SOC and nephropathy, severe retinopathy, and HbA1c
level in men
Nephropathy Severe retinopathy HbA1c??7.5%
Model 1
   Weak SOC 1.61 (1.08 – 2.41) 1.16 (0.80 – 1.68) 0.93 (0.61 – 1.40)
Model 2
   Weak SOC 1.68 (1.08 – 2.60) 1.13 (0.73 – 1.75) 0.91 (0.60 – 1.37)
   Diabetes duration 1.07 (1.05 – 1.09) 1.11 (1.09 – 1.13) 0.99 (0.97 – 1.00)
   Age at onset 0.99 (0.97 – 1.01) 0.99 (0.97 – 1.01) 0.98 (0.96 – 0.99)
Model 3
   Weak SOC 1.82 (1.03 – 3.22) 0.90 (0.52 – 1.56) 0.88 (0.54 – 1.42)
   Diabetes duration 1.10 (1.07 – 1.13) 1.12 (1.09 – 1.15) 0.99 (0.97 – 1.01)
   Age at onset 0.99 (0.96 – 1.03) 1.00 (0.97 – 1.03) 0.98 (0.96 – 1.00)
   Low SES 1.53 (0.77 – 3.02) 1.13 (0.59 – 2.20) 0.93 (0.52 – 1.68)
   HbA1c 1.38 (1.13 – 1.70) 1.37 (1.12 – 1.67) NA
SOC, sense of coherence; SES, socioeconomic status.
Table 9. The association between weak SOC and nephropathy, severe retinopathy, and HbA1c
level in women
Nephropathy Severe retinopathy HbA1c??7.5%
Model 1
   Weak SOC 1.09 (0.72 – 1.64) 1.04 (0.75 – 1.44) 1.70 (1.17 – 2.49)
Model 2
   Weak SOC 0.98 (0.64 – 1.52) 0.96 (0.66 – 1.41) 1.73 (1.18 – 2.53)
   Diabetes duration 1.04 (1.02 – 1.06) 1.10 (1.07 – 1.12) 1.00 (0.98 – 1.01)
   Age at onset 0.95 (0.92 – 0.98) 0.94 (0.92 – 0.97) 1.01 (0.99 – 1.03)
Model 3
   Weak SOC 0.89 (0.51 – 1.54) 1.07 (0.67 – 1.71) 1.67 (1.09 – 2.56)
   Diabetes duration 1.04 (1.01 – 1.06) 1.11 (1.08 – 1.13) 1.00 (0.98 – 1.02)
   Age at onset 0.95 (0.92 – 0.99) 0.95 (0.92 – 0.98) 1.02 (1.00 – 1.04)
   Low SES 1.97 (0.95 – 4.09) 1.39 (0.70 – 2.75) 0.66 (0.37 – 1.19)
   HbA1c 1.31 (1.07 – 1.60) 1.17 (0.98 – 1.40) NA
SOC, sense of coherence; SES, socioeconomic status.
6.6 The reliability and factor analysis of the diabetes questionnaire
The reliability analysis gave a Cronbach’s alpha of 0.625, and thus the questionnaire was
considered reliable. Factor analysis on the diabetes questionnaire yielded four factors (Table 10).
In all the factors, higher scores denoted less favourable situation, e.g., higher number of doctor’s
and nurse’s visits due to non-diabetes related reasons, the presence of other chronic diseases, and
higher amount of disturbance experienced by the diabetic complications in the “complications”
factor.
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Table 10. Formation of the factors from the diabetes questionnaire
Name Questions included Replies
Conceptions of HbA1c Please report your latest HbA1c value? _______________________%
What does this above-mentioned value tell about the preceding 6-
8 weeks’ average daily glycaemic control?
That it is at a 1. Good level; 2. Satisfactory
level; 3. High level
Are you satisfied with your current HbA1c level? 1. Yes; 2. No
Complications How many times, during the preceding year, have you visited a
doctor due to non-diabetes related reasons?
0; 1-2; 3-4; 5-6; 7-8; >8 times
How many times, during the preceding year, have you visited a
nurse due to non-diabetes related reasons?
0; 1-2; 3-4; 5-6; 7-8; >8 times
Besides diabetes, do you suffer from any other chronic diseases? 1. No; 2 Yes, which ___________________
How much do the potential diabetes related complications disturb
your normal life?
0. No complications; 1. Not at all; 2. Slightly;
3. Moderately; 4. Quite a lot; 5. Very much
Diabetes control How many times, during the preceding year, have you visited a
doctor due to diabetes related reasons?
0; 1-2; 3-4; 5-6; 7-8; >8 times
How many times, during the preceding year, have you visited a
nurse due to diabetes related reasons?
0; 1-2; 3-4; 5-6; 7-8; >8 times
Hypoglycaemia Are you afraid of hypoglycaemia? 1. Yes; 2. No
Are you satisfied with your current insulin regimen? 1. Yes; 2. No
How many times have you experienced perceptions of low blood
glucose levels (perceptions of hypoglycaemia) during the past 4
weeks?
0; 1-2; 3-4; 5-6; 7-8; >8 times
How much does diabetes per se and/or its treatment disturb your
normal life?
1. Not at all; 2. Slightly; 3. Moderately; 4.
Quite a lot; 5. Very much
How much do the potential diabetes related complications disturb
your normal life?
0. No complications; 1. Not at all; 2. Slightly;
3. Moderately; 4. Quite a lot; 5. Very much
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6.7 Sense of coherence and patients’ perceptions of diabetes
In men, the SOC score was negatively correlated with two of the factor scores; complications
(r??0.188, p<0.001), and hypoglycaemia (r??0.322, p<0.001). In women, correlations were
observed between the SOC score and factor scores for conceptions of HbA1c (r??0.142,
p<0.001), complications (r??0.133, p<0.001), and hypoglycaemia (r??0.353, p<0.001).
The associations between weak SOC (lowest SOC score tertile) and HbA1c as well as the four
factor scores were also studied in multivariate models. In these analyses, the interaction term
between gender and weak SOC was significant for measured HbA1c and complications.
Therefore, for these variables, separate analyses for the two sexes were performed. In men,
independent of diabetes duration, age at onset of diabetes, and socioeconomic status, weak SOC
was associated with the complications factor (Table 11). In a respective model, weak SOC was
associated with the measured HbA1c in  women.  Moreover,  in  the  whole  population  weak SOC
was associated with factors regarding conceptions of HbA1c and hypoglycaemia.
Table 11. The associations between weak SOC and HbA1c and  the  four  dimensions  of  the
diabetes questionnaire
Model 1
F(dfM, dfR) p ?2
Model 2
F(dfM, dfR) p ?2
HbA1c
   Men F(1,490)=0.06 0.815 0.000 F(1,375)=0.01 0.965 0.000
   Women F(1,617)=12.94 <0.001 0.021 F(1,487)=5.90 0.016 0.012
Conceptions of HbA1c F(1,1241)=18.54 <0.001 0.015 F(1,980)=13.07 <0.001 0.013
Complications
   Men F(1,552)=22.61 <0.001 0.039 F(1,429)=19.96 <0.001 0.044
   Women F(1,687)=3.46 0.063 0.005 F(1,548)=1.63 0.202 0.003
Diabetes control F(1,1241)=1.96 0.162 0.002 F(1,980)=1.85 0.175 0.002
Hypoglycaemia F(1,1241)=121.02 <0.001 0.089 F(1,980)=84.21 <0.001 0.079
Model 1 is adjusted for diabetes duration, age at onset of diabetes, and sex (except for HbA1c and
complications factor); Model 2 is further adjusted for socioeconomic status.
6.8 Associations between depression and the metabolic syndrome
Judged by the BDI score ?16 or the use of antidepressant agents, 214 participants (17%) were
defined depressed. The metabolic syndrome was more prevalent among those with depression
(57% vs. 46%, p=0.008). Moreover, those with depression more frequently fulfilled the criteria
for waist (63% vs. 49%, p=0.001), triglyceride (23% vs. 16%, p=0.022),  and HDL (20% vs.
14%, p=0.038) components. Examining the two genders separately, the metabolic syndrome, and
waist and HDL components were more frequently observed in depressed women, while
depressed men more frequently fulfilled the triglyceride component.
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Individuals with the metabolic syndrome had higher BDI scores than those without [(5 (2–11)
vs. 4 (1–9), p=0.001]. Moreover, the BDI score was observed to increase with the increasing
number of the components of the metabolic syndrome (p<0.001).
In  men  the  BDI  score  was,  independent  of  age,  associated  with  the  presence  of  the
triglyceride component (Table 12). In the full model, including age, socioeconomic status,
smoking status, nephropathy status and HbA1c, however, BDI score was not associated with
either the metabolic syndrome or any of its components.
Among women, the BDI score was associated with the metabolic syndrome and the waist and
triglyceride components when adjusted for age (Table 13). After further adjustments with
socioeconomic status, smoking status, nephropathy status and HbA1c, significant associations
were only observed for the waist and triglyceride components. Depression, entered as a
dichotomous variable, was not associated with the metabolic syndrome or its components in the
full models in either sex.
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Table 12. Logistic regression analysis on the associations between BDI score and metabolic syndrome and its components in men
Metabolic syndrome Waist Triglyceride HDL Blood pressure
Model 1
   BDI score 1.02 (0.99 – 1.04) 1.02 (0.99 – 1.04) 1.03 (1.01 – 1.06) 1.01 (0.98 – 1.04) 1.01 (0.98 – 1.05)
Model 2
   BDI score 1.01 (0.99 – 1.04) 1.01 (0.99 – 1.04) 1.03 (1.01 – 1.06) 1.01 (0.98 – 1.04) 0.99 (0.96 – 1.03)
   Age, years 1.03 (1.01 – 1.05) 1.03 (1.02 – 1.05) 1.00 (0.98 – 1.01) 1.00 (0.98 – 1.02) 1.09 (1.06 – 1.12)
Model 3
   BDI score 1.01 (0.99 – 1.04) 1.01 (0.98 – 1.04) 1.03 (1.00 – 1.06) 1.01 (0.97 – 1.04) 1.00 (0.97 – 1.04)
   Age, years 1.04 (1.02 – 1.06) 1.04 (1.02 – 1.06) 1.00 (0.99 – 1.02) 1.00 (0.98 – 1.03) 1.08 (1.05 – 1.11)
   Low SES 0.64 (0.36 – 1.13) 0.80 (0.46 – 1.38) 0.93 (0.50 – 1.75) 1.12 (0.55 – 2.32) 1.06 (0.47 – 2.42)
Model 4
   BDI score 0.99 (0.96 – 1.03) 0.99 (0.96 – 1.03) 1.01 (0.97 – 1.04) 0.97 (0.92 – 1.02) 0.98 (0.94 – 1.03)
   Age, years 1.04 (1.01 – 1.06) 1.03 (1.01 – 1.06) 1.00 (0.97 – 1.02) 0.99 (0.96 – 1.03) 1.08 (1.05 – 1.11)
   Low SES 0.40 (0.20 – 0.79) 0.66 (0.34 – 1.29) 0.44 (0.19 – 1.01) 0.43 (0.15 – 1.24) 0.54 (0.19 – 1.50)
   Smoking 1.00 (0.53 – 1.90) 0.74 (0.39 – 1.39) 1.48 (0.75 – 2.91) 0.79 (0.33 – 1.93) 1.05 (0.45 – 2.47)
   Nephropathy 3.38 (1.86 – 6.14) 2.11 (1.21 – 3.68) 3.41 (1.81 – 6.41) 4.52 (2.03 – 10.10) 19.42 (2.54 – 148.74)
   HbA1c 1.21 (0.99 – 1.47) 1.07 (0.88 – 1.29) 1.11 (0.90 – 1.37) 1.29 (1.01 – 1.66) 1.21 (0.94 – 1.55)
BDI, Beck Depression Inventory; SES, socioeconomic status.
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Table 13. Logistic regression analysis on the associations between BDI score and metabolic syndrome and its components in women
Metabolic syndrome Waist Triglyceride HDL Blood pressure
Model 1
   BDI score 1.04 (1.01 – 1.06) 1.05 (1.03 – 1.08) 1.03 (0.99 – 1.06) 1.02 (0.99 – 1.05) 1.01 (0.99 – 1.04)
Model 2
   BDI score 1.03 (1.01 – 1.06) 1.05 (1.02 – 1.07) 1.03 (1.01 – 1.06) 1.02 (0.99 – 1.05) 1.01 (0.99 – 1.04)
   Age, years 1.02 (1.01 – 1.04) 1.01 (0.99 – 1.02) 0.97 (0.95 – 0.99) 0.99 (0.97 – 1.01) 1.08 (1.06 – 1.10)
Model 3
   BDI score 1.04 (1.01 – 1.06) 1.06 (1.03 – 1.09) 1.03 (0.99 – 1.06) 1.02 (0.99 – 1.05) 1.00 (0.97 – 1.03)
   Age, years 1.02 (1.01 – 1.04) 1.01 (0.99 – 1.02) 0.97 (0.94 – 0.99) 0.99 (0.97 – 1.01) 1.07 (1.05 – 1.09)
   Low SES 0.79 (0.45 – 1.38) 0.73 (0.42 – 1.27) 1.06 (0.41 – 2.70) 1.11 (0.54 – 2.31) 1.09 (0.55 – 2.17)
Model 4
   BDI score 1.03 (0.99 – 1.06) 1.06 (1.03 – 1.10) 1.05 (1.01 – 1.10) 0.97 (0.92 – 1.03) 1.00 (0.97 – 1.04)
   Age, years 1.02 (1.00 – 1.04) 1.01 (0.99 – 1.03) 0.95 (0.91 – 0.98) 1.00 (0.97 – 1.03) 1.07 (1.04 – 1.10)
   Low SES 0.86 (0.44 – 1.70) 0.91 (0.46 – 1.81) 1.12 (0.33 – 3.78) 0.89 (0.32 – 2.51) 0.91 (0.38 – 2.17)
   Smoking 1.17 (0.65 – 2.11) 1.40 (0.77 – 2.54) 1.93 (0.83 – 4.47) 0.92 (0.38 – 2.22) 0.82 (0.43 – 1.56)
   Nephropathy 3.33 (1.64 – 6.74) 1.75 (0.89 – 3.46) 3.39 (1.46 – 7.90) 1.55 (0.66 – 3.64) 23.98 (3.23 – 178.01)
   HbA1c 1.19 (0.98 – 1.44) 1.04 (0.86 – 1.26) 1.04 (0.80 – 1.37) 1.01 (0.77 – 1.32) 1.39 (1.11 – 1.74)
BDI, Beck Depression Inventory; SES, socioeconomic status.
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6.9 Depression and mortality
In all 4,174 participants were followed for an average duration of 9 years. Of these patients, 313
(7.5%) and 758 (18.2%) had purchases of antidepressant agents at baseline and during follow-up,
respectively. A total of 474 (11.4%) deaths occurred during the follow-up. Mortality rate was
highest among those with purchases of antidepressant agents at baseline (19.8%), followed by
those with purchases during the follow-up (16.2%), and those without any such purchases (9.3%,
p<0.001). The 10-year cumulative mortality in the respective groups were 22.5% (95%
confidence interval 18.1%–22.6%), 18.0% (15.4%–20.5%), and 10.1% (9.0%–11.2%) (p<0.001).
Significant interaction was observed in the effect of gender and nephropathy, as well as
gender and HbA1c on mortality. Thus the results from the multivariate analyses are presented
separately for men and women. After adjustments for age, diabetes duration, diastolic blood
pressure and smoking, men and women with any purchases of antidepressant agents (either at
baseline or during the follow-up), compared to those without, had higher hazard ratios (HR) of
death during the follow-up (Table 14).  After  further  adjustments  for  HbA1c and nephropathy
status, however, only women with purchases at baseline showed increased mortality risk.
Table 14. Hazard ratios of death from all causes among groups of patients purchasing
antidepressant agents
Men Women
Purchases at Baseline Follow-up Baseline Follow-up
Model 1 1.55 (1.03 – 2.35) 1.39 (1.04 – 1.85) 1.99 (1.29 – 3.07) 1.70 (1.18 – 2.43)
Model 2 1.28 (0.83 – 1.99) 1.32 (0.98 – 1.77) 1.94 (1.25 – 3.02) 1.75 (1.22 – 2.52)
Model 3 1.12 (0.71 – 1.77) 1.17 (0.87 – 1.58) 2.15 (1.34 – 3.45) 1.41 (0.96 – 2.06)
Patients without purchases of antidepressant agents serve as reference group (1.00).
Model 1 is adjusted for age, diabetes duration, diastolic blood pressure and smoking.
Model 2 is further adjusted for HbA1c.
Model 3 is further adjusted for nephropathy.
The cumulative mortality curves of the final Cox proportional hazards model are seen in
Figure 1 of the article for Study V. The survival was highest among women without purchases of
antidepressant agents. These patients were followed by women with purchases during follow-up
and baseline, respectively. No such differences were observed among men.
Cardiovascular deaths (45.0%) and chronic diabetic complications (31.4%) were the leading
underlying causes of deaths (COD) among individuals without purchases of antidepressant
agents. However, among those with purchases at baseline or during the follow-up, chronic
diabetic complications were the leading COD (37.7% and 45.7%, respectively). These were
followed by cardiovascular deaths (30.5% and 32.8%, respectively). Acute diabetic
complications were the underlying COD in 10.2% of deaths in individuals with purchases of
antidepressant agents at baseline. Albeit not significant, this was twice the rate observed among
individuals with purchases during follow-up and in non-purchasers.
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7. DISCUSSION
7.1 Methodological evaluation
7.1.1 Study subjects
All the study subjects were participants in the FinnDiane study. Thorough examination of the
study subjects, within the FinnDiane study protocol, has ensured the collection of a well
characterized population base. Moreover, the availability of various national databases in Finland
has enabled register data to be linked with the data collected in the FinnDiane study.
More than 10% of all patients with type 1 diabetes in Finland are included in the FinnDiane
study. Moreover, although not population based, the distribution of the enrolled patients
resembles closely that of the population in Finland. However, as is often the case in many
studies, it can be assumed that some selection bias has also taken place in the FinnDiane study.
Importantly, this selection bias has most likely favoured individuals more interested in their
health. Overrepresented may also be, especially in case of substudies regarding diet and
psychological determinants, individuals with more prudent dietary habits and better mental
health, respectively. If such selection bias has taken place it has, at most, diluted the findings of
the present studies. Importantly, despite this potential limitation, we were able to capture data
also from individuals with less than optimum dietary intakes, judged by nutrient intakes below
recommendations. Furthermore, the proportion of individuals with symptoms of depression (BDI
score ?16) was comparable with those observed in other studies conducted among individuals
with diabetes.
The FinnDiane study was launched in 1997. Over the years the study protocol has, however,
evolved to include an increasing number of research spheres. The Beck Depression Inventory,
the Orientation to Life Questionnaire, and the diabetes questionnaire, for example, were not
introduced until 2003. Moreover, data on dietary variables has only been collected since 2007.
Thus, although close to 4,800 participants have been recruited to the FinnDiane study, various
substudies have been conducted with a smaller number of participants. In each study, however,
all patients with relevant data have been included.
7.1.2 Dietary data
Two methods were used to collect data on dietary intake. First, the diet questionnaire was used to
obtain an overall picture of participants’ habitual dietary intake and second, the food record was
applied to get more detailed information from which dietary intake on a nutrient level could be
calculated. Importantly, these two methods differ in their strengths and weaknesses, thus
complementing each other. The diet questionnaire, for example, is a retrospective method and is
therefore dependent on the subjects’ ability to retrospectively report their dietary intake. Such
ability is not, however, required for proper completion of the food records, where information is
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reported during or shortly after the food is ingested. Compared with the diet questionnaire,
however, completion of the food records asks for somewhat greater motivation. Thus, in order to
obtain  at  least  some  dietary  data  from  as  many  participants  as  possible,  the  diet  questionnaire
was first introduced. Hitherto the diet questionnaire has not been validated, however, limiting our
enthusiasm for the results.
According  to  the  protocol,  food  record  was  to  be  completed  from  a  total  of  six  days.  This
period was divided into two three-day periods separated by 2–3 months interval. For each 3-day
period, one weekend day and two weekdays were allocated. This procedure aimed at tackling
with  the  problem  faced  with  the  day-to-day  and  seasonal  variation.  In  practice,  however,  a
number  of  patients  who had  filled  in  the  food  record  for  the  first  three  days  were  unwilling  to
repeat the procedure for the second time. Importantly, not only was the proportion of these
patients were fairly low (<18%), the intake of most nutrients, among these patients, was no
different compared to the remaining patients.
7.1.3 Sense of coherence
The Orientation to Life Questionnaire is considered a valid and cross-culturally applicable
instrument to measure individuals’ sense of coherence (231). The SOC scores towards the higher
end of the scale denote that individuals have strong sense of coherence. That is, they possess and
exploit various resources to manage any stress-arousing situations, and therefore tend to stay
healthy. No distinct cut-off value has been defined for “weak SOC”. Therefore, for many of our
analyses, we have used the SOC score as a continuous variable. However, as commonly done not
only in research but also in clinical practice, people are often drawn to a dichotomized way of
thinking. Importantly, the attempts to dichotomize and to set cut-off values, are often based on an
artificial agreement, subject for change with increasing evidence. In case of the SOC score,
dichotomizing has frequently been done by dividing the population into certain fractiles based on
the distribution of the SOC scores in a given population. In the past, division based at least on
tertiles, quartiles and quintiles has been seen (236, 240, 247, 253, 315). Two of the current
papers, in this theses, concern the sense of coherence. In Study III, weak SOC was defined based
on the lowest SOC quartile while the bottom tertile constituted the group with weak SOC in
Study  II.  It  is  agreed  that,  for  the  sake  of  consistency,  the  use  of  one  system  to  dichotomize
would have been sensible. Should the analyses be conducted today, the weak SOC would, in all
studies, be defined as the lowest tertile. To conform with this, the results from the new analyses
based on dividing the population into tertiles are presented for the Study III in this thesis.
Importantly, the new results were comparable with the original ones.
7.1.4 Symptoms of depression
In clinical practice depression diagnosis is based on a clinical interview. However, in the current
study setting,  conduction of clinical  interviews were not possible.  Therefore a number of other
methods that provide data on the symptoms of depression were used. The Beck Depression
Inventory, used in Study IV, is a widely employed validated tool for measuring depression in
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diabetes (267). Being subjective in nature, any self-reported questionnaires are, however, subject
to misclassification. While keeping that in mind, the selected cut-off value of ?16 has shown to
have a good predictive value for depression (267).
Data from the Drug Prescription Register was used to obtain information on the
antidepressant agent purchases, and thus to identify subjects with depression. Compared to the
use of self-reported questionnaire, register data was considered a more objective method. The
use of register data has some limitations, though. First, not all depressed patients seek for
professional  help.  Thus,  when  relying  exclusively  on  register  data,  one  would  be  prone  to
misclassify a number of individuals. In order to minimize the effect of this shortcoming in Study
IV, we used the BDI data in conjunction with the register data. Thus, individuals fulfilling either
one of these criteria, were considered “depressed”. Due to the later start of the data collection
with the Beck Depression Inventory, these data were not available for all participants in the
Study V. Therefore, register data were only used. Another issue that should be noted, when using
the register data, is that antidepressant agents are also used to treat neuropathic pain. Currently,
indication for which the medication was prescribed is not available form the register.
Importantly, however, patients with neuropathic pain frequently suffer also from depression
(316). Therefore we may be confident that major misclassifications have not taken place. Finally,
while  the  BDI  data  may  provide  some  information  regarding  the  severity  of  the  symptoms  of
depression, such information is not available from the register data. Intuitively, the number of
antidepressant agent purchases could give indication about the severity of depression. It could,
however, also indicate the aggressiveness of treatment or medication adherence, thus preventing
us from making any firm conclusions about the associations between depression severity and
mortality.
7.1.5 Diabetes questionnaire
The diabetes questionnaire, used in Study III, was specifically designed for the FinnDiane study
and has not been validated. This questionnaire, that aims at capturing patients’ perceptions of
their disease, was assembled by a group of diabetes experts, a number of which have faced with
diabetes both in their personal and professional lives. Importantly, items of clinical and personal
relevance were included in this questionnaire. Instead of aiming at objective data on patients’
diabetes management, the adopted approach was rather to gain insight of the patients’ subjective
thoughts of their disease and its management. Thus, amongst others, patients were queried about
their satisfaction with their current insulin management and what they thought of their latest
HbA1c level. Due to the subjective approach of the questionnaire, its validation may be difficult,
and even unwarranted. Importantly, the questionnaire yielded meaningful factors in the factor
analysis. Moreover, based on the reliability analysis, the questionnaire was considered reliable.
7.1.6 Metabolic syndrome in type 1 diabetes
The idea of studying the metabolic syndrome in patients with type 1 diabetes is a fairly new one.
Importantly, the criteria for the metabolic syndrome have not been developed for patients with
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type 1 diabetes, in specifically. Compared to other populations, patients with type 1 diabetes may
differ with respect to their metabolic profile. Therefore it can be speculated whether these criteria
should be applied in this population, in the first place. Currently we do not know whether two
patients, one with type 1 and the other with type 2 diabetes, both defined as having the metabolic
syndrome actually “suffer” from comparable metabolic disorders. Importantly, it has been
previously shown in the FinnDiane population that, beyond traditional risk factors, the metabolic
syndrome is an independent risk factor for diabetic nephropathy (27). Moreover, in the same
study, all the components of the metabolic syndrome were independently associated with
diabetic nephropathy, supporting the use of the commonly used criteria also in patients with type
1 diabetes. The metabolic syndrome, as defined by the WHO (22), also increased the risk of
cardiovascular events and increased the risk of cardiovascular- and diabetes-related deaths (28).
These observations do not, however, exclude the possibility that other risk factors might better
serve as components of the metabolic syndrome in patients with type 1 diabetes.
7.1.7 Mortality
Data on mortality was obtained from the Finnish Cause of Death Register. This database
contains real-time information on all deaths of the Finnish citizens. Moreover causes of deaths,
although updated only once a year, are registered. Reported cause of death is based on the
coroner’s evaluation. In the current study, underlying causes of deaths were investigated. The
WHO defines underlying cause of death as the disease or injury that initiated the train of events
leading  directly  to  death,  or  the  circumstances  of  the  accident  or  violence  which  produced  the
fatal injury (317). Besides the underlying cause of death, contributory cause of death may also be
allocated. Contributory cause of death refers to a significant condition that unfavourably
influences the course of the morbid process and thus contributes to the fatal outcome, but which
is not related to the disease or condition directly causing death (318). It may be speculated that
distinguishing the underlying cause of death from the contributory cause of death in individuals
with many physical conditions may occasionally be challenging. This may especially be the case
when distinguishing between cardiovascular deaths and deaths from chronic diabetic
complications.  Thus  the  current  results  should  be  evaluated  in  the  light  of  this  potential
limitation. It is unlikely, however, that any systematic differences in cause of death evaluation
should have taken place between individuals with and without depression.
7.1.8 Causality
The design in Studies I–IV is cross-sectional. Therefore causality, in these studies, cannot be
assumed.  Based  on  the  SOC theory,  for  example,  it  could  be  expected  that  compared  to  those
with weak SOC individuals with strong are more likely to have adopted more prudent lifestyle.
Such lifestyle choices would, again, be translated in better glycaemic control and lower
complication prevalence. While this may be the case, the reverse may also be true. Thus, good
diet and physical fitness may induce the feeling of strong sense of coherence. Moreover, being
able to manage one’s disease and therefore stay free of complications can also foster strong SOC.
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Similar considerations may also be in order with regards to the association between depression
and the metabolic syndrome. However, it should be noted, the metabolic syndrome is not a
disease and is thus not diagnosed as such. Therefore it can be speculated whether affected
individuals actually know that they are “suffering” from it. Due to the longitudinal nature of
Study V, we have more confidence regarding the causality.
7.2 Energy and nutrient intakes in type 1 diabetes
Diet is a central factor in the management of diabetes. Dietary recommendations aim at guiding
individuals’ choices and thus at promoting good health. However, as has been seen in the past,
the recommendations are frequently unmet. Of note have been the intakes of total fat and
saturated fatty acids, the intakes of which frequently have exceeded the recommendations, and
carbohydrates and fibre which are generally consumed less than recommended (176). Our results
are in concordance with the observations Toeller et al. made more than two decades ago. In a
population of patients with type 1 diabetes, we observed low carbohydrate intakes together with
particularly low frequency of meeting the recommendations for fibre intakes. Moreover, the
proportion of patients meeting the recommendations for total fat and saturated fatty acids, in
particular, were low. These observations were accompanied by higher than recommended intakes
of sodium chloride and low intakes of vitamin D, folate, and iron.
According to the dietary recommendations, fats should provide between 25 to 35 percentage
of total daily energy intake. In the current study, however, 41% of the respondents exceeded
these recommendations. Of the macronutrients, fat is the most energy dense and thus its
excessive intake may predispose to obesity. Extremely low intakes, on the other hand, may
jeopardize the intake of essential fatty acids and fat-soluble vitamins. Of particular importance
was also the excessive intake of saturated fatty acids in this population. Importantly, high intake
of  saturated  fatty  acids  is  associated  with  an  increased  CHD  risk  (147-149).  Therefore,  as
patients with type 1 diabetes have an increased risk for developing vascular complications these
patients, in particular, could benefit from the reduced intakes.
Due to its effect on the glycaemic control, patients with type 1 diabetes could also benefit
from more abundant fibre intakes. To achieve these recommendations, carbohydrate-containing
foodstuffs with high fibre content should be selected. Indeed, the current findings regarding low
fibre intakes were accompanied by low mean carbohydrate intakes. It is possible that, in order to
maintain normoglycaemia, patients with type 1 diabetes tend to avoid carbohydrates.
Importantly, as long as an appropriate dose of exogenous insulin is administered to cover the
carbohydrates consumed, there should be no reason to limit the intakes below the recommended
45 percentage of total energy intake.
Due to the challenges faced in estimating the need of bolus insulin, corrective measures may
occasionally be taken in order to restore too high or too low postprandial blood glucose
concentrations. While a dose of bolus insulin is required to correct hyperglycaemia, additional
carbohydrate containing snack, or preferentially pure glucose, is consumed in case of
hypoglycaemia. In the current study we observed that, although on average the sucrose intakes
remained  at  the  recommended  level,  in  almost  one  fourth  of  the  patients  the  consumption
exceeded the recommendations. Interestingly, the proportion of patients exceeding the sucrose
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recommendations was identical to the proportion of participants postprandially hypoglycaemic in
another publication from the FinnDiane study (136). Regardless of whether these separate
observations are connected or not our results do, in general, suggest the need for an adequate
patient education to raise the awareness of the dietary recommendations and practical
instructions how to reach them.
Touching upon the issue about patient education, we also aimed to investigate whether
patients’ self-reported compliance with the dietary recommendations is reflected in the observed
compliance. After all, information about diet is abundantly available from many sources, all of
which may not comply with the official guidelines. Obtaining information from the non-official
sources, especially when they deviate from the official ones, may obscure individual’s
understanding what actually is advisable and what is not. In our study we found that self-reported
compliance  with  the  dietary  recommendations  did,  with  respect  to  some nutrients,  show better
observed compliance. Compared to those self-reportedly non-compliant, for example, those
compliant more frequently achieved the recommendations for carbohydrate intakes. It should be
noted, however, that a total of 45% of those self-reportedly compliant still failed to meet these
recommendations. Moreover, achieving sufficient fibre intakes was equally difficult for those
self-reportedly compliant and non-compliant. Similarly, although patients who claimed to be
compliant met the recommendations for total fat and saturated fatty acids more often, 35% and
65% of these patients, respectively, were still observed to consume them in amounts higher than
recommended. Moreover, for protein and monounsaturated fatty acids, those self-reportedly non-
compliant actually more frequently met the recommendations. As was the case for total
population, those self-reportedly compliant frequently failed to meet the recommendations for
vitamin D, folate, and iron. With regards to the two latter, however, those self-reportedly
compliant were more successful than those non-compliant. All in all, while self-reported
compliance was, for many nutrients, associated with better observed compliance, these patients
too face similar nutritional pitfalls as the remaining population.
7.3 The role of sense of coherence in the self-management
According to Antonovsky, individuals with strong sense of coherence have developed an
orientation to life that helps them to make sense of the internal and external worlds. Moreover, in
the course of their lives these individuals have obtained a set of, what Antonovsky called,
generalized resistance resources which they use to effectively cope in various spheres of life.
That is, individuals with strong SOC tend to take actions in their lives that support their well-
being. Such an approach is considered salutogenic, to bring about health.
In case of type 1 diabetes, the patients’ ability to impact the disease onset is, obviously,
grossly impaired. Due to increased risk of complications among these individuals the quality of
self care has, however, a direct effect on the subsequent risks. Here, maintenance of good
glycaemic control is of particular importance, and to that end, factors such as blood glucose self-
monitoring, meticulous insulin administration, adherence to the dietary recommendations, and
physical activity are stressed. Importantly, beyond their impacts on glycaemic control, prudent
diet and physical activity also possess other important qualities.
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In  the  current  thesis  we  assessed  the  role  sense  of  coherence  has  on  glycaemic  control,
dietary intake, and physical activity. According to our results, SOC seems to be a factor in
glycaemic control, but mainly among women. First, unlike in men, the SOC score correlated
with HbA1c in women. Second, compared to women with strong SOC, those with weak were less
likely  to  reach  the  HbA1c goal  of  <7.5%,  while  no  such  difference  was  observed  in  men.  The
association between SOC and glycaemic control has also been evaluated in a number of other
studies, most of which did not observe any such association (245, 249-251). In one study,
however, SOC was linked to glycaemia but only via adherence to self care behaviours (252).
Compared to the present study the above mentioned studies were, however, small and potentially
underpowered to detect such a difference.
In order to study the association between SOC and dietary intake, a diet score was calculated.
This score reflected the extent to which patients’ dietary habits conformed with the current
recommendations. In these analyses, the SOC score correlated with the diet score both in men
and women, suggesting that individuals with strong SOC tend to make dietary choices that more
closely adhere with recommendations. In line with this, women with weak SOC had lower diet
scores. Moreover, in linear regression analysis, the SOC score was independently associated with
the diet score among women. A number of large studies have previously assessed the association
between SOC and dietary intake. In these studies, individuals with strong SOC have, repeatedly
shown to make healthier choices. For example, the intakes of fruits, vegetables, and fibre is
higher, and those of soft drinks, french fries and candies lower amongst those with strong SOC
(239, 240).
Regarding physical activity, the SOC score correlated positively with the score describing the
level of leisure-time physical activity (weekly MET h) in women. Moreover, the median weekly
MET h was higher among women with strong SOC. While such tendency was also observed in
men, it did not reach statistical significance. Compared to women with strong SOC, those with
weak were also more likely to be sedentary. However, in linear regression analysis, the SOC
score independently predicted the level of physical activity only in men. Wainwright et al. also
investigated the association between SOC and physical activity (239). In their study, independent
of  age,  gender,  social  class,  and  education,  individuals  with  strong  SOC were  less  likely  to  be
physically inactive. Consistent with these observations, higher SOC scores have been associated
with more frequent participation in physical activity (241).
All in all SOC was, at some level, observed to affect all investigated spheres of diabetes
management. Thus, our results provide some support for the SOC theory. However, why SOC
affects the self-management in women and men differentially, is not known. In women, weak
SOC seemed to affect the ability to effectively manage glycaemia and to make more health-
promoting dietary choices. Interestingly, however, SOC did not appear to affect the dietary
choices in men. Indeed it can be speculated that, in many families, it is women who primarily are
in charge of the groceries and cooking. Thus, in these families, it could actually be the woman’s
SOC that would be associated with man’s dietary habits. Unfortunately this can only be
speculated as, in our diet questionnaire, we did not ask who in the family is responsible for the
abovementioned chores.
In men, however, weak SOC was independently associated with lower level of physical
activity. Physical activity may have a different role in the health and health behaviour patterns
among men and women. Indeed, a positive relationship between vigorous-intensity physical
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activity and mental health among men has previously been observed (319). In the same study,
however, women seemed to benefit from physical activities of milder intensity. The gender-
specific differences observed in the present study will need to be confirmed in the future.
7.4 Sense of coherence in diabetic complications
In the current study, weak SOC was associated with the presence of diabetic nephropathy in
men. Importantly, weak SOC was observed to predict the presence of diabetic nephropathy even
after adjusting for a number of important risk factors including diabetes duration and HbA1c. In
women,  no  such  association  was  observed.  One  potential  explanation  is  that,  compared  to
women, men in general were more frequently affected by diabetic nephropathy.
No association was observed between SOC and diabetic retinopathy in either men or women.
Importantly, diabetic retinopathy is an extremely common complication in patients with type 1
diabetes. Indeed, after two decades of diabetes, some degree of diabetic retinopathy can be
observed in almost all patients (61). Therefore, considering this almost deterministic progression
of the condition, it is possible that factors unrelated to the SOC are more important in
determining diabetic retinopathy.
Studies regarding SOC and diabetic complications are scarce. However, in one cross-
sectional study in patients with type 1 diabetes, compared with those with multiple
complications, individuals with one or less were observed to have stronger SOC (245). As is the
case with the current study, however, cross-sectional studies cannot reveal causality. Therefore
one has to consider that the emergence of complications could have also negatively affected
individual’s SOC. Importantly, however, longitudinal studies have also revealed negative health
consequences among those with weak SOC, suggesting that SOC may have importance in the
development of complications (247).
7.5 Sense of coherence and patients’ perceptions of diabetes
In patients with type 1 diabetes, monitoring glycaemic control and any signs of vascular
complications are obviously of great importance. However, individuals’ cognitive appraisals of
their disease are also important as they may affect how patients take care of themselves.
Important for the overall well-being of the individual, such perceptions may also reveal
something about patients’ satisfaction of the diabetes management. Previously the concept of
sense of coherence has been associated with the degree of disease acceptance among patients
with insulin-dependent diabetes (245). In the current study we evaluated whether patients with
weak  and  strong  SOC  differ  with  respect  to  their  conceptions  of  their  disease.  Indeed,  it  was
hypothesized that individuals with weak SOC would report more negative perceptions of type 1
diabetes.
Using factor analytic approach, four factors were formed from the diabetes questionnaire. In
the order of appearance, the factors were named as conceptions of HbA1c, complications,
diabetes control, and hypoglycaemia. Higher factor scores in each factor implicated a less
88
favourable situation. Thus, for example, in the complications –factor higher scores denoted that
these individuals have more non-diabetes related doctors’ and nurses’ visits, besides diabetes
they reported having some other chronic diseases, and they reported experiencing more
substantial disturbance from diabetes related complications.
Both in men and women the SOC score was negatively correlated with the complications and
hypoglycaemia –factors. Moreover, in women, negative correlation was observed for the
conceptions of HbA1c –factor. In a multivariate model, however, weak SOC in men was
associated  with  the  complications  –factor.  In  men  and  women  combined,  weak  SOC  was  also
associated with the conceptions of HbA1c and hypoglycaemia –factors.
The association between SOC and complications –factor, in men, was consistent with the
results we obtained for men regarding SOC and diabetic nephropathy. The finding regarding the
hypoglycaemia –factor is, however, a new one and suggests that individuals with weak SOC bear
more negative perceptions of hypoglycaemia. Interestingly, weak SOC has previously been
positively associated with the trait anxiety (320), and self-reported anxiety of hypoglycaemia, on
the other hand, formed part of the hypoglycaemia –factor. These observations may, indeed,
partly explain our findings.
7.6 Depression in the metabolic syndrome
A number of studies have linked depression with the metabolic syndrome or its components
(269, 293, 294). However, this association has not previously been investigated in patients with
type 1 diabetes. Of note is that patients with type 1 diabetes frequently fulfil the criteria for the
metabolic syndrome (27) which, beyond the traditional risk factors, increase the risk of
macrovascular complications (28).
Consistent with previous observations, the metabolic syndrome was more frequently
observed among those depressed. This was more pronounced in women, however, a finding also
supported by earlier research (294-296). Moreover, in the current multivariate models, the BDI
score predicted the presence of the waist and triglyceride components of the metabolic syndrome
only  in  women.  The  association  between  depression  and  waist  component  in  women  has  also
previously been reported (294, 295). As previously shown by Skilton et al. (321), we also
observed that the BDI score, denoting the severity of symptoms of depression, increased with an
increasing number of the components of the metabolic syndrome.
A number of physiological and behavioural pathways could explain the association between
depression and the metabolic syndrome. Chronic dysregulation of the hypothalamic pituitary
adrenal axis, observed in depression, can result in excess glucocorticoid secretion. When
sustained, this contributes to visceral obesity, insulin resistance, hypertension, and heightened
lipid concentrations (322), that is factors central to the metabolic syndrome. Reduced brain
serotonin activity, that is seen both in the metabolic syndrome (323) and depression (324), could
be a mediating link between the two conditions. Finally, poor compliance with the self care
regimen, related to depression (325), could lead to untoward consequences such as accumulation
of central adiposity.
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7.7 Depression and mortality
The detrimental effect of depression on mortality has previously been documented (7, 8, 297-
299). In the current study depression, defined as purchases of antidepressant agents, were also
associated with increased mortality during an average of 9 years follow-up. Indeed, 10-year
cumulative mortality among individuals with antidepressant purchases at baseline and follow-up
was 23% and 18%, respectively. However, the observed rate among non-purchasers was 10%.
Separate analyses for men and women, again, revealed gender-specific differences. Here,
depression contributed to reduced survival only in women. Previous studies regarding gender-
specific mortality rates in depression have been inconsistent (326-328). However, a meta-
analysis containing random samples from different communities concluded that the relative
mortality risk between depressed men and women were no different (297).
For the analyses, purchasers of antidepressant agents were divided into two groups; those
with such purchases at around the baseline visit and those with purchases during the follow-up
period. Importantly, women with antidepressant agent purchases at baseline were observed most
vulnerable. Such a difference, it may be speculated, could have been a result from a more long-
standing  depression,  judged  by  its  presence  already  at  baseline.  It  is  also  possible  that,  on
average, those with antidepressant purchases at baseline and during follow-up differed with
respect to the severity of their depression. Indeed, the customs of prescribing antidepressant
agents may have changed over the years. Perhaps earlier antidepressants were more readily
prescribed to more severe cases of depression, while later such medication has also been
prescribed to less severe cases.
The presence of diabetic complications especially that of diabetic nephropathy has shown,
not  only  to  be  associated  with  depression  (6),  but  also  to  increase  the  risk  of  death  in  patients
with  type  1  diabetes  (4).  In  our  analyses,  the  presence  of  diabetic  nephropathy  was,  however,
controlled for suggesting that depression independently contributes to the mortality.
The mechanisms by which depression increases mortality are not known. One potential
explanation could be increased suicide rates among those depressed. In the present study,
however, suicides accounted for a total of six deaths with no differences between the groups.
Moreover,  exclusion  of  these  patients  from  the  analyses  did  not  alter  the  results.  It  can  be
speculated also that depression could be associated with less prudent self-management of
diabetes, a phenomenon not assessed in this study. The negative association between the BDI
and SOC scores (data not shown), however, suggest that this could partly contribute to our
finding. Finally, the unfavourable effects of depression on the endocrine, neurologic, and
immune processes are likely to impact, too. It is likely, however, that many different factors in
combination contribute to the observed association between depression and excess mortality.
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8. SUMMARY AND CONCLUSIONS
I  Dietary  intake  among patients  with  type  1  diabetes  did  not,  for  many nutrients,  meet  the
recommendations. Of note are total fat, saturated fatty acids, and sodium chloride, the
intakes of which frequently exceeded the recommendations. At the same time, the intakes
of fibre, vitamin D, and folate remained, on average, below the recommendations.
Moreover,  almost  half  of  the  participants  failed  to  meet  the  iron  recommendations.
Although self-reported compliance with dietary guidance was associated with higher
frequencies of meeting the recommendations for carbohydrates, total fat, saturated fatty
acids, sodium chloride, folate, and iron, the observed frequencies were only modest.
Patients with type 1 diabetes could benefit from intensified dietary counselling that aims at
increasing the intake of carbohydrates with high fibre content, and reducing that of
saturated fatty acids. A generous intake of legumes, whole grain products, and fruits and
vegetables are encouraged also to improve the vitamin and mineral densities of the diets.
II Strong sense of coherence was associated with more prudent food choices in women, and
higher level of leisure-time physical activity in men. Whether these differences are
clinically relevant, is not known. The possibility to use the Orientation to Life
Questionnaire as a screening instrument for patients in need of intensified diabetes
counselling should be investigated. Moreover, the efficacy of such counselling would need
to be evaluated.
III Weak sense of coherence predicted the presence of nephropathy in men. Women with
strong sense of coherence, on the other hand, were more likely to reach the HbA1c goal of
<7.5%. Of the four factors formed from the diabetes questionnaire, weak SOC was
independently associated with patients’ conceptions of HbA1c and hypoglycaemia. In
respective models, weak SOC was also associated with the complications –factor in men.
Whether sense of coherence is also longitudinally associated with complications needs to
be investigated in the future.
IV An association was observed between depression and the metabolic syndrome, but this was
more pronounced in women. Of the individual components of the metabolic syndrome, the
BDI score predicted the presence of waist and triglyceride components in women. The
longitudinal association between depression and the metabolic syndrome in patients with
type 1 diabetes will need to be investigated.
V During  an  average  period  of  9  years,  mortality  rate  was  highest  among patients  who had
purchased antidepressant agents at around the baseline visit. These were followed by
individuals with any such purchases during follow-up and non-purchasers, respectively. In
multivariate models, purchases of antidepressant agents at baseline were associated with
increased mortality only in women. The underlying mechanisms behind this phenomenon
should be investigated in order to reduce the increased risk among these individuals.
Purchasers of antidepressant agents more frequently died of chronic diabetic complications,
while the most common COD among non-purchasers were cardiovascular diseases.
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9. APPENDIX
9.1 Diet questionnaire
1. How many cups of coffee or tea do you usually drink per day?
    I usually drink  _____________ cups of coffee a day
    I usually drink  _____________ cups of tea a day
2. How is the coffee made, that you usually drink? Mark one.
1 Mostly filtered coffee, or coffee made with coffee maker
2 Mostly coffee cooked in a pot, or coffee made with espresso machine
3 Mostly instant coffee
4 Mostly other type of coffee, what kind_____________________________
5 I do not usually drink coffee
3. How many glasses (2 dl) of milk of sour milk do you usually drink per day? Take also into
account the milk you use with coffee, tea, or cocoa, but not that used in cooking. Register also
how many portions (2dl) of yoghurt you use per day.
         I usually drink  _____________ glasses of milk per day
    I usually drink  _____________ glasses of sour milk per day
    I usually eat  _____________ portions of yoghurt per day
4. What kind of milk do you usually drink? Mark one.
1 Skim milk or lactose free skim milk drink
2 Milk or lactose free milk drink with 1 – 1,5 % fat
3 Full fat milk or unprocessed milk from farm
4 Organic milk with 1 – 1,5 % fat
5 Skim organic milk
6 Milk with stanols or sterols added
7 Other type of milk, what kind____________________________________
8 I do not usually drink milk
5. What kind of sour milk do you usually drink? Mark one.
1 Skim sour milk
2 Sour milk with 0,5 – 1,5 % fat
3 Sour milk with 2 % or more fat
4 Skim organic sour milk
5 Sour milk with stanols
6 Other type of sour milk, what kind________________________________
7 I do not usually drink sour milk
6. What kind of yoghurt do you usually eat? Mark one.
1 Skim or low fat yoghurt
2 Yoghurt with normal amount of fat
3 I do not usually eat yoghurt
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7. How many slices of bread do you usually eat per day? Mark 0 if none.
        I usually eat ____________  slices of bread per day
8. What kind of bread do you usually eat almost daily? Mark all that apply.
1 Rye bread or bread made mainly of rye
2 Bread made from mixed flour
3 Wheat bread
4 Rye crisp
5 Other type of bread, what kind___________________________________
6 I do not usually eat bread
9. What kind of spread do you usually consume on bread? Mark one.
1 I do not use any spread on bread
2 Butter
3 Butter and vegetable oil mix
4 Margarine with 70 – 80 % fat
5 Low fat spread with 65 % fat or less
6 Margarine with stanols or sterols
7 Unripened cheese, cheese spread or like
8 I do not usually eat bread
10. What kind of fat do you usually use for cooking at home? Mark one.
1 I do not use any fat for cooking
2 Vegetable oil
3 Butter
4 Butter and vegetable oil mix
5 Margarine or fluid margarine
6 Cooking margarine
7 Margarine with stanols or sterols
8 I do not cook at home
11. How often do you add salt to your food at table?
1 Almost never
2 Usually when food does not taste salty enough
3 Almost always prior tasting
12. Do you usually choose products (like cheeses, bread, cold cuts) low in salt?
1 Never
2 Seldom
3 Sometimes
4 Mostly
5 Always
13. Have you used foods with added lactic acid bacteria during the last moth?
1 No         2   Yes, trade name of the product and dose: _________________
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14. Have you used any dietary supplements (e.g., vitamin or mineral supplements or oil
capsules) or any other supplements during the last month?
1 No         2   Yes, trade name and the dose of the product: ______________
15. Have you used any natural products during the last month?
1 No         2   Yes, trade name and dose of the product _________________
16. Have you received any instructions concerning your diet from someone working at the
health care system? Mark all that apply.
1 No
2 Yes, from a dietitian
3 Yes, from a diabetes nurse
4 Yes, from a doctor
5 Yes, from someone else. Whom?_________________________________
17. When have you received instructions regarding your diet from the health care system? Mark
all that apply.
1 I have not received any instructions from the health care system
2 At the time of diabetes diagnosis
3 At the time of other diagnosis. Which disease, and when ______________
4 At other occasion, when ______________
 18. Do you follow the dietary instructions given to you at the health care system?
1 I have not received any instructions
2 Never
3 Seldom
4 Sometimes
5 Most of the time
6 Always
19. Do you follow any special diet at the moment? Mark all that apply.
1  No
2  Low lactose or lactose free – diagnosis or recommendation from the health
      care system
3  Low lactose or lactose free – own decision
4  Gluten free (celiac disease) – diagnosis or recommendation from the
      health care system
5  Gluten free (celiac disease) – own decision
6  Protein restricted – diagnosis or recommendation from the health care
      system
7  Protein restricted – own decision
8  Vegetarian or vegan – diagnosis or recommendation from the health care
      system
9  Vegetarian or vegan – own decision
10  Vegetarian or vegan – other reasons
11  Other, which and why?_________________________
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20. How often have you consumed the following items during the last month? Mark one on each row.
several
times a day
once a
day
4-6 times
a week
2-3 times
a week
once a
week
1-3 times
a month
less
frequently
Fish dishes
Meat dishes (cattle, pork, lamb, game)
Chicken, broiler, or other bird
Sausages or cold cuts
Eggs; boiled, fried, or as omelettes
Peas, beans, or other legumes
Fresh vegetables (salad and so on)
Cooked vegetables (excluding potatoes)
Potatoes
Pasta or rice
Fruits or berries (excluding juices)
Cheeses containing 20 % fat or more
Low fat cheese (fat less than 20 %)
Yoghurt, curd
Ice cream
Soft drinks
Sweet pastries (like cakes, cookies and so on)
Sweets or chocolate
Fried or grilled food
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9.2 An example page of an exercise and diet record
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9.3 Leisure-time physical activity questionnaire
1. Leisure-time physical activity (current and previous)
1.1. How often do you currently participate in leisure-time physical activities (e.g., walking,
hiking, running, jogging, cycling, rowing, gymnastics, aerobics, gym training, ball games,
swimming, dancing, cross country skiing, downhill skiing, skating)?
0   Never 4   2 times a week
1   Occasionally 5   3 times a week
2   1-3 times per month 6   4-5 times a week
3   Once a week 7   >5 times a week
1.2. From the list of activities in section 1.1., please mention the ones you currently do:
Most frequently:_________________________________
Second frequently: _______________________________
Third frequently: ________________________________
1.3. What is the average duration of your leisure-time physical activity session? ____________
1.4. Has your leisure-time physical activity habits changed during the past 10 years?
0   Substantially reduced 3   Somewhat increased
1   Somewhat reduced 4   Substantially increased
2   No changes
1.5. How strenuous is the leisure-time physical activity that you nowadays participate in?
0   Very light (e.g., stretching)
1   Quite light (e.g., slow walking, habitual gymnastics, golf, bowling, downhill skiing)
2   Moderately strenuous (e.g., brisk walking, habitual cycling, aerobics, gym training, light ball
     games, dancing, skating)
3   Strenuous (e.g., hiking, jogging, brisk cycling, some ball games, fitness swimming, skiing)
4   Very strenuous (e.g., running, heavy ball games, fitness skiing)
1.6. When 14-17 years old, how often did you participate in leisure-time physical activities?
0   Never 4   2 times a week
1   Occasionally 5   3 times a week
2   1-3 times a month 6   4-5 times a week
3   Once a week 7   >5 times a week
1.7. Have you at some occasion practiced competitive sports?
0   No 1   Yes
If yes, for how long?___________ At what age?__________ Which sport?________________
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2. Leisure-time physical activity during the past 12 months
Which of the following activities have you participated in during the past 12 months? For each
activity, please estimate the habitual level of strenuousness by selecting one of the following
categories:
Category Strenuousness Shortness of breath Sweating
0 Light None None
1 Moderate Light None
2 Strenuous Some Some
3 Very strenuous Heavy Heavy
How many times per month?
Ja
nu
ar
y
Fe
br
ua
ry
M
ar
ch
Ap
ril
M
ay
Ju
ne
Ju
ly
A
ug
us
t
S
ep
te
m
be
r
O
ct
ob
er
N
ov
em
be
r
D
ec
em
be
r
Av
er
ag
e 
tim
e
C
at
eg
or
y 
(0
-3
)
Commute walking
Walking, hiking
Jogging, running
Skiing
Commute cycling
Other cycling
Swimming
Gymnastics
Ball games
Gardening
Berry picking
Fishing
Renovating
Rowing
Forestry
Downhill skiing
Skating
Gym training
Dancing
Bowling
Household chores
Other:__________
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9.4 Orientation to Life Questionnaire (SOC-13)
Scaling for each question: 1 2 3 4 5 6 7Question (component)
Anchor at 1 (R)a Anchor at 7
1. Do you have the feeling that you don’t really
care about what goes around you? (ME)
very seldom or never
(R)
very often
2. Has it happened in the past that you were
surprised by the behaviour of people whom you
thought you knew well? (C)
never happened (R) always happened
3. Has it happened that people whom you
counted on disappointed you? (MA)
never happened (R) always happened
4. Until now your life has had: (ME) no clear goals or
purpose at all
very clear goals and
purpose
5. Do you have the feeling that you are being
treated unfairly? (MA)
very often very seldom or never
6. Do you have the feeling that you are in an
unfamiliar situation and don’t know what to do?
(C)
very often very seldom or never
7. Doing the things you do every day is: (ME) a source of deep
pleasure and
satisfaction (R)
a source of pain and
boredom
8. Do you have very mixed-up feelings and
ideas? (C)
very often very seldom or never
9. Does it happen that you have feelings inside
you would rather not feel? (C)
very often very seldom or never
10. Many people – even those with a strong
character – sometimes feels like sad sacks
(losers) in certain situations. How often have you
felt this way in the past? (MA)
never (R) very often
11. When something happened, have you
generally found that: (C)
you over- or
underestimated its
importance
you saw things in the
right proportion
12. How often do you have feeling that there’s
little meaning in the things you do in your daily
life? (ME)
very often very seldom or never
13. How often do you have feelings that you are
not sure you can keep under control? (MA)
very often very seldom or never
a reverse scoring is applied. ME, meaningfulness: C, comprehensibility; MA, manageability.
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9.5 Beck Depression Inventory
Q1 0 I do not feel sad  Q6 0 I don’t feel I am being punished
1 I feel blue or sad 1 I have a feeling that something
2a I am blue or sad all the time and I bad may happen to me
can’t snap out of it 2 I feel I am being punished or will
2b I am so sad or unhappy that it is be punished
very painful 3a I feel I deserve to be punished
3 I am so sad or unhappy that I can’t 3b I want to be punished
stand it  Q7 0 I don’t feel disappointed in myself
Q2 0 I am not particularly pessimistic or 1a I am disappointed in myself
discouraged about the future 1b I don’t like myself
1 I feel discouraged about the future 2 I am disgusted with myself
2a I feel I have nothing to look 3 I hate myself
forward to  Q8 0 I don’t feel I am any worse than
2b I feel that I won’t ever get over my anybody else
troubles 1 I am very critical of myself for
3 I feel that the future is hopeless my weaknesses or mistakes
and things cannot improve 2 I blame myself for everything that
Q3 0 I do not feel like a failure goes wrong
1 I feel I have failed more than the 3 I feel I have many bad faults
average person  Q9 0 I don’t have any thoughts of
2a I feel I have accomplished very harming myself
little that is worthwhile or that 1 I have thoughts of harming myself
means anything but I would not carry them out
2b As I look back on my life all I can 2a I feel I would be better off dead
see is a lot of failures 2b I have definite plans about
3 I feel I am complete failure as a committing suicide
person 2c I feel my family would be better
Q4 0 I am not particularly dissatisfied off if I were dead
1a I feel bored most of the time 3 I would kill myself if I could
1b I don’t enjoy things the way I  Q10 0 I don’t cry any more than usual
used to 1 I cry more now than I used to
2 I don’t get satisfaction out of 2 I cry all the time now. I can’t stop it
anything anymore 3 I used to be able to cry but now I
3 I am dissatisfied with everything can’t cry at all even though I want
Q5 0 I don’t feel particularly guilty to
1 I feel bad or unworthy a good part  Q11 0 I am no more irritated now than I
of the time ever am
2a I feel quite guilty 1 I get annoyed or irritated more
2b I feel bad or unworthy practically easily than I used to
all the time now 2 I feel irritated all the time
3 I feel as though I am very bad or 3 I don’t get irritated at all at the
worthless things that used to irritate me
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9.5 (Continued)
Q12 0 I have not lost interest in other  Q17 0 I don’t get any more tired than usual
people 1 I get tired more easily than I used to
1 I am less interested in other people 2 I get tired from doing anything
now than I used to be 3 I get too tired to do anything
2 I have lost most of my interest in   Q18 0 My appetite is no worse than usual
other people and have little feeling 1 My appetite is not as good as it
for them  used to be
3 I have lost all my interest in other 2 My appetite is much worse now
people and don’t care about them 3 I have no appetite at all any more
at all  Q19 0 I haven’t lost much weight, if any,
Q13 0 I make decisions about as well as  lately
ever 1 I have lost more than 5 pounds
1 I am less sure of myself now and 2 I have lost more than 10 pounds
try to put off making decisions 3 I have lost more than 15 pounds
2 I can’t make decisions any more  Q20 0 I am no more concerned about my
without help  health than usual
3 I can’t make any decisions at all 1 I am concerned about aches and
any more  pains or upset stomach or
Q14 0 I don’t feel I look any worse than  constipation or other unpleasant
I used to  feelings in my body
1 I am worried that I am looking 2 I am so concerned with how I feel
old or unattractive  or what I feel that it’s hard to think
2 I feel that there are permanent  of much else
changes in my appearance and 3 I am completely absorbed in what
they make me look unattractive  I feel
3 I feel that I am ugly or repulsive  Q21 0 I have not noticed any recent
looking  change in my interest in sex
Q15 0 I can work about as well as before 1 I am less interested in sex than I
1a It takes extra effort to get started at  used to be
doing something 2 I am much less interested in sex
1b I don’t work as well as I used to  now
2 I have to push myself very hard 3 I have lost interest in sex completely
to do anything
3 I can’t do any work at all
Q16 0 I can sleep as well as usual
1 I wake up more tired in the
morning than I used to
2 I wake up 1-2 hours earlier than
usual and find it hard to get back
to sleep
3 I wake up early every day and
can’t get more than 5 hours sleep
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9.6 Diabetes questionnaire
Q1 How many times, during the preceding year, have you visited a doctor?
Due to diabetes                         0    1–2    3–4    5–6    7–8    >8 times
Due to other reasons                 0    1–2    3–4    5–6    7–8    >8 times
Q2 How many times, during the preceding year, have you visited a nurse?
Due to diabetes                         0    1–2    3–4    5–6    7–8    >8 times
Due to other reasons                 0    1–2    3–4    5–6    7–8    >8 times
Q3 How much does diabetes per se and/or Q4 How much do the potential diabetes
its treatment disturb your life related complications disturb your life?
1   Not at all 4   Quite a lot 0   No complications 3   Moderately
2   Slightly 5   Very much 1   Not at all 4   Quite a lot
3   Moderately 2   Slightly 5   Very much
Q5 What is your latest HbA1c value? _______________
Q6 What does it tell you about your Q7 Are you satisfied with your current
average daily glycaemic control during HbA1c level?
the preceding 6–8 weeks? 1   Yes 2   No
1   That it is at a good level Q8 Are you satisfied with your current
2   That it is at a satisfactory level insulin regimen?
3   That it is at a high level 1   Yes 2   No
Q9 When have you last discussed about Q10 When have you last visited a dietician?
nutrition with a diabetes nurse? 0   Never 3   3–4 years ago
0   Not once 3   3–4 years ago 1   Within a year 4   5–6 years ago
1   Within a year 4   5–6 years ago 2   1–2 years ago 5   >6 years ago
2   1–2 years ago 5   >6 years ago
Q11 How often have you experienced Q12 How often, during the past 4 weeks,
perceptions of low blood glucose levels have you measured blood glucose
(perceptions of hypoglycaemia) during values below 3 mmol/l without having
the past 4 weeks? felt that you have low blood glucose
0   0 times 3   5–6 times levels (asymptomatic low)?
1   1–2 times 4   7–8 times 0   0 times 3   5–6 times
2   3–4 times 5   >8 times 1   1–2 times 4   7–8 times
Q13 Are you afraid of hypoglycaemia? 2   3–4 times 5   >8 times
1   Yes 2   No
Q14 If you are afraid of hypoglycaemia, is Q15 Has your fear of hypoglycaemia led you
this fear directed to to eat “just in case”
1   Diurnal hypoglycaemia 1   At daytimes 3   Both
2   Nocturnal hypoglycaemia 2   In the evenings 4   Neither
3   Both
Q16 Besides diabetes, do you suffer from any other chronic diseases?
1   No 2   Yes, which? _________________________________________
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